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ABSTRACT 
Recent advancements in mass spectrometry have facilitated new analytical approaches 
capable of comprehensively characterizing metabolites in biological samples.  Fourier 
transform ion cyclotron resonance mass spectrometry (FTICR-MS) combines excellent mass 
accuracy (ppm<1) and ultra-high resolution, which enables the separation and identification of 
individual components within complex mixtures, and the determination of elemental 
composition for each detected mass.  FTICR-MS is an ideal method for non-targeted 
metabolomics as the majority of small molecular compounds (100-1000 Da) in a biological 
sample can be detected.  The objective of this research was to investigate metabolomic 
alterations associated with key cellular processes deemed fundamental to cancer development 
and progression. 
Differentiating U937 cells, fibroblasts synchronously progressing through the cell cycle 
and a transformed cell line containing a temperature sensitive oncogene were collected and 
subject to FTICR-MS analysis for non-targeted comprehensive metabolomics.  Putative 
metabolite identifications were confirmed with targeted metabolite analysis using multiple 
reaction monitoring triple quadrupole mass spectrometry.  Analysis of the resulting metabolic 
profiles revealed robust metabolic alterations associated with fundamental cellular processes.  
Changes in glycerolipid content were observed in all cellular processes studied.  During cell 
cycle progression, elevated levels of triacylglycerols and vinyl acylglycerols were detected as 
cells approached mitosis; increased levels of plasmalogens were detected during the induced 
differentiation of human leukemic cells and activation of the oncogene p130
gag-fps 
in fibroblasts 
resulted in increased levels of phospholipids, including plasmalogens.  When de novo fatty acid 
synthesis was inhibited in the differentiation cell model, the cells were not able to complete the 
differentiation process.  Removal of the inhibitor resulted in increased lipid content, 
particularly plasmalogens, and the continuation of differentiation, suggesting a requirement for 
the de novo synthesis of lipids during this cellular process.   
This work demonstrates the advantages of non-targeted metabolic profiling for 
identifying non-intuitive metabolic associations with specific cellular processes.  Collectively, 
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the results of this thesis have implicated glycerolipids, in particular phospholipids, in the 
processes of cell cycle progression, differentiation and tumourigenic transformation.  A 
broadened understanding of the role of global lipid metabolism during fundamental cellular 
processes may one day lead to new approaches for their modulation, and potentially new 
therapeutic strategies. 
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1 OVERVIEW 
The use of functional genomics and systems biology approaches in combination with 
mathematical modeling and advancements in bioinformatics has continued to increase our 
understanding of cancer development and progression.  The systematic analysis of cancer is 
well on its way due to the availability of high-throughput genomic and proteomic technologies.  
However, changes that occur in the genome, transcriptome or proteome do not necessarily 
correspond to phenotypic alterations.  Metabolomics is a logical progression from the analyses 
of genes, RNA and protein at the systems level.  It provides the correlation between genes and 
the functional phenotype of an organism, which is the ultimate purpose of a functional 
genomics approach.  Surprisingly, few studies have been carried out to investigate the 
comprehensive metabolic composition of cancer cells, and metabolism associated with cancer 
development and progression. 
The objective of this research was to investigate phenotypic changes associated with 
key cellular processes deemed fundamental to cancer development. Using a non-targeted global 
metabolomics strategy, I have investigated the metabolic changes associated with cell cycle 
progression, cellular differentiation and tumourigenic transformation.  Non-targeted 
metabolomics is a non-conventional biochemical analysis. The results obtained can be used to 
generate a data-driven hypothesis rather than to prove a theoretical hypothesis. 
There are many stages required in a metabolomics analysis.  Initially it must be decided 
if a targeted or non-targeted approach should be applied.  This decision will be based on 
whether a specific aspect of the metabolome is to be studied, in which case a targeted analysis 
can be used to accurately quantify the metabolites of interest.  On the other hand, if little is 
known about the expected metabolome changes and therefore no hypothesis can be formed, a 
global non-targeted metabolic analysis should be utilized. An analytical technology must then 
be selected to detect, quantify or structurally elucidate the metabolites. Such technologies 
include mass spectrometry (MS) or nuclear magnetic resonance (NMR), depending on the type 
of analysis required.   
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If a non-targeted metabolomics approach is selected, a bioinformatics platform is often 
required to organize and visualize the immense amounts of data produced from the analysis.  
Non-targeted metabolomics datasets are often large and likely not easy to comprehend in their 
raw form.  Unsupervised statistical approaches can be used to reduce the complexity of 
metabolomics data and to visualize patterns of metabolite expression across samples.  
Metabolite identifications can then be made based on databases of known metabolites, formula 
assignments based on accurate masses or further analyses such as a targeted strategy or 
structural elucidation using NMR. 
Our metabolomic investigation of cancer development and progression has identified a 
potential role of lipids in key cellular processes that are fundamental to the malignant 
phenotype.  Lipids are a very diverse group of metabolites with a wide variety of biological 
functions in the cell, including structural components in cellular membranes, storage of fatty 
acids and cell signalling.  To our knowledge, this is the first comprehensive metabolomic 
investigation of key cellular processes associated with cancer development and progression.  
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2 LITERATURE REVIEW 
2.1 Understanding Biological Processes Using Systems Approaches 
2.1.1 Functional Genomics 
There have been many scientific discoveries and technological advances over the past 
fifty years that have allowed the study of biological systems at levels of complexity once never 
thought possible.  In 1953, James D. Watson and Francis H. Crick introduced the structure of 
the deoxyribonucleic acid (DNA) helix (Watson and Crick, 1953).  With this discovery, 
comprehension of the basic mechanisms of DNA replication, gene expression and protein 
synthesis followed closely behind.  In the 1970s a group of researchers from Johns Hopkins 
University discovered type II restriction endonucleases and DNA ligases, enzymes capable of 
cutting and re-joining DNA at specific sequences sites (Smith and Wilcox, 1970; Danna and 
Nathans, 1971).  It was quickly realized that these enzymes could be used to create 
recombinant DNA molecules, a fundamental technique upon which the science of 
biotechnology relies.  Over the next decade further advancements in technology were made, 
including polymerase chain reaction (PCR) (Mullis, 1990) and automated DNA sequencing 
(Sanger et al., 1977).  Each of these very important milestones in molecular science has led to 
the completion of numerous large-scale genome sequencing projects, including that of the 
human genome. 
The completion of the Human Genome Project (Lander et al., 2001) has had a major 
impact on life science research, in particular human health and molecular medicine.  The 
manner in which biological research is viewed, and approached, has changed dramatically 
throughout the post-genomic era.  The genome project permitted the development of numerous 
high-throughput technologies and created the requirement for computer science, mathematics 
and statistics in molecular science (Hood, 2003).  The sequencing of all human genes also 
brought hope for improved diagnosis, preventative medicine, earlier detection of genetic 
predispositions to disease, gene therapy and personalized drug design. Although the completion 
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of the human genome project was a significant milestone, it has not led to the advancements in 
molecular medicine which were predicted.  This is because genomics represents only one piece 
of a very complicated puzzle.  To fully understand the responses of a biological system, one 
must consider all of its components (Butcher et al., 2004).  Omics, systems biology and 
functional genomics are all terms for a similar goal: that is, to describe and understand the 
operation of a complex biological system through the analyses of its molecular building blocks 
(genes, RNAs, proteins and metabolites).  Functional genomics allows the system-wide 
analysis from genotype to phenotype (Edwards and Batley, 2004).  This global approach 
enables the identification of interactions between macromolecules, the determination of 
functional linkages between phenotypic expressions, and the construction of models which 
quantitatively describe the dynamics of the biological system (Bino et al., 2004).  Combining 
the analyses of genes, gene expression, proteins and metabolites could provide the insights 
required to understand the processes within a cell, and allow the progression from prediction to 
experimental validation of gene expression (Bino et al., 2004; Heijne et al., 2005). 
2.1.2 OMICS 
OMICS is a term that informally encompasses all of the molecular fields of study that 
end in omics, including genomics, transcriptomics, epigenomics, proteomics, and 
metabolomics.  The omics technologies provide the molecular tools to analyze large sets of 
biological molecules such as DNA, RNA, protein and metabolites.  The technical 
advancements in the omics assays have allowed analyses of entire signalling pathways, 
complete genomes, and all cellular components.  For many years scientists were only able to 
analyze a single gene at a time.  However, the discovery of high-throughput technologies 
brought the ability to study the genome of a system as a whole.  Genomics involves studying 
the genome through the analysis of the nucleotide sequence, genome structure and its 
composition.  Determining the composition of the genome can lead to the elucidation of 
molecular mechanisms which control a system.  One of the main limitations of genomics is that 
the analysis often leads to the identification of a gene; however, the function of this gene at the 
biochemical level is typically not identified or is simply inferred from homology of previously 
investigated sequences (Fridman and Pichersky, 2005).  Transcriptomics is the global analysis 
of all transcripts in a given organism. This molecular approach determines changes in gene 
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expression through the measurement of messenger ribonucleic acid (mRNA) and non-coding 
RNA levels in a system under a specific condition.  The most common types of analysis used 
for transcriptomics are Northern Blots (Alwine et al., 1977), Real-time PCR (RT-PCR) 
(Higuchi et al., 1993), Serial Analysis of Gene Expression (SAGE) (Velculescu et al., 1995) 
and DNA microarrays (Schena et al., 1995).  The study of gene expression can provide 
significant insight towards the cellular mechanisms that are affected at the gene expression 
level by the disease or drug treatment.  Depending on the systems being compared, there can be 
either relatively few or thousands of differences.  Understanding how all of these changes fit 
together can be very challenging.  Proteomics is the analysis of the proteins synthesized under a 
given set of conditions.  Proteomics has significant prospects for advancing our understanding 
of the life sciences, due to its direct relationship with gene and transcript data.  However; the 
measurement of proteins can be complex due to their different properties, such as mass, 
isoelectric point, solubility, stability and post-translational modifications (Heijne et al., 2005).  
There is also still a need for a high-throughput analysis for protein expression patterns.  
Metabolomics might be considered by some to be the key to integrated systems biology 
because it represents a direct measurement of the phenotype, measuring quantitative and 
qualitative traits (Fiehn, 2002).  “Metabolomics is a burgeoning science that brings together 
analytical technology, genomics and computation, and lies at the core of the systems biology 
agenda” (Kell, 2004). 
2.1.3 Metabolomics 
Although genomics has dominated the scientific community for the past few decades, 
the analysis of metabolism and the correlations of specific metabolites to human health have 
taken place for centuries.  Metabolomics is a scientific discipline that aims to identify and 
quantify the metabolome, which is the total quantitative collection of small molecular 
compounds present in an organism or biological sample.  Metabolomics was first discussed in 
1998 by Stephen Oliver, who not only coined the term but saw the enormous potential of the 
application of metabolomics for functional genomics (Oliver et al., 1998).  Metabolites are the 
reactants and products of a metabolic network; therefore, the quantification of the metabolome 
provides a direct method for the analysis of internal metabolism kinetics (Buchholz et al., 
2002).  Metabolomics is a logical progression from the analyses of genes, RNA and protein at 
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the systems level.  It provides the correlation between genes and the functional phenotype of an 
organism, which is the ultimate purpose of a functional genomics approach.  In contrast to 
transcriptomics and proteomics, metabolomics can provide direct evidence rather than 
indications of changes in biochemical pathways (Heijne et al., 2005).  Metabolomics is 
considered to be a downstream analysis, in that the changes occurring in the metabolome 
reflect amplifications of the changes that occurred in the transcriptome and the proteome (Kell, 
2005).  Another benefit of metabolomics is that, unlike a transcript or protein, a given 
metabolite is the same in every organism that contains it. 
Although the development of metabolomic methods and technologies is progressing 
rapidly, there are still issues and drawbacks that must be considered.  DNA, RNA and proteins 
all have some structural properties in common, allowing the development of analytical methods 
that apply to basically all members of the class.  On the other hand, metabolites within a cell 
have no shared chemical features on which a single general isolation, separation or 
identification method can be developed (Fridman and Pichersky, 2005).  The number of 
metabolites and derivatives of known metabolites expected in mammals, plants and bacteria is 
still largely unknown.  The metabolome is made up of very diverse compounds, ranging from 
ionic inorganic species to hydrophobic lipids, in a dynamic range of concentrations (Villas-
Boas et al., 2005b).  Many major advances in the design and applications of analytical 
instrumentation for metabolomics have been made over the past few decades, allowing a 
broader and more comprehensive study of small molecules.  However, in order for the true 
potential of metabolomics to be realized, efforts must be focused on improving sensitivity as a 
truly comprehensive analysis of the metabolome is not yet technically possible. 
2.2 Metabolomics profiling technologies 
There are numerous technologies available for studying the metabolome, each with 
advantages and limitations.  There are two fundamental approaches that can be used when 
analyzing metabolites: targeted and non-targeted.  A targeted analysis is restricted to the 
analysis of a single class of compounds or a specific pathway.  A non-targeted approach, 
however, is aimed at identifying a large number of different metabolites in a sample with no 
prior knowledge about the sample itself.   The power of a non-targeted approach allows for the 
generation of a data-driven hypothesis, whereas a targeted approach is intended to answer a 
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hypothesis and not generate one.  To date there is not a single analytical method capable of 
detecting and quantifying all metabolites in a system. This is largely due to the chemical 
complexity of compounds that comprise the metabolome.  However, there have been many 
advances made in metabolomics analyses and the combination of these technologies may make 
the detection of all metabolites attainable in the near future.  Mass spectrometry (MS) and 
nuclear magnetic resonance (NMR) are the most commonly applied analytical technologies in 
metabolomics studies.  NMR is a powerful technique and is particularly useful in the structure 
elucidation of unknown organic compounds.  The main limitations of this approach are the 
complex computational requirements to resolve complex mixtures, the low sensitivity and that 
the cost of the NMR equipment can be significantly more expensive than MS-based 
technologies (Villas-Boas et al., 2005a).  Mass spectrometry is a widely applied technology in 
the study of metabolites as it provides a system which is both sensitive and capable of 
identifying and quantifying a wide range of metabolites (Dunn et al., 2005).  Mass 
spectrometry was the profiling technique utilized in this thesis and will be further explained in 
the following sections. 
2.2.1 Types of Mass Spectrometry 
The technology of mass spectrometry is based on the principle that molecules can be 
ionized into charged particles and detected, allowing both the determination of the mass and the 
structure of the ion.  The mass spectrometer uses a beam of high-energy electrons to ionize 
organic molecules in a sample, which are then separated on the basis of their mass-to-charge 
(m/z) ratios and measured for relative abundance in the sample.  The spectrum that is produced 
from a mass spectrometry approach is simply a display of the masses of the ionized molecules 
in a sample versus the relative intensity of each of the molecules.  Mass spectrometers consist 
of an ionization source, ion filters or traps, an ion detector, vacuum pumps, and a data 
collection system (Figure 2.1).  The sample is injected into the mass spectrometer at the inlet 
where it undergoes vaporization and ionization in the ionization source. There are numerous 
methods available for generating ionized molecules, including electrospray ionization (ESI) 
and atmospheric pressure chemical ionization (APCI), both of which are commonly used 
sources of ionization (Werner et al., 2008).  ESI generates ionized molecules through the use of 
a fine needle, to which a voltage is applied, which in turn causes the spray to be charged as it is  
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Figure 2.1  A generalized schematic of the main components of a mass spectrometer. 
The sample is injected into the mass spectrometer at the inlet. The molecules of the sample are 
then ionized into charged particles at the ionization source.  These charged particles are then 
separated by mass or charge depending on the type of mass analyzer being used.  The ions then 
travel to the ion detector under vacuum pressure to the detector.  When the ion hits the detector 
either the charge that is induced or the current that is produced is recorded.  
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nebulised.  The sample is forced through the needle and uniformly charged droplets are 
produced. The droplets continue to break down, due to the evaporation of the solvent, resulting 
in individually charged ions.  In comparison, APCI utilizes a co-axial flow of nitrogen, heat and 
a corona discharge needle to create ions from the injected liquid sample.  The APCI source is 
more suitable for the study of less polar compounds as compared to the ESI source (Villas-
Boas et al., 2005a). 
The ions are then filtered or trapped by the mass analyzer, such as time-of-flight (TOF), 
quadropole or cyclotron resonance (Werner et al., 2008).  With time-of-flight, ions travel 
through a vacuum tube to a detection plate, and the speed at which the ion travels through the 
tube is proportional to its mass (Lewandrowski et al., 2005).  The quadropole mass analyzer 
detects ions by scanning a radiofrequency for each mass across four parallel rods, and also 
measures the number of ions that passes through at each frequency (Bajad et al., 2006).  Ion 
cyclotron resonance detects ions through the measurement of an image current that is produced 
when ions, in the presence of a magnetic field, move in a cyclotron motion, which is the motion 
of a charged particle in a constant magnetic field, (Reemtsma, 2009).  Ion cyclotron resonance 
is discussed further in the following section. 
If the analyte components are separated prior to ionization, the capability of the mass 
spectrometer can be greatly increased.  Gas or liquid chromatography are commonly used as 
separation methods and have been found to improve sensitivity and resolution of mass 
spectrometers (Werner et al., 2008).  Traditionally, gas chromatography-mass spectrometry 
(GC-MS) and liquid chromatography-mass spectrometry (LC-MS) have been used to study 
metabolites in a biological system.  GC-MS can be used for the simultaneous separation, 
identification and quantification of volatile and non-volatile metabolites.  The advantages of 
using GC-MS for the analysis of biological metabolites are the high chromatographic resolution 
and the ability to simultaneously analyze different classes of metabolites (Villas-Boas et al., 
2005a).  The major drawbacks of this technology are that non-volatile compounds must be 
derivatized before they can be analyzed, large thermally-liable compounds cannot be detected 
due to their limited volatility, and that electron impact causes fragmentation (Dunn et al., 2005; 
Villas-Boas et al., 2005a).  LC-MS is also capable of separating, identifying and quantifying a 
broad range of metabolites, especially metabolites with similar molecular masses.  The 
advantages of this approach are that derivatization is not needed and thermo-labile metabolites 
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can be analyzed; however, the potential for identification can be a limitation unless a MS-MS 
fragmentation approach is used (Dunn et al., 2005). 
Fourier Transform Ion Cyclotron Resonance-Mass Spectrometry (FTICR-MS) is a mass 
spectrometry platform which is highly attractive for non-targeted metabolic profiling as it 
offers the highest mass accuracy and resolution of any other mass spectrometry technology. 
2.2.2 FTICR-MS 
FTICR-MS is derived from ion cyclotron resonance (ICR) spectrometry and is based on 
the principle of a charged particle orbiting in the presence of a strong magnetic field (Marshall, 
2002). FTICR-MS have excellent mass accuracy and ultra-high resolution.  Mass accuracy 
(measured in parts per million (ppm)) is a measurement of how well the observed mass-to-
charge (m/z) correlates with the actual true mass of a specific elemental composition (Barrow et 
al., 2005).  FTICR mass spectrometers typically have mass accuracies less than 1 ppm, which 
allow for the elemental composition of each mass detected during the analysis to be 
determined.  Metabolites with different molecular formulas have a different accurate mass.  
Therefore, if the mass of a metabolite can be accurately determined it will be possible to 
determine the corresponding molecular formula.  However, before one can calculate the 
accurate mass of a metabolite, one must first be able to resolve the mass from the other masses 
in the sample.  The FTICR-MS is currently the highest resolution mass spectrometer available, 
with a resolving power sufficient enough that individual components of a complex mixture can 
be identified and quantified without any prior separation (Werner et al., 2008).  Resolution is 
extremely important in mass spectrometry, as high resolution imparts the ability to separate 
closely spaced signals that occur in complex mixtures.  Masses differing by only hundredths of 
a Dalton (Da) can be resolved, which is why there is no need for chromatography when using 
FTICR-MS (Stenson et al., 2003).  The FTICR-MS is therefore ideal for non-targeted, 
metabolomic analyses, and when properly deployed, can rapidly identify the similarities and 
dissimilarities between numerous types of biological samples (Bhalla et al., 2005). 
As reviewed by Barrow et al, there are five main components to a FTICR-MS; an 
ionization source, a vacuum system, a superconducting magnet, an analyzer cell, and a data 
converting and collecting system (Figure 2.2).  Samples are directly injected into an ionization  
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Figure 2.2  A generalized schematic of the main components of a Fourier transform ion 
cyclotron resonance mass spectrometer (FTICR-MS). 
The sample is injected into the mass spectrometer at the inlet. The molecules of the sample are 
then ionized into charged particles at the ionization source. The ions then travel under vacuum 
pressure to the mass analyzer cell located inside a superconducting magnet. The ions each 
move in a cyclotron motion as a result of the opposing Lorentz force and radial forces. Through 
the use of a radio frequency (RF) potential, which is applied to the two excitation plates located 
in the analyzer cell, the orbiting radius of the cycling ions becomes larger and detectable. The 
frequency at which the ions cycle in the cell is then converted to a mass spectrum (m/z) using 
the mathematical procedure known as a Fourier transform. 
 
Ionization 
Source
Inlet
Data Converting 
and Collection 
System
(Fourier 
Transform)
Vacuum 
Pump
Data Output
Sample Injection 
Site
Analyzer Cell
Superconducting 
Magnet
Excitation Plate
Detection Plate
12 
source, most commonly with electrospray ionization (ESI) or an atmospheric pressure chemical 
ionization (APCI) source, which vaporizes and ionizes the injected sample.  The vaporized 
sample then travels under vacuum pressure towards the analyzer cell which is located within 
the strong magnetic field of a superconducting magnet (Barrow et al., 2005).  The ions each 
move in a cyclotron motion as a result of the opposing Lorentz force, the force exerted on a 
charged particle in an electromagnetic field,  and centrifugal (or radial) forces (Heeren et al., 
2004).  The cyclotron orbits are too small to be detected when they initially enter the analyzer 
cell; however, through the use of a radio frequency (RF) potential, which is applied to the two 
excitation plates located in the analyzer cell, the orbiting radius of the cycling ions becomes 
larger and detectable (Barrow et al., 2005).  The frequency at which the ions cycle in the cell is 
then converted to a mass spectrum (m/z) using the mathematical procedure known as a Fourier 
Transform (FT) (Barrow et al., 2005). 
I have exploited the analytical power of the FTICR-MS to generate a non-targeted 
metabolomics platform.  The combination of metabolite extraction, FTICR-MS analysis, and 
bioinformatics software enables the detection and identification of nearly all metabolites in a 
biological sample.  A detailed description of the metabolite extraction and analysis is provided 
in the materials and methods section of this thesis. 
Although this analytical technique is very powerful, and extremely useful in metabolomic 
studies, it does have a few limitations that must be overcome in order for it to be a stand-alone 
metabolomic tool.  These include the inability to discriminate between isomers, and a lower 
mass limit of approximately 100 Da.  These limitations can be dealt with through the use of a 
targeted mass spectrometry platform, such as a liquid chromatography tandem mass 
spectrometer (LC MS/MS), which can be optimized to detect lower weight masses and 
discriminate between isomers. 
2.3 Methods for the analysis of multivariate data 
Large-scale biological datasets are often enormous and likely not easily comprehensible 
in their raw form.  The most effective method for dealing with such data is with the application 
of statistical approaches.  Through the use of statistics it is possible to discover naturally 
occurring groupings in the data, as well as to compress very large datasets into smaller, more 
discernable, informative datasets (Kristal, 2002).  There are two types of commonly used 
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statistical approaches for mining multivariate data; supervised and unsupervised.  Supervised 
methods are used to find features that fit a predetermined pattern, whereas unsupervised 
methods characterize the dataset without any prior input or knowledge (Butte, 2002).  
Unsupervised statistical approaches are very useful when attempting to reduce the complexity 
of metabolomics data and to visualize patterns of metabolite expression in samples.  There are 
many different unsupervised statistical techniques including principal component analysis, 
nearest neighbour clustering, self-organizing maps, k-means clustering, and hierarchical 
clustering (Butte, 2002).  Hierarchical clustering and principal component analyses are 
particularly useful in the simplification and visualization of metabolomic datasets, and are used 
repeatedly throughout this thesis. 
Hierarchical cluster analyses (HCA) use algorithms to reduce the complexity of datasets 
and organize the data into natural groupings, or clusters, based on expression patterns.  
Dendrograms are used to visually represent the clusters identified through the hierarchical 
cluster analysis.  The dendrogram is organized like a tree, with branches of varying lengths 
connected to all of the features in a dataset.  The length of each of the branches corresponds to 
the similarity between the features, or other branches (Butte, 2002).  The shorter the branch, the 
more similar the expression patterns are between the features or other branches of features.  
This type of analysis generates small organized clusters, which can be useful in determining 
how groups of features are responding to a system.  The hierarchical clustering used throughout 
this thesis utilized a Pearson correlation coefficient, which clusters metabolites with similar 
signal-to-noise (S/N) patterns across multiple samples.  This method is ideal for MS-generated 
metabolomic data because of the arbitrary intensities of different molecules. 
Principal Component Analysis (PCA), also known as an Eigenvector analysis, is a 
statistical technique that can be used to determine linear combinations of features that account 
for maximal variation in a dataset (Kristal, 2002).  PCA is a key statistical application for the 
visualization of large complicated datasets, and is therefore suitable for reducing the 
dimensionality of large metabolomics datasets.  PCA is a linear transformation that converts the 
data to a new coordinate system such that the greatest variance within the data comes to lie on 
the first coordinate (called the first principal component), the second greatest variance on the 
second coordinate, etc.  Principal components are sets of vectors that decreasingly capture that 
variation in a dataset (Butte, 2002).  The first principal component will capture more variation 
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than the second principal component, and so on.  The great strength of a PCA is that it provides 
a rapid, and powerful view of a dataset that is simplified into a two or three dimensional graph 
(Kristal, 2002).  In the case of a metabolomic analysis, samples with similar metabolite profiles 
will group closely on the PCA graph; whereas those with different metabolite profiles will 
cluster separately on the plot.  The distance that the samples are separated on the plot is directly 
proportional to the differences between the metabolic profiles of the samples.  Metabolites 
responsible for the separation between clusters can then be determined and further 
characterized. 
A movement has begun in the science community towards the use of systems biology 
approaches in biological research.  Integrating all available molecular-biological and 
phenotypic knowledge will provide a far more comprehensive picture of a system of interest.  
Determining the molecular differences between a normal and tumour cell or tissue is a crucial 
step in understanding cancer and in the development of anticancer therapies (Fan et al., 2004).  
Although a complete understanding of cancer is not yet realistic, the use of systems approaches, 
in combination with mathematical modeling and advancements in bioinformatics, will continue 
to increase our understanding of cancer.  The systematic analysis of cancer is well on its way 
due to the availability of high-throughput genomic and proteomic technologies.  However, little 
has been reported on the comprehensive chemical composition of cancer cells, primarily due to 
the lack of adequate technology. 
2.4 Understanding Cancer through the Study of Model Systems 
According to the Canadian Cancer Society, 173,800 new cases of cancer, and 76,200 
deaths due to cancer, will occur in Canada in 2010 (www.cancer.ca, 2010).  Although research 
is continually adding to our understanding of how cancer develops, the ability to diagnose, treat 
and prevent the disease remains limited. Cancer, generally regarded as a genetic disease, can 
arise from a variety of alterations at the genetic, epigenetic and chromosomal levels (Khalil and 
Hill, 2005).  The majority of research efforts have focused directly on genes and signalling 
pathways that lead to genetic alterations (Fan et al., 2004).  In a recent paper published in 
Nature Reviews Cancer, it was reported that there were precisely 291 genes which are 
implicated in cancer development (Futreal et al., 2004)!  The genomes of cancer cells acquire 
mutant alleles of oncogenes, tumour suppressor genes and other genes that play roles in cell 
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proliferation (Hahn and Weinberg, 2002).  The pathways in which the products of these „cancer 
genes‟ act have also been highly investigated, resulting in the realization that signalling does 
not necessarily occur in a linear pathway, but rather a complex web of interacting pathways 
(Hornberg et al., 2006).  In addition, it is also well established that environment, such as diet 
and lifestyle, play a large role in the risk of developing cancer. 
The goal of this thesis was to use a comprehensive metabolomic approach to investigate 
phenotype changes in key cellular processes that are fundamental to cancer development and 
progression. There are currently many different cancer model systems used in research.  These 
systems allow researchers to focus on a particular aspect of cancer development through a cell 
line, or animal model, which express the mutation or tumour of interest.  Division, growth and 
differentiation are fundamental cellular processes (Sulic et al., 2005).  These, along with the 
alterations in a cell that collectively influence malignant growth, are commonly the focus in 
many cancer model systems.  To date, very few reports have been published that examine the 
metabolic changes that accompany these processes.  Developing a thorough understanding of 
the basic cellular mechanisms that drive a cell into malignancy is a fundamental step in cancer 
research.  This project focused on the application of comprehensive metabolomic analyses on 
three cell based model systems, including transformation, differentiation and cell cycle 
progression. 
2.4.1 The Role of Cell Cycle and Differentiation in Cancer 
Hanahan and Weinberg suggest that there are six essential alterations in cell physiology 
that lead to transformation and tumorigenesis in nearly all cancers: self-sufficiency in growth 
signals, insensitivity to growth-inhibitory signals, evasion of apoptosis, limitless replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis (Hanahan and Weinberg, 
2000).   
In addition to these six hallmarks, it is believed that aerobic glycolysis, also commonly 
referred to as the Warburg effect, should be considered the seventh hallmark of cancer, as it 
was one of the first biochemical alterations detected in cancer (Hsu and Sabatini, 2008; Yeung 
et al., 2008).  Nutrients, energy and biosynthetic activity are all required for a cell to proliferate 
successfully.  It is a massive energetic undertaking for a cell to double all of its biomass (for 
example proteins, lipids and nucleic acids) during a cell division.  Metabolism in highly 
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proliferative cells, such as cancer cells, differs significantly from those that are quiescent.  In 
1926 Warburg proposed a model of tumourigenesis involving altered energy production in 
tumours.  This model, which is now known as the Warburg hypothesis, or effect, states that 
cancer cells shift to a high level of aerobic glycolysis, even in the presence of oxygen, and low 
respiration to metabolize glucose (Figure 2.3) (Warburg et al., 1927).  Under normal 
physiological conditions, cellular energy metabolism is preferentially based on oxidative 
phosphorylation, which is considerably more efficient than glycolysis (Warburg et al., 1927) .  
Warburg hypothesized an alternative state of energy metabolism in cancer systems, which 
included an impaired mitochondrial function and increased dependence on glycolysis as a 
source of energy, even under aerobic conditions (Warburg, 1956).  According to this 
hypothesis, the ability of cancer cells to generate ATP via mitochondrial respiration is 
impaired, which likely triggers alternative metabolic pathways by the over-expression of 
glycolytic enzymes (Warburg, 1956).  This alternative method of energy production may be a 
response, or perhaps a requirement, due to the rapid growth of cancer cells and consequently 
the expansion of a tumour mass which may result in an insufficient supply of blood to the 
tissue.  This would create a hypoxic environment with limited mitochondrial respiration, 
causing cancer cells to utilize the glycolytic pathway as their main source of energy (Xu et al., 
2005).  This way, if the cancer cells automatically switch to glycolysis, rather than respiration, 
as a source of energy, then a lack of oxygen will not prevent the cells from growing. 
Recent findings in cancer research have rekindled interest in Warburg‟s theory, 
including an observation that, during tumourigenesis, an increase in glucose uptake and lactate 
production occurs and that the fully transformed state is most dependent on glycolysis and 
minimally dependent on the mitochondria for ATP synthesis (Ramanathan et al., 2005).  The 
increase in glucose uptake in malignant cells has been clearly linked to the increased and 
deregulated expression of glucose transporter proteins, in particular GLUT1 and GLUT3 
(Macheda et al., 2005).  There have also been reports that increased GLUT expression directly 
correlates to increased tumour aggressiveness and inversely correlates to patient survival 
(Kawamura et al., 2001).  The strong correlation between the rate of aerobic glycolysis and the 
aggressiveness of the cancer likely indicates that the glycolytic phenotype offers a significant 
proliferative advantage and may be a crucial component of the malignant phenotype (Gatenby 
and Gillies, 2004).  The glycolytic phenotype suppresses apoptosis and the by-products of  
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Figure 2.3  Otto Warburg’s hypothesis- aerobic glycolysis in cancer. 
This model, which is now known as the Warburg hypothesis, states that cancer cells shift to a 
high level of aerobic glycolysis (green arrows), even in the presence of oxygen, and low 
respiration (red arrow) to metabolize glucose.  Warburg also suggested that the elevated levels 
of lactate in cancer cells are a direct effect of aerobic glycolysis. 
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glycolysis contribute to the degradation of the extracellular matrix, thus increasing cell mobility 
and metastatic potential (Bonnet et al., 2007).  Another possible advantage for a cancer cell to 
shift to glycolysis is to provide a source of acetyl CoA for the mitochondrial synthesis of 
citrate, which in turn provides the source for cytosolic acetyl CoA (Costello LC, 2005).  
Cytosolic acetyl CoA is the essential precursor molecule for the synthesis of fatty acids, which 
in turn are the major building blocks for lipid molecules.  The following section 2.5 will 
provide further detail on lipid synthesis and classification. 
There have also been many connections made between cancer-causing genes and 
glucose metabolism, including the AKT family of proteins, also known as protein kinase B, 
which has been found to stimulate glucose metabolism in cancer cells, as well as AMP-
activated protein kinase, which links glucose metabolism and cell cycle (Langbein et al., 2006).  
Reports have also showed that mitochondria in rapidly growing tumour cells are generally 
smaller and show less cristae than mitochondria from normal tissues, and also that the actual 
number of mitochondria in tumour cells is reduced (Ristow, 2006).  It is still unknown whether 
this is due to the reduced mitochondrial activity, or rather that the mitochondria activity is 
reduced due to the increased glycolytic activity.  Despite numerous reports by many different 
scientists whose research complements, or supports, Warburg‟s theory, the underlying cause of 
the effect is still not well understood.  It is also unknown if the same causes always underlie 
this effect in cancers, or if genetic influences play any part (Unwin et al., 2003). 
Cell cycle regulation and cellular differentiation are two fundamental cellular processes 
that are lost during cancer development and progression.  There has been a direct link made 
between the deregulation of the cell cycle components and cancer (Sulic et al., 2005).  The cell 
cycle is a highly organized, tightly regulated series of events in eukaryotic cells.  The cycle can 
be divided into four phases; G1, S, G2 and M.  The G1, or gap1, phase of the cycle is where 
cell growth primarily occurs, and it is also the portion of the cycle where cells decide to 
replicate and divide or to exit the cell cycle into a quiescent state (G0).  The S phase, or 
synthesis phase, is the point in the cell cycle in which DNA replication occurs.  During the 
second gap phase, G2, the integrity of the DNA replication is confirmed, and the cell prepares 
for cell division in the M phase.  The M phase, or mitotic phase, of the cell cycle is the point in 
which nuclear division and cytokinesis takes place, and two new identical daughter cells are 
produced.  Few cells exit the cell cycle during the early developmental stages of an organism; 
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however, once an adult stage is reached the majority of cells enter a quiescent state, G0, in 
which they will no longer divide (Malumbres and Barbacid, 2001), or they enter into a 
differentiation program (Deane et al., 2005).  However, upon stimulation by growth factors, 
most quiescent cells are capable of re-entering the cell cycle, unless they have reached a state of 
terminal differentiation (Sherr, 2000).  
The activation of cell cycle promoting factors (oncogenes) or inactivation of cycle 
inhibiting factors (tumour suppressors) can lead to the deregulation of cell proliferation and 
often malignancy (Tessema et al., 2004).  This imbalance of growth-inhibiting and growth-
promoting factors greatly influences the cell cycle and the development of cancer (Deane et al., 
2005).  Defects in the G1 and G2 checkpoints, including the inactivation of the checkpoint 
regulatory proteins Rb and p53, can also lead to uncontrolled proliferation and potentially result 
in the development of cancer (Tessema et al., 2004; Deane et al., 2005).  These checkpoints 
ensure that the cells are large enough, that the environment is suitable and that there has not 
been any damage to the cell structure or the genetic material: defects in any one of which 
would preclude successful division.  The checkpoint in late G1 portion of the cell cycle is 
particularly important for tumour development as this is where the DNA is assessed for 
damage.  Under normal cell conditions, DNA found to be intact will continue through to the 
synthesis phase of the cycle, whereas those with irreparable damage will undergo apoptosis 
(Seville et al., 2005). However, through the deregulation of the checkpoints, cancer cells are 
able to continue dividing without regard to any DNA damage that the cells may contain 
(Seville et al., 2005). 
Any meaningful study of the cell cycle in an in vitro system requires a population of 
synchronized cells.  One of the most common methods of synchronization is through serum 
starvation (Winkles, 1998; Cheong et al., 2003; Liu et al., 2004b; Memili et al., 2004).  In 
order to proliferate in culture, normal fibroblasts require growth factors, typically supplied in 
the form of foetal calf serum in the cell media. If the growth factors are removed, or more 
typically greatly diminished, normal fibroblasts enter into the quiescent state G0 of the cell 
cycle (Iyer et al., 1999).  In one study of goat fibroblasts, serum starvation yielded a 
synchronized population of G0 cells, which made the transition into bona fide G1 stage cells 
five hours after serum stimulation (Memili et al., 2004).  This serum deprivation model 
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provides a system to analyze the molecular changes that occur as quiescent cells re-enter the 
cell cycle and progress through G1, S, G2 and mitosis. 
Differentiation is the process in which pluripotent stem cells, or multipotent progenitor 
cells, irreversibly mature into specialized cell types.  For example hematopoietic stem cells 
from the bone marrow differentiate into white and red blood cells as well as platelets, whereas 
mesenchymal stem cells in the bone marrow differentiate into stromal cells and fat cells 
(Verhoeckx et al., 2004).  A number of mechanisms have been identified by which 
transcription factors regulate differentiation, including: auto regulation (factors that positively 
regulate their own expression), activation of lineage-specific genes, inhibition of alternative 
pathways, and inhibition of proliferation (Tenen, 2003).  In addition to the loss of cell cycle 
control, the loss of cellular differentiation is another common feature in many different types of 
human cancer.  It has been hypothesized that disruptions in the cell cycle may be the cause for 
the loss of differentiation, or that differentiation mechanisms are affected as secondary effects 
of carcinogenesis (Tenen, 2003).  It is also possible that the expression of oncogenes and 
inhibition of tumour suppressors directly impacts both the cell cycle and the differentiation 
process. To date the mechanism in which the neoplastic cells are able to block differentiation is 
still not completely understood. 
The human promyelomonocytic leukemic cell line, U937, is a well established model 
system for studying monocyte-macrophage differentiation (Piquemal et al., 2002).  Under 
normal conditions the process of monocyte to macrophage differentiation occurs once the 
monocyte arrives at the target tissue, where differentiation stimuli activate the differentiation 
process (Gonzalez-Mejia and Doseff, 2009).  In Acute Myeloid Leukemia the transcription 
factors that are crucial for the differentiation of monocytes are disrupted, either through 
mutations or chromosomal translocations (Tenen, 2003).  The U937 cell line originated from 
the pleural fluid of a patient diagnosed with acute promyelocytic lymphoma (Harris and Ralph, 
1985).    Treatment of U937 cells with phorbol 12-myristate 13-acetate (PMA), a protein kinase 
C activator, induces maturation from a monocytic cell into a macrophage (Kitamura et al., 
2004).  A number of phenotypic changes occur during this process, including adherence to the 
plate surface, gain of macrophage characteristics (phagocytosis, antibody-dependent cellular 
cytotoxicity, antigen presentation and chemotaxis), and the loss of proliferative potential 
(Kwon and Kim, 2003; Verhoeckx et al., 2004).  To date, numerous types of analyses have 
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been performed on this cell line, including gene expression (Tamayo et al., 1999; Piquemal et 
al., 2002; Kitamura et al., 2004), and proteomics (Verhoeckx et al., 2004) in an attempt to 
understand the process of differentiation.  Major gene expression changes occurring during 
differentiation have been reported, and involve genes associated with transcription and 
translation, as well as cytoskeleton and macrophage associated functions (Piquemal et al., 
2002).  Proteomic analysis of differentiating U937 cells revealed 226 proteins which were 
found to be significantly (p<0.05) up-regulated and largely involved with immune response, 
chemotaxis, cell growth, transport, cell adhesion, signal transduction and differentiation 
(Verhoeckx et al., 2004).  However, there is not a single report to date showing metabolic 
changes that are associated with this process. 
2.5 The Role of Lipids in Cellular Processes 
Cellular growth and maintenance in normal tissue is tightly regulated by the availability 
of nutrients and a balance of glycolysis and fatty acid synthesis, whereas tumour cells are able 
to bypass these regulatory checks and balances of lipogenesis to meet the high energy demands 
of increased proliferation and metabolism (Little and Kridel, 2008).  Lipogenesis has been 
recognized as one of the metabolic hallmarks of a tumour cell (Kuhajda, 2000).  
Lipids are a class of biological molecules that are typically hydrophobic in nature and 
soluble in organic solvents such as methanol, acetone, benzene and chloroform but only 
sparingly, if at all, in water (Fahy et al., 2005).  In general, there are three biological roles of 
lipids; they act as (a) storage molecules, (b) structural components of cellular membranes, and 
(c) cofactors and signalling molecules (van Meer, 2005; Watson, 2006).  Lipids are divided into 
eight distinct categories; fatty acids, glycerolipids, glycerophospholipids, sphingolipids, sterol 
lipids, prenol lipids, saccharolipids and polyketides (Fahy et al., 2005). 
Fatty acids are carboxylic acids with long-chain hydrocarbon side groups, which can 
either be saturated or unsaturated.  Fatty acids are rarely found to be free in nature; rather they 
are typically in an esterified form as the major lipid building block of complex lipids (such as 
glycerolipids and glycerophospholipids) (Fahy et al., 2005).  There are two sources of fatty 
acids for animal metabolism; they can be exogenously derived and attained through diet, or 
they can be endogenously synthesized by the animal (Menendez and Lupu, 2007). The de novo 
synthesis of fatty acids mainly occurs in the liver or adipose tissue in humans.  Pyruvate, the 
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end-product of glycolysis, is transported into mitochondria where it is converted into acetyl-
CoA by pyruvate dehydrogenase.  Acetyl-CoA is then condensed with oxaloacetate by citrate 
synthase to produce citrate.  Citrate molecules are then exported out of the mitochondria and 
into the cytosol, via the tricarboxylate transport system, where they are broken down into 
acetyl-CoA and oxaloacetate by ATP citrate lyase.  The oxaloacetate that is produced is 
converted by malate dehydrogenase back into malate, which in turn can either be transported 
back into the mitochondria or can be oxidatively decarboxylated to pyruvate by malic enzyme 
and then be returned to the mitochondria in this molecular form. 
Cytosolic acetyl-CoA and malonyl-CoA are then utilized in the synthesis of fatty acids in 
seven enzymatic reactions carried out by fatty acid synthase (FASN).  FASN is a 250-270kD 
multifunctional homodimeric polypeptide, comprised of seven separate functional domains; it 
is the sole protein that is capable of de novo synthesis of long-chain fatty acids from acetyl-
CoA, malonyl-CoA and nicotinamide adenine dinucleotide phosphate (NADPH) (Menendez et 
al., 2005; Kuhajda, 2006).  In healthy, well nourished individuals sufficient levels of fatty acids 
are acquired from dietary fat, which results in decreased demand for endogenous fatty acid 
synthesis (Menendez and Lupu, 2007).   
De novo fatty acid synthesis is active during embryogenesis, in foetal lung cells, and in 
hormone-sensitive cells where it is regulated by progesterone and oestradiol (Menendez and 
Lupu, 2007).  Over-expression and increased activity of FASN occurs during tumour 
development and progression, and is considered to be one of the most frequent phenotypic 
alterations to occur in carcinogenic cells (Kuhajda, 2000; Menendez et al., 2005).  FASN 
expression has been correlated with poor prognosis in numerous types of cancer (Little and 
Kridel, 2008).  In both breast and prostate cancer high levels of FASN expression have been 
associated with increased chance of recurrence and increased risk of death (Kuhajda, 2006). 
The endogenous de novo synthesis of fatty acids occurs in cancer cells regardless of the levels 
of exogenous lipids.  In fact, almost all esterified fatty acids in tumour cells are endogenously 
derived (Menendez and Lupu, 2007).  Growth factors and growth factor receptors have been 
identified as key players in the over-expression of FASN in cancer cells (Menendez and Lupu, 
2007).  
The discovery of the activation of FASN in tumours has led many researchers to focus 
their work on discovering methods of inhibiting the activity of the enzyme and many have had 
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success with small molecule inhibitors of FASN (Little and Kridel, 2008). FASN inhibition in 
cancer cells results in a decline of endogenous fatty acids as well as a decrease in cell 
proliferation, which is typically followed by apoptosis (Menendez and Lupu, 2007).  This 
inhibition of growth suggests that FASN may regulate metabolism, proliferation and survival in 
cancer cells. 
Fatty acids, either endogenously or exogenously synthesized, typically have two fates 
depending on the organism‟s metabolic needs.  During periods of rapid cellular growth the fatty 
acids are often incorporated into phospholipids, which are utilized in the synthesis of cellular 
membranes (van Meer et al., 2008). When the organism is not actively growing, the fatty acids 
are incorporated into glycerolipids, in particular triacylglycerols, for the storage of energy 
(Fahy et al., 2005). 
The generalized pathway illustrated in Figure 2.4 can be used as a reference for the 
following explanation of lipid synthesis in mammalian cells. Glycerolipids and phospholipids 
are synthesized from the same precursor metabolites, glycerol-3-phosphate and fatty acyl-CoA 
(activated fatty acid), and initially the same biosynthesis pathway.  The majority of glycerol-3-
phosphate is synthesized in the glycolytic pathway through the action of glycerol-3-phosphate 
dehydrogenase using dihydroxyacetone phosphate as a precursor (Bell and Coleman, 1980).  
The activation of a fatty acid to fatty acyl-CoA, by fatty acyl-CoA synthetase, is a requirement 
for nearly all of the metabolic fates of fatty acids in eukaryotes (Bell and Coleman, 1980). 
Glycerol-3-phosphate acyltransferase (GPAT) and acyl-glycerol-3-phosphate acyltransferase 
(AGPAT) transfer fatty acyl groups to glycerol-3-phosphate (Fagone and Jackowski, 2009).  
The acylation of glycerol-3-phosphate yield a molecule of phosphatidic acid, or diacylgycerol 
phosphate, an important intermediate in lipid synthesis (Fagone and Jackowski, 2009).  Both 
GPAT and AGPAT have been isolated from the endoplasmic reticulum (ER) and the 
mitochondria (Fagone and Jackowski, 2009).  If there is only one acylation of glycerol-3-
phosphate or hydrolysis of phosphatidic acid by phospholipase A2, the result is 
lysophosphatidic acid (LPA).  LPA was originally thought to merely be an intermediate in lipid 
metabolism, however, more recently it has been determined that LPA stimulates cell 
proliferation, migration and survival and in some cell types LPA is a lipid mediator that 
promotes growth-factor-like responses (Mills and Moolenaar, 2003).  Due to LPA‟s role in cell 
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Figure 2.4  The synthesis pathways of fatty acids, glycerolipids, glycerophospholipids, and ether lipids. 
This figure summarizes how and where lipids are synthesized in cells.  The pathway initiates with the transport of glucose into the cell, after 
which it continues through the glycolytic pathway and the TCA cycle in the mitochondria. Citrate that is synthesized in the mitochondria is 
exported out into the cytosol where it is used in the synthesis of fatty acids.  The fatty acids are transported to the endoplasmic reticulum for 
desaturation and elongation.  Glycerolipids and glycerophospholipids are synthesized in the endoplasmic reticulum.  The first two steps in the 
synthesis of ether lipids occur in the peroxisome, and are completed in the endoplasmic reticulum.  
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proliferation and migration it has become a target molecule of interest to cancer researchers, 
especially since the discovery that LPA is a key contributor to the metastasis in cancer (Mills 
and Moolenaar, 2003).  The next step in the lipid synthesis pathway is the dephosphorylation of 
phosphatidic acid by phosphatidic acid phosphatase, yielding 1,2-diacylglycerol.  
Diacylglycerols play many different functional roles in the cell, not only are they the precursor 
molecules for many classes of lipids (including triacylglycerols, phosphatidylcholines and 
phosphatidylethanolamines), but they also function as secondary messengers that are required 
for the activation protein kinase C (PKC) (Bell and Coleman, 1980). 
The structure of the major lipid classes in mammalian cells is illustrated in Figure 2.5.  
A description of each of these classes is detailed in the following paragraphs.  The sn-1, sn-2 
and sn-3 positions, which denote the first, second and third carbon atoms of the glycerol in a 
glycerol containing metabolite respectively, are labelled on the diacylglycerol structure.  The 
"sn" stands for stereospecifical or stereoselective numbering and indicates that only compounds 
with S configuration for glycerol are known to exist in living systems. The polar head group of 
a phospholipid is located at the sn-3 position.  The vinyl ether bond at the sn-1 position of ether 
lipids has also shown on the plasmenylethanolamine (ethanolamine plasmalogen) structure. 
A major component of eukaryotic cells are glycerolipids, in particular triacylglycerols, 
making up 10 to 90% of the dry weight of the cell depending on the cell type (Bell and 
Coleman, 1980).  Triacylglycerols, also known as triglycerides or neutral fats, are composed of 
three fatty acids each in ester linkage to a single glycerol (Turkish and Sturley, 2007). In most 
eukaryotic cells triacylglycerols form oily droplets in the cytosol, which are available as 
metabolic fuel when energy is required (Turkish and Sturley, 2007).  In most vertebrates 
triacylglycerols are actually stored in specialized fat cells, called adipocytes, in the form of fat 
droplets (Bell and Coleman, 1980).  These fat cells contain enzymes, called lipases, that 
catalyze the hydrolysis of the triacylglycerols releasing the fatty acids when the organism 
requires them for energy (Bell and Coleman, 1980). 
Glycerophospholipids are the major structural lipids in eukaryotic membranes, and 
include: phosphatidylcholine (PtdCho), phosphatidylethanolamine (PtdEtn), phosphatidylserine 
(PtdSer) and phosphatidylinositol (PtdIns) (van Meer et al., 2008).  PtdCho is the most 
abundant phospholipid in mammalian membranes, accounting for more than 50% of the lipid 
species in the membrane (van Meer et al., 2008; Fagone and Jackowski, 2009). 
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Figure 2.5  The structures of glycerolipids, glycerophospholipids and ether lipids. 
The „R‟ in the structures represents a fatty acid side chain.  The carbon atoms of the glycerol 
backbone in lipids are labelled as sn-1, sn-2 and sn-3.  The polar head groups of phospholipids 
are located at sn-3 position of the glycerol backbone and the vinyl-ether bond in ether lipids is 
located at sn-1.  Structures of these lipids were obtained from the Kyoto Encyclopedia of Genes 
and Genomes (KEGG) (www.genome.jp/kegg). 
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Glycerophospholipids are amphipathic lipids, consisting of two hydrophobic, non-polar, 
hydrocarbon chains and a hydrophilic phosphorylated polar head group (Fagone and 
Jackowski, 2009).  When exposed to water the glycerophospholipids can arrange into a lipid 
bilayer with the hydrophobic tails pointing towards the center of the bilayer and the polar head 
group facing out, creating a membrane (van Meer et al., 2008).  Cellular membranes are 
required for segregation and protection from the environment, cell-cell interactions, 
compartmentalization, storage, protein synthesis and secretion, phagocytosis and movement 
(Fagone and Jackowski, 2009).  The synthesis of PtdCho and PtdEtn requires the activation of 
choline, or ethanolamine, to CDP-choline and CDP-ethanolamine before the attachment of the 
head group to the diacylglycerol (Bell and Coleman, 1980). The addition of the choline head 
group to diacylglycerol, to yield PtdCho, is facilitated by diacylglycerol 
cholinephosphotransferase, and ethanolaminephosphotransferase facilitates the addition of the 
ethanolamine head group to form PtdEtn (Bell and Coleman, 1980). 
PtdCho is synthesized in the endoplasmic reticulum (ER) and the Golgi apparatus, and 
PtdEtn is synthesized in the ER (van Meer et al., 2008). Another important class of lipids are 
the ether-phospholipids, a special type of phospholipid characterized by the presence of ether 
linkage at the sn-1 position of the glycerol backbone, as compared to the ester bond present at 
the sn-1 position in diacylglycerophospholipids (Brites et al., 2004).  Two main types of ether 
bonds exist in nature: the ether bond found in platelet activating factor (PAF), and the vinyl-
ether bond that is found in plasmalogens (Brites et al., 2004).  Plasmalogens represent one in 
every five lipids in the human body (Nagan and Zoeller, 2001). 
Plasmalogens are not only structural components in the membrane, but they also play 
many other key roles in the cell.  Plasmalogens affect membrane dynamics, such as fusion and 
ion transport, they are also reservoirs for polyunsaturated fatty acids, and they are involved in 
intracellular signalling and may serve in a protective role during periods of oxidative stress 
(Farooqui and Horrocks, 2001; Nagan and Zoeller, 2001).  The vinyl-ether bond that is present 
in plasmalogens contains a cis double bond, adjacent to the ether bond, on the alkyl chain at the 
sn-1 position of the lipid (Nagan and Zoeller, 2001). The first step in the biosynthesis of 
plasmalogens requires dihydroxyacetone phosphate acyltransferase (DHAP-AT), which carries 
out the esterification of the free hydroxyl group of dihydroxyacetone phosphate (DHAP) with a 
long-chain acyl-CoA ester (Figure 2.6) (Brites et al., 2004).  The second step in the 
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Figure 2.6  Ether lipid synthesis. 
Ether lipid synthesis begins in the peroxisome with the esterification of DHAP by DHAPAT.  
The second step of the pathway is the addition of the ether bond at sn-1, which is catalyzed by 
ADHAP-S.  The third reaction is the reduction of the ketone group at sn-2, producing alkyl-
glycerone-3-phosphate (1-alkyl-G3P).  1-alkyl-G3P is then transported to the endoplasmic 
reticulum where it is acylated by AAG3P-AT in the fourth reaction. The fifth reaction is the 
removal of the phosphate group by a phosphohydrolase, producing 1-alkyl-2-acyl-sn-glycerol.  
The sixth reaction involves the addition of the ethanolamine head group by EPT, resulting in 
the synthesis of alkylacyl-GPE.  The final step of the pathway is the desaturation of alkylacyl-
GPE, which results in the synthesis of an ethanolamine plasmalogen.  Adapted from 
http://www.peroxisomedb.org  
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plasmalogen synthesis pathway creates the ether bond at the sn-1 position.  The reaction is 
catalyzed by alkyl-dihydroxyacetone phosphate synthase (ADHAP-S), and results in the 
replacement of the fatty acid at sn-1 with a long-chain fatty alcohol (Nagan and Zoeller, 2001; 
Brites et al., 2004).  These first two reactions in the synthesis of plasmalogens take place 
exclusively in the peroxisomes of the cell (Nagan and Zoeller, 2001).  Acyl/alkyl-
dihydroxyacetone phosphate reductase (AADHAP-R) catalyses the third reaction, which is the 
reduction of the ketone group at the sn-2 position of 1-alkyl-DHAP resulting in the formation 
of 1-alkyl-sn-glycero-3-phosphate (1-alkyl-G3P) (Brites et al., 2004).  Researchers have 
discovered that AADHAP-R is utilized in both the ether-lipid and diacyl-phospholipid 
pathways, and is therefore located in the peroxisome as well in the ER (Nagan and Zoeller, 
2001). The fourth reaction involves the acylation of 1-alkyl-G3P by alkyl/acyl-glycero-3-
phosphate acyltransferase (AAG3P-AT), resulting in 1-alkyl-2-acyl-glycero-3-phosphate 
(Brites et al., 2004).   When the phosphate group is removed from 1-alkyl-2-acyl-G3P by 
phosphohydrolase, 1-alkyl-2-acyl-sn-glycerol is formed (Brites et al., 2004).  At this point 
cytidine-diphosphate-ethanolamine (CDP-ethanolamine) phosphotransferase (EPT) catalyzes 
the attachment of the phosphoethanolamine head group to the lipid, resulting in 1-alkyl-2-acyl-
sn-glycero-3-phosphoethanolamine (alkylacyl-GPE) (Nagan and Zoeller, 2001).  The final step 
in the synthesis of an ethanolamine plasmalogen is the desaturation carried out by a cytochrome 
b5-dependent microsomal electron transport system and a 1-alkyl desaturase, resulting in 1-
alk-1-enyl-2-acyl-GPE (PE-plasmalogen) (Brites et al., 2004).  The choline plasmalogens (1-
alk-1-enyl-2-acyl-GPC) are typically formed from PE-plasmalogens with a polar-head group 
modification executed by a transferase.  Another type of ether lipid that can be synthesized in 
this pathway is 2-acyl-1(1-alkenyl)-sn-glycerol, a diacyl-ether lipid.  This type of ether lipid 
results from either the action of phospholipase C on ethanolamine plasmalogens or the 
phosphate removal from plasmenic acid by a hydrolase enzyme (Brites et al., 2004). 
Ether lipids, including plasmalogens, are probably one of the least known classes of 
lipids, likely due to the difficult process required to isolate them from cells (Nagan and Zoeller, 
2001).  A couple of decades ago many scientists would likely not have been familiar with ether 
lipids.  However, there has been a renewed interest in these lipids, likely inspired by the 
implication of plasmalogen deficiencies in various degenerative diseases, such as Zellweger‟s 
Syndrome (Schutgens et al., 1985), and Alzheimer‟s disease (Goodenowe et al., 2007).  With 
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the progress and ingenuity of scientific research today, in combination with the advancements 
made in technology, the isolation and analysis of these lipids is achievable and their importance 
in mammalian cells and systems has become more evident. 
 
The objective of this thesis was to investigate phenotypic changes in key cellular 
processes that are fundamental to cancer development and progression, using FTICR-MS, and 
to generate a data-driven hypothesis regarding how the metabolome of the cell is altered during 
the processes studied. 
The specific objectives were to characterize metabolic changes associated with: 
a) Cell-cycle progression; 
b) Differentiation; 
c) Oncogenic transformation. 
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3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Cell Lines 
CNA14 cells are derived from a parental rat fibroblast cell line, Rat2, and contain a 
temperature-sensitive mutation of the oncogene p130gag-fps.  P130gag-fps is the product of the 
Fujinami sarcoma virus (FSV) (Park and Seo, 1995). The parental Rat2 cell line was 
transfected with wild type FSV cDNA producing the NW16 cell line, and with the AX9m 
mutant FSV (which contains an insertion N-terminal to the kinase domain) which produced the 
NA9 line (Sadowski et al., 1986).  It was determined that the AX9m mutant cDNA could not 
transform the Rat2 cells; however, once the AX9m mutant gene was introduced into chicken 
cells, transformation occurred in a temperature-dependent manner (Sadowski et al., 1986).  
These results suggested that the chicken cells possess a cellular factor which allows the mutant 
FSV protein to transform the cells.  It was then discovered that transfection of the NA9 line 
with DNA from chicken cells gave rise to the CNA14 line, which was transformed at 34ºC but 
not at 39ºC.  CNA14 cells have a normal phenotype at 39ºC but are tumourigenic at 34ºC, due 
to the apparent incompatibility between a temperature-sensitive version of the oncogene 
p130gag-fps of FSV(functional at 34ºC, but not at 39ºC) and wild type p53 (expressed at 39ºC, 
but not at 34ºC) (Sadowski et al., 1986).  This model system allows comparisons to be made 
between normal and cancer cells with not only essentially „isogenic‟ cells, but also with a well 
characterized oncogene.  
Two cell lines were used as controls; Rat2 and NW16 cells.  The Rat2 cell line is the 
parental rat fibroblast cell line from which the CNA14 cells were derived, and the NW16 cells 
are a fibroblast cell line that constitutively expresses the wild type form of oncogene p130gag-
fps.  A mouse embryo cell line (10T1/2) was also used as a control cell line in the temperature 
shift experiments.  The CNA14, NW16 and Rat2 cells were supplied by Dr. Lambert Loh 
(University of Saskatchewan), and the 10T1/2 cells were purchased from ATCC (CCL-226, 
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Manassas, VA, USA).  Human promyelomonocytic leukemic U937 cells were used as a model 
system for the differentiation of monocytes into macrophages. These cells were derived by 
Sundstrom and Nilsson in 1974 from malignant cells obtained from the pleural effusion of a 
patient with histiocytic lymphoma (Sundstrom, 1976).  The treatment of U937 cells with 
phorbol 12-myristate 13-acetate (PMA) induces them to undergo monocytic differentiation.  
These cells were obtained from ATCC (CRL-1593.2; Manassas, VA, USA). 
MRC5 cells, low-passage human lung fibroblasts (Jacobs et al., 1970), were used for 
the metabolomic analysis of cell cycle progression.  When human cells, such as MRC5 cells, 
are grown in media containing low serum levels (0.1%) for 48 hours the cells arrest in the G0 
phase of the cell cycle (Schorl and Sedivy, 2007).  After the starvation period the low serum 
media is replaced with media containing normal serum levels (10%) and the cells re-enter the 
cell cycle where they complete one complete growth cycle as a synchronous population (Schorl 
and Sedivy, 2007).  MRC5 cells were obtained from ATCC (CCL-171; Manassas, VA, USA). 
3.1.2 Reagents and Supplies  
All chemicals, media and enzymes used were of analytical grade or higher, and were 
purchased from Sigma, Invitrogen or VWR unless otherwise stated.  RNA purification kits and 
Atlas Plastic Rat 4K microarray were purchased from BD Biosciences Clontech.  
3.2 Methods 
3.2.1 Tissue Culture Media and Techniques 
3.2.1.1 Cell Culture 
CNA14, Rat2, NW16, 10T1/2 and MRC5 cells were cultured in HyQ Dulbecco‟s 
modified Eagles medium (DMEM)/ High Glucose media, supplemented with 10% Fetalclone 
II serum (HyClone Laboratories, Logan, Utah, U.S.A), 100 U/mL penicillin and 100 μg/mL 
streptomycin (Gibco).  U937 cells were cultured in HyQ RPMI-1640 media, supplemented 
with 10% Fetalclone II serum or Bovine Calf Serum (HyClone Laboratories, Logan, Utah, 
USA), 100 U/mL penicillin and 100 μg/mL streptomycin (Gibco), 4.5 g/L of glucose and 10 
mM Hepes.  Cultures of U937 and MRC5 were maintained at 37˚C with 5% CO2 and 100% 
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relative humidity.  CNA14, Rat2, NW16 and 10T1/2 cells were grown at 37˚C, 34˚C and 39˚C 
with 5% CO2 and 100% relative humidity. 
To harvest adherent cells, the existing media was removed and cells were covered in a 
Dulbecco‟s Phosphate buffered saline (DPBS) solution containing 0.25% (w/v) trypsin-EDTA 
(4Na
+
) (Gibco) for 5 minutes, or until the cells began to lift off the plate.  To block the 
proteolytic action of the trypsin-EDTA, an excess of media containing serum was added.  The 
cells were resuspended and transferred to a 15 mL conical centrifuge tube for pelleting by 
centrifugation at 450 X g for 5 minutes.  Cell pellets were re-suspended in complete media and 
an aliquot of the cells was seeded into a new plate containing complete media.   
Cells used for mass spectrometry or microarray analysis were harvested as described 
above.  However, after the removal of the media, cells were rinsed three times with 5 mL of 
DPBS and on the final centrifugation the cells were spun at 500 X g for five minutes.  The 
DPBS was removed and the pellets were stored at -80°C until extraction could be completed.  
The storage of cells for later use were generated as follows: cells in 150 x 25 mm plates 
of approximately 80% confluence (log-phase growth) were harvested, as described above, and 
resuspended in 5 mL complete media with 10% (v/v) dimethyl sulfoxide (DMSO).  
Approximately 1.5 mL of cell suspension (10
6 
cells/mL) was added to 1.8 mL Cryotube™ vials 
(NUNC Brand Products), and the tubes were immediately placed at –80°C, and if required, 
transferred to liquid nitrogen for long-term storage. 
3.2.1.2 Temperature Shift Experiments 
The CNA14 cells were initially grown at 34˚C and 39˚C on 25 cm2 plates until they 
reached 50-60% confluence.  They were then shifted to the alternative temperatures (i.e. 34˚C 
to 39˚C and 39˚C to 34˚C), and samples were then collected at 0, 8, 16, 24, 48, 72 and 96 hours 
for analysis.  Along with the CNA14 cells, Rat2, 10T1/2 and NW16 cells were also cultured 
and grown at 34˚C, 39˚C and 37˚C to ensure that any metabolic changes observed were due to 
the oncogene expression and not merely due to the different growth conditions.  All harvested 
cells were extracted (protocol explained below) and analyzed by FTICR-MS. 
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3.2.1.3 Differentiation Experiment 
The treatment of U937 cells with phorbol 12-myristate 13-acetate (PMA) induces them 
to undergo monocytic differentiation (Harris and Ralph, 1985).  The cells were seeded at a 
density of 20 x 10
6
/ 30 mL 16 hours before PMA treatment.  A PMA stock was prepared by 
dissolving 1mg PMA in 1 mL DMSO (Sigma Aldrich, Oakville, ON).   The cells were treated 
with PMA (10 ng/mL) for 0, 1, 3, 6, 12, 24, 48, 72 and 96 hours.  Differentiated cells that had 
attached to the plate surface were detached from the plates with Trypsin/EDTA, they were then 
rinsed with PBS and immediately frozen at -80 C until extraction.  Untreated U937 cells 
(monocytes that grow in suspension) were also grown and harvested for use as a control. 
3.2.1.4 Cell Cycle Experiment 
Serum starvation was used in order to synchronize the cell populations for cell cycle 
analyses on the FTICR-MS.  MRC5 cells were grown to about 60% confluence in 150 cm Petri 
dishes.  The cells were then washed three times with HyQ Dulbecco‟s modified Eagle‟s 
medium (DMEM)/ High Glucose media (without serum), and then low serum media (0.1% 
foetal calf serum) was added to the plates.  The cells were incubated in the low serum media 
for a period of 48 hours, after which time the media was replaced with normal serum media 
(10%).  Cells were harvested at 0, 30 min, 2 hours, 6 hours, 12 hours, 24 hours and 48 hours.  
Cells that were not serum starved, and will be referred to as -48 hour timepoint, were also 
harvested.  Cell counts were completed using trypan blue stain and a haemocytometer to ensure 
that the same number of cells was harvested at each of the time points.  The cells were 
analyzed by flow cytometry, to determine the stage of the cell cycle the cells were in at each 
time point, and FTICR-MS to identify global metabolic changes that occur during the cell 
cycle (see method below). 
3.2.1.5 1,2,3-Benzene Tricarboxylic Acid (BTA) Treatment 
1,2,3-Benzentricarboxylic acid  (BTA) is used to inhibit the export of citrate out of the 
mitochondria, which in turn inhibits the de novo synthesis of lipids (Kajimoto et al., 2005).  
BTA was dissolved in ethanol to make a 0.5 M stock solution (Sigma Aldrich, Oakville, ON).  
U937 cells were treated with the BTA (5 mM) for three hours prior to the addition of PMA in 
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order to inhibit fatty acid synthesis prior to the initiation of differentiation.  After the 3 hours of 
pre-treatment with the BTA the PMA was added to the cells for 24 and 48 hours.  Some of the 
cells that were treated with both BTA and PMA for 24 hours were re-plated in fresh media 
after being rinsed with PBS, and left to grow for 24 and 48 hours after the re-plating.  The cells 
were counted before harvesting to ensure that 6 million cells were harvested from of each plate 
for metabolomics analysis.  The re-plated samples only had 2 million cells total to harvest, so 
metabolomics data has been adjusted three fold to account for the cell number difference. 
3.2.2 Fourier Transform Ion Cyclotron Resonance Mass Spectrometry (FTICR-MS) 
3.2.2.1 Metabolite Extraction 
Cell pellets were initially extracted with 0.5 mL of 1% ammonium hydroxide and 4 x 
2.5 mL of ethyl acetate.  Samples were sonicated for 20 seconds, then centrifuged at 4˚C for 10 
minutes at 1000 X g.  An additional 1.5 mL of 1% formic acid was added to each sample and 
the aqueous fraction was transferred to a new tube.  A portion (5 mL) of the ethyl acetate 
fraction was removed and evaporated to dryness, then reconstituted in 1mL of butanol.  All 
fractions were stored at -80˚C until needed for analysis. 
The extracted sample fractions were diluted prior to analysis using methanol: 0.1% 
(v/v) ammonium hydroxide (50: 50, v/v) for the negative ionization modes and methanol: 0.1% 
(v/v) formic acid (50: 50, v/v) for the positive ionization modes.  An internal standard mixture, 
which included; serine, tetra-alanine, reserpine, Hewlett-Packard tuning mix and the 
adrenocorticotrophic hormone fragment 4-10, was also added to each sample for the internal 
calibration of each sample spectrum (Aharoni et al., 2002). 
3.2.2.2 Sample Analysis 
The mass spectrometry analyses were performed on a Bruker Daltonics APEX III 
Fourier Transform Ion Cyclotron Resonance Mass Spectrometer that contains a 7.0 Tesla 
actively shielded superconducting magnet (Bruker Daltonics, Billerica, MA).  The organic and 
aqueous sample fractions were directly injected into an electrospray ionization (ESI) or 
atmospheric pressure chemical ionization (APCI) source in both positive and negative 
ionization modes (Gray, 2005).  Table 3.1 lists each of the analyses that were completed on the  
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Table 3.1  The different types of analyses completed on the FTICR-MS. 
Phenomenome Discoveries completes six analyses on each sample to ensure that as many 
metabolites are detected as possible.  Organic and aqueous extracts are collected from the 
sample.  Using an electrospray ionization source (ESI), both the organic and aqueous extracts 
are analyzed using positive and negative ionization.  The atmospheric pressure chemical 
ionization source (APCI) is used to analyze an organic extract of the sample, and both positive 
and negative ionization are applied. 
Ionization 
Source Extract 
Positive ESI Aqueous 
Negative ESI Aqueous 
Positive ESI Organic (butanol) 
Negative ESI Organic (butanol) 
Positive APCI Organic (Ethyl Acetate) 
Negative APCI Organic (Ethyl Acetate) 
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FTICR-MS.  The instrument conditions were tuned and optimized for ion intensity and 
broadband accumulation for a mass range between 100-1,000 accurate mass units (amu) 
(Aharoni et al., 2002). 
3.2.2.3 XMASS Peak Picking 
XMASS software (Bruker Daltonics) was used to acquire 1 megaword data files, which 
were then zero-filled to 2 megawords, and transformed prior to Fourier transformation and 
magnitude calculations (Aharoni et al., 2002; Gray, 2005).  The result is a complex mass 
spectrum of highly resolved mass-to-charge ratios.  The spectra from each of the samples was 
then put through a combination of automated and manual peak picking processes, selecting 
only sample specific compounds in the range of 100-2000 m/z.  Once all of the modes had 
been analyzed, the files were merged and converted into a form that could be viewed using 
Phenomenome Discoveries DISCOVAmetrics
TM
 bioinformatics software.  The software 
creates an array that allows multiple samples to be easily compared and mined for both known 
and novel metabolites. 
3.2.2.4 DISCOVAmetricsTM Data Mining and Statistics 
DISCOVAmetrics
TM
 software was used to generate two-dimensional (mass vs. sample 
intensity) arrays and for statistical analyses of the datasets.  Each row in the array contains the 
data for a unique mass, and each column is for an individual sample.  Unsupervised statistical 
techniques were used in order to identify significant metabolic changes between each of the 
samples, these approaches included; hierarchical clustering and principal component analysis 
(PCA).  These statistical strategies allow groups of similarly expressed metabolites to be 
identified and the visualization of the samples with similar, or dramatically different, metabolic 
profiles.  An explanation of these approaches can be found in the literature review of this 
thesis.  Hierarchical cluster analyses (HCA) and principal component analyses (PCA) were 
completed on the complete data sets in order to visualize them as a whole, and to determine if 
any masses were specific to specific samples or treatments.  The data was then analyzed with a 
two-tailed Student‟s t-test to identify the metabolites with the most significant intensity 
changes between samples, and those with a p<0.05 were deemed statistically significant.  Both 
HCA and PCA were completed on the data with p<0.05 (in some cases more stringent cut–offs 
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were used).  Each dataset was also normalized to the control samples in order to determine 
metabolic changes that were due to treatment or growth condition.  Student‟s t-tests were also 
used to filter out the significant changes between specific samples.   
Once the key masses had been identified through the different statistical analyses, a 
putative molecular formula and corresponding metabolite name were assigned to each of the 
masses. 
3.2.3 Multiple Reaction Monitoring (MRM) Triple Quadrupole Method 
All of the MRM triple quadrupole analyses were performed according to previously 
published methods (Goodenowe et al., 2007; Pastural et al., 2009).  The high-throughput 
screening of the lipids of interest was performed with a linear ion-trap mass spectrometer (4000 
Q Trap: Applied Biosystems) coupled with the Agilent 1100 LC system.  The sample was 
prepared by adding 15 μL of internal standard (5 μg/mL of [24-13C]-cholic acid (Cambridge 
Isotopes Laboratories, Andover, MA) in methanol) to 120 μL of the ethyl acetate fraction of 
each of the samples.  100 μL of the sample was injected by flow injection analysis, and 
monitored under negative atmospheric pressure chemical ionization (APCI) mode.  The 
method was based on multiple reaction monitoring of one parent/fragment for each metabolite 
of interest and (24-
13
C)-cholic acid.  Each transition was scanned for 70 ms.  The mobile phase 
was made up of 10% ethyl acetate in methanol at a flow rate of 360 μL/min.  The source 
parameters were set as follows: curtain gas (CUR): 10.0, collision-activated dissociation gas 
(CAD): 8, nebulizing current (NC): -4.0, temperature: 400, ion source gas 1: 30, ion source gas 
2: 50, interface heater: on.  The compound parameters were set as follows: declustering 
potential: -120, entrance potential: -10, NC: -4.0, collision energy (CE): -40, collision cell exit 
potential (CXP): -15.  The transitions that were used in these analyse are listed in Table 3.2.  
Standard curves were generated for all of the analytes to verify instrument linearity by serial 
dilution of a healthy normal serum extract, or a cell pellet extract, with a constant concentration 
of (24- 
13
C)-cholic acid.  All samples were analyzed in a randomized blinded manner and were 
bracketed by known standard dilutions.  All standard curves had R
2
 values more than 0.98. 
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Table 3.2(a-d).  Molecular formulae and MS/MS transitions for lipids analysed with the 
high-throughput Multiple Reaction Monitoring (MRM) Triple Quadrupole Method. 
a. Phosphatidylethanolamines (PtdEtn) and Ethanolamine Plasmalogens (PlsEtn), b. 
Phosphatidylcholine (PtdCho) and Choline Plasmalogens (PlsCho), c. Diacylglycerols (DAGs) 
and Triacylglycerols (TAGs) and d. Vinyl acylglycerols (VAGs) (b, c and d on following 
pages). 
a.  Phosphatidylethanolamines and ethanolamine plasmalogens  
 
 
 
Metabolite Name Molecular Formula Parent Mass M-H Mass Diagnostic Fragment Mass MS/MS Transition
PtdEtn 16:0/18:0 C39H78N1O8P1 719.54648 718.5 R1 (C16H31O2) - 255 718.5 / 255.2
PtdEtn 16:0/18:1 C39H76N1O8P1 717.53083 716.5 R1 (C16H31O2) - 255 716.5 / 255.2
PtdEtn 16:0/18:2 C39H74N1O8P1 715.51518 714.5 R1 (C16H31O2) - 255 714.5 / 255.2
PtdEtn 16:0/18:3 C39H72N1O8P1 713.49953 712.5 R1 (C16H31O2) - 255 712.5 / 255.2
PtdEtn 16:0/20:4 C41H74N1O8P1 739.51518 738.5 R1 (C16H31O2) - 255 738.5 / 255.2
PtdEtn 16:0/22:6 C43H74N1O8P1 763.51518 762.5 R1 (C16H31O2) - 255 762.5 / 255.2
PtdEtn 18:0/18:1 C41H80N1O8P1 745.56213 744.5 R1 (C18H35O2) - 283 744.5 / 283.2
PtdEtn 18:0/18:2 C41H78N1O8P1 743.54648 742.5 R1 (C18H35O2) - 283 742.5 / 283.2
PtdEtn 18:0/18:3 C41H76N1O8P1 741.53083 740.5 R1 (C18H35O2) - 283 740.5 / 283.2
PtdEtn 18:0/20:4 C43H78N1O8P1 767.54648 766.5 R1 (C18H35O2) - 283 766.5 / 283.2
PtdEtn 18:0/22:6 C45H78N1O8P1 791.54648 790.5 R1 (C18H35O2) - 283 790.5 / 283.2
PlsEtn 16:0/18:1 C39H76N1O7P1 701.53591 700.5 R2 (C18H33O2) - 281 700.5 / 281.2
PlsEtn 16:0/18:2 C39H74N1O7P1 699.52026 698.5 R2 (C18H31O2) - 279 698.5 / 279.2
PlsEtn 16:0/18:3 C39H72N1O7P1 697.50461 696.5 R2 (C18H29O2) - 277 696.5 / 277.2
PlsEtn 16:0/20:4 C41H74N1O7P1 723.52026 722.5 R2 (C20H31O2) - 303 722.5 / 303.2
PlsEtn 16:0/22:6 C43H74N1O7P1 747.52026 746.5 R2 (C22H31O2) - 327 746.5 / 327.2
PlsEtn 18:0/18:1 C41H80N1O7P1 729.56721 728.5 R2 (C18H33O2) - 281 728.5 / 281.2
PlsEtn 18:0/18:2 C41H78N1O7P1 727.55156 726.5 R2 (C18H31O2) - 279 726.5 / 279.2
PlsEtn 18:0/18:3 C41H76N1O7P1 725.53591 724.5 R2 (C18H29O2) - 277 724.5 / 277.2
PlsEtn 18:0/20:4 C43H78N1O7P1 751.55156 750.5 R2 (C20H31O2) - 303 750.6 / 303.2
PlsEtn 18:0/22:6 C45H78N1O7P1 775.55156 774.5 R2 (C22H31O2) - 327 774.5 / 327.2
PtdEtn 18:1/18:1 C41H78N1O8P1 743.54651 742.5 R1 (C18H33O2) - 281.2 742.5 / 281.2
PtdEtn 18:1/18:2 C41H76N1O8P1 741.53086 740.5 R1 (C18H33O2) - 281.2 740.5 / 281.2
PtdEtn 18:1/18:3 C41H74N1O8P1 739.51521 738.5 R1 (C18H33O2) - 281.2 738.5 / 281.2
PtdEtn 18:1/20:4 C43H76N1O8P1 765.53086 764.5 R1 (C18H33O2) - 281.2 764.5 / 281.2
PtdEtn 18:1/22:6 C45H76N1O8P1 789.53086 788.5 R1 (C18H33O2) - 281.2 788.5 / 281.2
PlsEtn 18:1/18:1 C41H78N1O7P1 727.55159 726.5 R2 (C18H33O2) - 281 726.5 / 281.2
PlsEtn 18:1/18:2 C41H76N1O7P1 725.53594 724.5 R2 (C18H31O2) - 279 724.5 / 279.2
PlsEtn 18:1/18:3 C41H74N1O7P1 723.52029 722.5 R2 (C18H29O2) - 277 722.5 / 277.2
PlsEtn 18:1/20:4 C43H76N1O7P1 749.53594 748.5 R2 (C20H31O2) - 303 748.5 / 303.2
PlsEtn 18:1/22:6 C45H76N1O7P1 773.53594 772.5 R2 (C22H31O2) - 327 772.5 / 327.2
Free 22:6 C22H32O2 328.24022 327.2 283 327.2 / 283.2
Free 20:4 C20H32O2 304.24022 303.2 259 303.2 / 259.2
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b.  Phosphatidylcholines and choline plasmalogens  
 
 
Metabolite Name Molecular Formula Parent Mass M+H Mass Diagnostic Fragment Mass Transition
PtdCh 16:0/18:0 C42H84NO8P 761.5935 762.6 R1 (C16H31O2) - 255.2 762.6 / 184.2
PtdCho 16:0/18:1 C42H82N1O8P1 759.5778 760.6 R1 (C16H31O2) - 255 760.6 / 184.2
PtdCho 16:0/18:2 C42H80N1O8P1 757.5621 758.6 R1 (C16H31O2) - 255 758.6 / 184.2
PtdCho 16:0/18:3 C42H78N1O8P1 755.5464 756.5 R1 (C16H31O2) - 255 756.5 / 184.2
PtdCho 16:0/20:4 C44H80N1O8P1 781.5600 782.6 R1 (C16H31O2) - 255 782.6 / 184.2
PtdCho 16:0/22:6 C46H80N1O8P1 805.5622 806.6 R1 (C16H31O2) - 255 806.6 / 184.2
PtdCho 18:0/18:1 C44H86N1O8P1 787.6090 788.6 R1 (C16H31O2) - 255 788.6 / 184.2
PtdCho 18:0/18:2 C44H84N1O8P1 785.5900 786.6 R1 (C16H31O2) - 255 786.6 / 184.2
PtdCho 18:0/18:3 C44H82N1O8P1 783.5778 784.6 R1 (C16H31O2) - 255 784.6 / 184.2
PtdCho 18:0/20:4 C46H84N1O8P1 809.5930 810.6 R1 (C16H31O2) - 255 810.6 / 184.2
PtdCho 18:0/22:6 C48H84N1O8P1 833.5930 834.6 R1 (C16H31O2) - 255 834.6 / 184.2
PlsCho 16:0/18:1 C42H84N1O7P1 745.5985 746.6 R2 (C18H33O2) - 281 746.6 / 184.2
PlsCho 16:0/18:2 C42H82N1O7P1 743.5829 744.6 R2 (C18H31O2) - 279 744.6 / 184.2
PlsCho 16:0/18:3 C42H80N1O7P1 741.5672 742.6 R2 (C18H29O2) - 277 742.6 / 184.2
PlsCho 16:0/20:4 C44H82N1O7P1 767.5829 768.6 R2 (C20H31O2) - 303 768.6 / 184.2
PlsCho 16:0/22:6 C46H82N1O7P1 791.5829 792.6 R2 (C22H31O2) - 327 792.6 / 184.2
PlsCho 18:0/18:1 C44H88N1O7P1 773.6298 774.6 R2 (C18H33O2) - 281 774.6 / 184.2
PlsCho 18:0/18:2 C44H86N1O7P1 771.6141 772.6 R2 (C18H31O2) - 279 772.6 / 184.2
PlsCho 18:0/18:3 C44H84N1O7P1 769.5985 770.6 R2 (C18H29O2) - 277 770.6 / 184.2
PlsCho 18:0/20:4 C46H86N1O7P1 795.6142 796.6 R2 (C20H31O2) - 303 796.6 / 184.2
PlsCho 18:0/22:6 C48H86N1O7P1 819.6142 820.6 R2 (C22H31O2) - 327 820.6 / 184.2
PtdCho 18:1/18:1 C44H84N1O8P1 785.5934 786.6 R1 (C16H31O2) - 255 786.6 / 184.2
PtdCho 18:1/18:2 C44H82N1O8P1 783.5778 784.6 R1 (C16H31O2) - 255 784.6 / 184.2
PtdCho 18:1/18:3 C44H80N1O8P1 781.5621 782.6 R1 (C16H31O2) - 255 782.6 / 184.2
PtdCho 18:1/20:4 C46H82N1O8P1 807.5770 808.6 R1 (C16H31O2) - 255 808.6 / 184.2
PtdCho 18:1/22:6 C48H82N1O8P1 831.5778 832.6 R1 (C16H31O2) - 255 832.6 / 184.2
PlsCho 18:1/18:1 C44H86N1O7P1 771.6142 772.6 R2 (C18H33O2) - 281 772.6 / 184.2
PlsCho 18:1/18:2 C44H84N1O7P1 769.5985 770.6 R2 (C18H31O2) - 279 770.6 / 184.2
PlsCho 18:1/18:3 C44H82N1O7P1 767.5828 768.6 R2 (C18H29O2) - 277 768.6 / 184.2
PlsCho 18:1/20:4 C46H84N1O7P1 793.5985 794.6 R2 (C20H31O2) - 303 794.6 / 184.2
PlsCho 18:1/22:6 C48H84N1O7P1 817.5985 818.6 R2 (C22H31O2) - 327 818.6 / 184.2
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c.  Diacylglycerols and triacylglycerols  
 
 
R1 R2
TAG 16:0/14:0 C53H96O6 828.7561 829.8 (C16H31O) - 239.2 (10%) (C14H27O) - 211.2 (8%) 829.8 / 239.2
TAG 16:0/14:0 C53H96O6 828.7561 829.8 (C16H31O) - 239.2 (10%) (C14H27O) - 211.2 (8%) 829.8 / 211.2
TAG 16:0/18:1 C53H98O6 830.7876 831.8 (C16H31O) - 239.2 (22%) (C18H33O) - 265.2 (27.8%) 831.8 / 239.2
TAG 16:0/18:1 C53H98O6 830.7876 831.8 (C16H31O) - 239.2 (22%) (C18H33O) - 265.2 (27.8%) 831.8 / 265.2
TAG 16:1/18:1 C53H100O6 832.8206 833.8 (C16H29O) - 237.2 (50%) (C18H33O) - 265.2 (50%) 833.8 / 237.2
TAG 16:1/18:1 C53H100O6 832.8206 833.8 (C16H29O) - 237.2 (50%) (C18H33O) - 265.2 (50%) 833.8 / 265.2
TAG 16:0/18:2 C55H100O6 856.7900 857.8 (C16H31O) - 239.2 (5.5%) (C18H31O) - 263.2 (4%) 857.8 / 239.2
TAG 16:0/18:2 C55H100O6 856.7900 857.8 (C16H31O) - 239.2 (5.5%) (C18H31O) - 263.2 (4%) 857.8 / 263.2
TAG 16:0/18:1 C55H102O6 858.8197 859.8 (C16H31O) - 239.2 (5%) (C18H33O) - 265.2 (5%) 859.8 / 239.2
TAG 16:0/18:1 C55H102O6 858.8197 859.8 (C16H31O) - 239.2 (5%) (C18H33O) - 265.2 (5%) 859.8 / 265.2
DAG 18:0/18:1 C39H74O5 622.5536 623.5 (C18H35O) - 267.2 R2 (C18H33O) - 265.2 623.5 / 267.2
DAG 18:0/18:2 C39H72O5 620.5379 621.5 (C18H35O) - 267.2 R2 (C18H31O) - 263.2 621.5 / 267.2
DAG 18:1/18:1 C39H72O5 620.5379 621.5 (C18H33O) - 265.2 R2 (C18H33O) - 265.2 621.5 / 265.2
DAG 18:1/18:2 C39H70O5 618.5223 619.5 (C18H33O) - 265.2 R2 (C18H31O) - 263.2 619.5 / 265.2
DAG 18:1/18:3 C39H68O5 616.5066 617.5 (C18H33O) - 265.2 R2 (C18H29O) - 261.2 617.5 / 265.2
DAG 18:1/20:4 C41H70O5 642.5223 643.5 (C18H33O) - 265.2 R2 (C20H31O) - 287.2 643.5 / 265.2
DAG 16:0/18:3 C37H66O5 590.4910 591.5 (C16H31O) - 239.2 R2 (C18H29O) - 261.2 591.5 / 239.2
DAG 16:1/18:2 C37H66O5 590.4910 591.5 R1 (C16H29O) - 237.2 R2 (C18H31O) - 263.2 591.5 / 237.2
DAG 18:0/18:3 C39H70O5 618.5223 619.5 (C18H35O) - 267.2 R2 (C18H29O) - 261.2 619.5 / 267.2
DAG 18:0/20:4 C41H72O5 644.5379 645.5 (C18H35O) - 267.2 R2 (C20H31O) - 287.2 645.5 / 267.2
DAG 18:0/22:6 C43H72O5 668.5379 669.5 (C18H35O) - 267.2 R2 (C22H31O) - 311.2 669.5 / 267.2
DAG 18:1/22:6 C43H70O5 666.5223 667.5 (C18H33O) - 265.2 R2 (C22H31O) - 311.2 667.5 / 265.2
DAG 16:0/18:1 C37H70O5 594.5223 595.5 (C16H31O) - 239.2 R2 (C18H33O) - 265.2 595.5 / 239.2
DAG 16:0/18:2 C37H68O5 592.5066 593.5 (C16H31O) - 239.2 R2 (C18H31O) - 263.2 593.5 / 239.2
DAG 16:0/20:4 C39H68O5 616.5066 617.5 (C16H31O) - 239.2 R2 (C20H31O) - 287.2 617.5 / 239.2
DAG M16:0/22:6 C41H68O5 640.5066 641.5 (C16H31O) - 239.2 R2 (C22H31O) - 311.2 641.5 / 239.2
DAG 16:1/18:1 C37H68O5 592.5067 593.5 R1 (C16H29O) - 237.2 R2 (C18H33O) - 265.2 593.5 / 237.2
DAG 16:1/18:3 C37H64O5 588.4753 589.5 R1 (C16H29O) - 237.2 R2 (C18H29O) - 261.2 589.5 / 237.2
DAG 16:1/20:4 C39H66O5 614.4910 615.5 R1 (C16H29O) - 237.2 R2 (C20H31O) - 287.2 615.5 / 237.2
DAG 16:1/22:6 C41H66O5 638.4910 639.5 R1 (C16H29O) - 237.2 R2 (C22H31O) - 311.2 639.5 / 237.2
(Intensity %) MS/MS TransitionParent Mass M+H MassMetabolite Name Molecular Formula
Diagnostic Fragment Mass
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d.  Vinylacyl glycerols (2-Acyl-1-(1-alkenyl)-sn-glycerols  
 
  
R1 R2
VAG 18:0/18:1 C39H74O4 606.5587 607.5 (C18H35O) - 267.2 R2 (C18H35O) - 267.2 607.5 / 267.2
VAG 18:0/18:2 C39H72O4 604.543 605.5 (C18H35O) - 267.2 R2 (C18H33O) - 265.2 605.5 / 267.2
VAG 18:0/18:3 C39H70O4 602.5274 603.5 (C18H35O) - 267.2 R2 (C18H31O) - 263.2 603.5 / 267.2
VAG 18:0/20:4 C41H72O4 628.543 629.5 (C18H35O) - 267.2 R2 (C20H33O) - 289.2 629.5 / 267.2
VAG 18:0/22:6 C43H72O4 652.543 653.5 (C18H35O) - 267.2 R2 (C22H33O) - 313.2 653.5 / 267.2
VAG 18:1/18:1 C39H72O4 604.543 605.5 (C18H33O) - 265.2 R2 (C18H35O) - 267.2 605.5 / 265.2
VAG 18:1/18:2 C39H70O4 602.5274 603.5 (C18H33O) - 265.2 R2 (C18H33O) - 265.2 603.5 / 265.2
VAG 18:1/18:3 C39H68O4 600.5117 601.5 (C18H33O) - 265.2 R2 (C18H31O) - 263.2 601.5 / 265.2
VAG 18:1/20:4 C41H70O4 626.5274 627.5 (C18H33O) - 265.2 R2 (C20H33O) - 289.2 627.5 / 265.2
VAG 18:1/22:6 C43H70O4 650.5274 651.5 (C18H33O) - 265.2 R2 (C22H33O) - 313.2 651.5 / 265.2
VAG 16:0/18:1 C37H70O4 578.5274 579.5 (C16H31O) - 239.2 R2 (C18H35O) - 267.2 579.5 / 239.2
VAG 16:0/18:2 C37H68O4 576.5117 577.5 (C16H31O) - 239.2 R2 (C18H33O) - 265.2 577.5 / 239.2
VAG 16:0/18:3 C37H66O4 574.4961 575.5 (C16H31O) - 239.2 R2 (C18H31O) 18- 263.2 575.5 / 239.2
VAG 16:0/20:4 C39H68O4 600.5117 601.5 (C16H31O) - 239.2 R2 (C20H33O) - 289.2 601.5 / 239.2
VAG 16:0/22:6 C41H68O4 624.5117 625.5 (C16H31O) - 239.2 R2 (C22H33O) - 313.2 625.5 / 239.2
VAG 16:1/18:1 C37H68O4 576.5118 577.5  (C16H29O) - 237.2 R2 (C18H35O) - 267.2 577.5 / 237.2
VAG 16:1/18:2 C37H66O4 574.4961 575.5  (C16H29O) - 237.2 R2 (C18H33O) - 265.2 575.5 / 237.2
VAG 16:1/18:3 C37H64O4 572.4804 573.5 (C16H29O) - 237.2 R2 (C18H31O) - 263.2 573.5 / 237.2
VAG 16:1/20:4 C39H66O4 598.4961 599.5  (C16H29O) - 237.2 R2 (C20H33O) - 289.2 599.5 / 237.2
VAG 16:1/22:6 C41H66O4 622.4961 623.5 (C16H29O) - 237.2 R2 (C22H33O) - 313.2 623.5 / 237.2
VAG 14:0/18:1 C35H66O4 550.4961 551.5 (C14H27O) - 211.2 R2 (C18H35O) - 267.2 551.5 / 211.1
VAG 14:0/18:2 C35H64O4 548.4805 549.5 (C14H27O) - 211.2 R2 (C18H33O) - 265.2 549.5 / 211.1
VAG 14:0/18:3 C35H62O4 546.4846 547.5  (C14H27O) - 211.2 R2 (C18H31O) - 263.2 547.5 / 211.1
VAG 14:0/20:4 C37H64O4 572.4804 573.5  (C14H27O) - 211.2 R2 (C20H33O) - 289.2 573.5 / 211.1
VAG 14:0/22:6 C39H64O4 596.4805 597.5  (C14H27O) - 211.2 R2 (C22H33O) - 313.2 597.5 / 211.1
VAG 12:0/18:2 C33H60O4 520.4492 521.4 (C12H23O) - 183.2 R2 (C18H33O) - 265.2 521.4 / 183.2
VAG 12:0/2:0 C17H32O4 300.23 301.2  (C12H23O) - 183.2 301.2 / 183.2
Parent Mass M+H Mass
Diagnostic Fragment Mass
MS/MS Transition(Intensity %)Metabolite Name Molecular Formula
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3.2.4 Real Time-Polymerase Chain Reaction (RT-PCR) 
Total RNA was isolated from cell pellets using the Qiagen RNeasy Mini Kit as per 
manufacturer‟s instruction.  The RNA pellets were resuspended in 50 μL of DEPC-treated 
water and stored at -80°C.  RNA concentration and purity were determined by 
spectrophotometry at 260 nm (DNA) and 280 nm (protein) repectively.  Reverse transcription 
was performed using qScript cDNA super mix (Quanta Biosciences) on an Applied Biosystems 
Step one Plus Real-time PCR system.  The real-time PCR primers that were used are listed in 
Table 3.3. 
3.2.5 Gene Expression of CNA14 Cells at 34ºC and 39ºC 
3.2.5.1 RNA Isolation 
Total RNA was isolated using a Nucleospin RNA II Kit (BD Biosciences).  Cells were 
grown to approximately 80% confluency in complete media in a 15 cm
2
 plate as described 
above.  The media was removed from the plate and the cells were rinsed with phosphate-
buffered saline (PBS).  Total RNA was isolated according to the manufacturer‟s instructions 
for RNA isolation from cultured cells.  The mRNA was isolated from the total RNA using BD 
Biosciences NucleoTrap Nucleic Acid Kit, following the manufacture‟s protocol for mRNA 
purification.  The poly (A)
+ 
mRNA was concentrated using a protocol obtained from Protocol-
online.org.  One tenth volume of 3 M NaAc (pH 5.2) and 2.5 volumes of 100% ethanol were 
added to the mRNA pellet.  The pellet was mixed and incubated at -20°C overnight. The tube 
was then centrifuged at 15,000 X g for 20 minutes at 4°C.  The pellet was washed twice with 
80% ethanol and then air dried.  The pellet was re-suspended in RNAse-DNAse free water, and 
then stored at -80°C until needed.  RNA concentrations and purity were determined by 
measuring the absorbance of the RNA samples at wavelengths of 260 and 280 nm using a 
spectrophotometer.  
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Table 3.3.  Real-time polymerase chain reaction (RT-PCR) primers. 
The primer sequences used for the quantitative analysis of transcript levels for the following 
genes: glyceraldehyde 3-phosphate dehydrogenase (GAPDH), fatty acid synthase (FASN), 1-
acylglycerol-3-phosphate O-acyltransferase (AGPAT1 and AGPAT2), glycerol-3-phosphate 
acyltransferase (GPATM), peroxisomal membrane protein 11a (Pex11A), phospholipase C 
(PLC). 
 
 
Gene Amplicon Sequences (5' to 3')
GAPDH- Forward 226 bp GAAGGTGAAGGTCGGAGTC
GAPDH- Reverse GAAGATGGTGATGGGATTTC
FASN- Forward 156 bp GAGAGCCTCTTCTCCAGGGT
FASN- Reverse CTTCAGAGACTCCACCCAGC
AGPAT1- Forward 191 bp CATCAGGTGCTGCACTCACT
AGPAT1- Reverse AGTTGTGGGAACAGGTCTGG
AGPAT2- Forward 192 bp GTACTTTTACGGGCTCCGCT
AGPAT2- Reverse AGGTACATGATGAGGCCCAC
GPATM- Forward 183 bp CCAGCCTGTGCTACCTTCTC
GPATM- Reverse GAAGCTTCTTGTCCCACTGC
Pex11a- Forward 94 bp TGGCATCATTGGACTTGGAGGTCT
Pex11a- Reverse AACACCCTAACGGGTCTTCAGCTT
PLC-b1-Forward 194 bp CGTGGCTTTCCAAGAAGAAG
PLC-b1-Reverse GCTTCCGATCTGCTGAAAAC
PLC-g2-Forward 208bp CCTGTCCATTGAGGACCACT
PLC-g2-Reverse CATGGATGTAGGCACCTCCT
PLC-d1-Forward 123bp ACAAGATCATCCACCACTCAGGCT
PLC-d1-Reverse TCTGCAGCTCCTTGAAGCTCATCT
PLC-e1-Forward 194pb AATGATGCTGAAGAACGCCAGCC
PLC-e1-Reverse AGCAAAGGTAGTCGACTGGCAAGA
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3.2.5.2 MicroArray Analysis 
A BD Atlas
TM
 plastic rat 4K microarray (BD Biosciences Clontech) was used to 
analyze the gene expression differences between the CNA14 cells grown at 34°C and 39°C.  
As per manufacturer‟s directions, cDNA probes were prepared and were purified using column 
chromatography.  The radioactivity of the probe was determined by scintillation spectrometry.  
The plastic microarray was pre-rinsed and then the cDNA probes were hybridized to the array 
overnight at 60°C.  The next day the microarray was rinsed and air dried completely.  Once it 
had dried, the microarray was exposed to a 
33
P Phosphorimaging screen for 48 hours.  
However, after this period it was determined a longer exposure was necessary, so it was left for 
a period of 10 days.  The phosphorimaging screen was scanned and analyzed at the Saskatoon 
Cancer Center.  Quantity-One software (Bio-Rad) was used to visualize and analyze the 
microarray. 
3.2.6 Cell Cycle Analysis 
3.2.6.1 Flow Cytometry 
Harvested cells were re-suspended in 1% (vol/vol) of formaldehyde, and left for 15 
minutes at room temperature.  The cells were then centrifuged at 500 X g for 5 minutes in 
order to remove the formaldehyde from the cells.  The pellets were resuspended in ice-cold 
ethanol (70%).  After a 12 hour fixation period at -20°C the samples were centrifuged at 500 X 
g for 5 minutes and then resuspended in PBS containing 18 μg/mL propidium iodide and 40 
μg/mL heat-treated pancreatic ribonuclease A for 20 min at room temperature.  The cells 
were then kept on ice and shielded from light.  The flow cytometry work was completed on an 
EPICS XL flow cytometer (Coulter Electronics, Miami, FL) at the Saskatoon Cancer Center. 
3.2.7 Western Blot Analysis 
The Western blot analysis was completed under the supervision and direction of Dr. 
Gerald Davies of Phenomenome Discoveries.  The differentiated (attached) U937 cells were 
removed from tissue culture dishes using with Versene and TrypLE Express (Invitrogen), and 
rinsed with PBS three times.  The cells that were growing in suspension were pelleted by 
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centrifugation at 1000 X g to remove the media, and where then rinsed with PBS three times. 
The cells were pelleted by chilled (4°C) centrifugation at 1000 X g and the pellets resuspended 
in ice-cold lysis buffer (20 mM HEPES (pH 7.5), 50 mM KCl, 10% glycerol, 0.5 mM EDTA, 
0.1 mM EGTA, 1 mM DTT plus 1X mammalian cell anti-protease cocktail (Sigma-Aldrich 
Ltd). The cells were lysed using multiple freeze-thaw cycles followed by pulse sonication and 
centrifugation at 1000 X g to remove cell debris.  Western blot analysis of these protein lysates 
was performed as previously described (Davies et al., 2005).  Briefly, equivalent amounts of 
protein (assessed by Bradford protein assay (Bradford, 1976) using BioRad Protein Reagent) 
were resolved by 10% sodium dodecyl sulfate–polyacrylamide gel electrophoresis (SDS-
PAGE). Following electrophoresis the proteins were trans-blotted onto nitrocellulose 
membranes (Pall-VWR). The membranes were blocked overnight at 4°C on a gyratory plate 
with 5% molecular grade skim milk powder (BioRad Laboratories Ltd.) in phosphate-buffered 
saline (PBS) containing 0.1% Tween-20 (PBST). Primary and secondary antibody incubations 
and subsequent washes were carried out in the same buffer. Primary antibodies were obtained 
from Santa Cruz Biotechnology. The primary antibody for GAPDH was purchased from 
Sigma-Aldrich Ltd.. Secondary HRP-conjugated antibodies were purchased from BioRad 
Laboratories Ltd.. Blots were immunoprobed overnight with primary antibodies at a 1:1000 
dilution.  Secondary antibodies were applied at room temperature on a gyratory plate at a 
concentration of 1:10,000 for 30 min. Following multiple washes, an enhanced 
chemiluminescence detection system (Dupont-NEN) was used to detect the target 
antigen/antibody complexes. Blots were then stripped at 50°C for 30 minutes in a Tris-buffered 
20% SDS/1% 2-mercaptoethanol stripping solution, washed and re-probed with GAPDH to 
verify protein loading equivalency. 
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4 RESULTS 
4.1 Metabolic Alterations Associated with Cell Cycle Progression 
4.1.1 Flow Cytometry 
Serum starvation of low passage MRC5 cells, a human fibroblast cell line, was used as 
a model system for studying metabolic alterations associated with cell cycle progression.  
Reduction of serum levels in the media to 0.1% for 48 hours forced the MRC5 cells into the G0 
stage, or quiescent state, of the cell cycle.  Once normal levels of serum were returned to the 
media, cells re-entered the cell cycle and continued to grow as a synchronous population for 
one complete cell cycle.  Cells were collected before, during and after the serum starvation to 
ensure that populations of cells at each of the stages in the cell cycle were captured. 
Flow cytometry is a method used to distinguish cells in different phases of the cell 
cycle.  Flow cytometry can be used to quantitatively measure the DNA content in the cells.  
The DNA in a cell doubles during the synthesis phase (S phase) of the cell cycle, therefore it is 
possible to determine whether cells are in the G0 phase and G1 phase (prior to DNA doubling), 
or in the G2/M stage (after the DNA doubling) solely based on DNA content.  The results of 
our flow cytometry analysis of the MRC5 cells suggest that the cells were synchronized in the 
G0 phase of the cell cycle after the serum starvation (Figure 4.1). 
The control cells, those growing asynchronously, appear to be mostly in the G0 or G1 
stage of the cell cycle.  The broadness of the peak suggests that cells are in various stages of 
the cell cycle.  The analysis of the 0 hour time point, which was collected immediately 
following the 48 hour serum starvation, revealed that the cells were in the G0/G1 phase of the 
cell cycle.  The more defined peak shape suggests that the cells appear to be synchronized in 
G0.  Very few changes in DNA content were observed in the cells collected up to 12 hours 
after the synchronization.  It is likely that the cells have entered the G1 stage of the cycle 
within 6 hours, which is the stage when cells are doubling all cellular components except 
DNA.  
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Figure 4.1.  Flow cytometry analysis of MRC5 cells (low passage human fibroblasts) as 
they progress through the cell cycle. 
Flow cytometry was employed to determine which stage of the cell cycle each collection was 
at.  The cell count for each sample is listed on the Y axis of each plot, and the DNA content on 
the X axis.  It is not possible to discriminate between G1 and G0 using flow cytometry as the 
DNA content at the two stages will be the same.  The cells that have entered into the G2 phase 
of the cell cycle have twice the amount of DNA content as they have completed the synthesis 
(S) phase of the cell cycle. 
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As expected, 24 hours after the starvation period I see a large increase of cells in the S phase of 
the cell cycle.  All cells appeared to have completed one cell cycle by 24 hours and were more 
than 100% confluent.  Consequently, there were also numerous suspended cells in these plates, 
which were not observed in any of the other time points.  The flow cytometry analysis revealed 
that the attached cells had likely arrested in G1, or into G0 probably due to contact inhibition, 
whereas the suspended cells were mostly apoptotic, or arrested in G1/G0. 
4.1.2 Data Alignment and Array Generation 
Samples at corresponding time points were extracted into aqueous and organic phases, 
as described in the materials and methods section, and then analyzed of the FTICR-MS using 
both electrospray ionization and atmospheric pressure chemical ionization.  Accurate masses 
for 1075 compounds were detected in the analysis.  The resulting spectra were aligned and a 
two dimensional array was created, allowing the visualization of the FTICR-MS analysis 
(Figure 4.2).  Each column in the array represents a sample, and each row represents a unique 
mass.  The samples are ordered with the control samples at the left hand side followed by the 0 
hour time point (samples collected after the 48 hour serum starvation), then the 30 min, 2 
hours, 6 hours, 12 hours, 24 hours and 48 hours samples.  Duplicate samples were collected at 
each time point.  Reproducibility of the mass spectrometry analyses was determined for each of 
the replicates by plotting the log2 intensity of the replicates and calculating the R
2
 values 
(Pearson correlation coefficient) (Figure 4.3).  The R
2 
value for the entire experiment was 
found to be 0.88, suggesting good reproducibility in the experiment. 
4.1.3 Unsupervised Statistical Analyses 
Masses with p-value less than 0.001 (292 masses) were further selected and statistical 
analyses were performed.  The principal component analysis (PCA) plot indicates that 
synchronization of the cells by serum starvation alone results in a substantial metabolic shift 
(Figure 4.4).  The difference between the location of the control samples and the cluster of 
samples containing the 0, 30 min and 2 hour time points indicate metabolic changes occur after 
the cells have gone through serum starvation.  There is then a significant separation between 
the early time point cluster (up to 2 hours after serum re-introduction to the starved cells) and 
the 6, 12 and 24 hour time points.  The later time points cluster on the opposite side 
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Figure 4.2  Metabolite array of all metabolites detected in MRC5 cells as they progress through 
the cell cycle. 
A two dimensional array of masses detected in the analysis of MRC5 cells as they progress through the 
cell cycle (p<0.001).  Each sample is in duplicate.  Each column is 1 sample, and each row is 1 
metabolite.  The colour of each cell in the array represents the relative intensity of the metabolite in 
each sample.  The samples are ordered from asynchronous population (control), then the 0 hour time 
point (after the 48 hour serum starvation), 30 min, 2 hr, 6 hr, 12 hr, 24 hr and 48 hr post serum 
reintroduction (left to right).  
low high 
Relative intensity of metabolites  
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Figure 4.3  Quality assurance and quality control (QAQC) results from the cell cycle 
experiment. 
Correlation plots for each of the replicates of each time point collected.  The analytical 
reproducibility was monitored by analyzing the replicate samples.  Each of the replicate 
profiles was compared to each other by plotting the log2 relative intensities of the replicates.  
The closer the R
2
 value is to 1, the more reproducible the experiment was. 
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Figure 4.4  Principal component analysis of metabolites (p<0.001) detected in cells as they 
progress through the cell cycle. 
PCA is a linear transformation that converts data to a new coordinate system such that the 
greatest variance within the data comes to lie on the first coordinate (called the first principal 
component, PC1), the second greatest variance on the second coordinate (PC2), and so on.  The 
closer the samples cluster together in a PCA plot the more metabolically similar they are, and 
likewise the further the samples separate from each other along the more metabolically distinct 
they are.  The 0, 30 min and 2 hr time points cluster together on the left hand side of principal 
component 1 (PC1).  The 6, 12 and 24 hr time cluster at coordinates different from the rest of 
the samples on the right hand side of PC1.  The control and 48 hr time points localize to the 
same region of the PCA. 
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of PC1 as opposed to the earlier time points, signifying a dramatic difference in their metabolic 
profiles.  The separation of these samples suggests that a metabolic shift takes place between 2 
and 6 hours after the re-introduction of serum.  Interestingly, the 48 hour time point clusters 
most closely to the control samples.  This may be due to the fact that the samples are no longer 
synchronized and are possibly metabolically similar to the control population that is also an 
unsynchronized population. 
It is also important to note that by 48 hours the cells had become slightly overgrown, 
and so metabolic differences may be due to non-adherent cells or cells becoming apoptotic due 
to lack of space. Overall the result of this analysis demonstrated that the largest metabolic 
change which occurred during the cell cycle took place between two and six hours following 
the addition of serum to the synchronized cells.  The masses that are responsible for the 
separation of the control, 30 minute and 2 hour samples from the 6, 12 and 24 samples along 
PC1 are listed in Table 4.1.  The masses that are elevated in the later time points, resulting in a 
positive loadings score, were all detected in the same analysis mode 1203 (organic fraction, 
positive ionization, APCI source) and are all quite large in size (Table 4.1).  The masses with a 
negative loadings score along PC1 were mostly detected in the analysis modes 1101 and 1102 
(aqueous fraction, positive and negative ionization respectively, ESI source).  The masses with 
the most positive and negative loadings along PC2 separate the control samples from the 
samples collected after the serum starvation (Table 4.2).  The masses that increase after 
synchronization, which therefore have a positive loadings score, were detected in modes 1101 
(aqueous fraction, positive ionization, ESI source) and 1203 (organic fraction, positive 
ionization, APCI source).  The masses with negative loadings, which decrease after 
synchronization, are detected in all different analysis modes (1203, 1101, 1102 and 1201). 
The hierarchical cluster analysis, using a Pearson correlation with complete linkage, of 
the cell cycle dataset (p<0.0001, log2 normalized) identified clusters of metabolites showing 
slightly different patterns of expression over the cell cycle period (Figure 4.5). Each of these 
clusters contains metabolites that have similar expression patterns as the MRC5 progressed 
through the cell cycle, and in this case there appears to be four overall distinct clusters of 
metabolites. 
The first step in identifying the metabolites in each of the clusters of the analysis is to 
screen the masses for known metabolites in Phenomenome Discoveries‟ metabolite database. 
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Table 4.1  Masses responsible for the separation of the MRC5 samples along principal 
component 1 (PC1) in the principal component analysis (PCA). 
The masses listed in these tables are responsible for the separation of the samples along PC1. 
Masses that increase 6 hours after the synchronization period are listed in the first table on the 
left (positive loadings score, highlighted green), and the masses that decrease 6 hours after 
synchronization are listed in the table on the right (negative loadings score, highlighted red).  
The first column in each table contains the detected mass.  The second column lists the analysis 
mode that the mass was detected in (1101- positive ESI aqueous, 1102- negative ESI aqueous, 
1201- positive ESI organic butanol, 1202- negative ESI organic butanol, 1203- positive APCI 
organic ethyl acetate and 1204- negative APCI organic ethyl acetate).  The third column 
contains the PC1 loadings score from the PCA.  The last column lists the p-value of the mass. 
 
Detected 
Mass
Analysis 
Mode
PC1- 
loadings 
score
P_Value
Detected 
Mass
Analysis 
Mode
PC1- 
loadings 
score
P_Value
1 885.7864 1203 0.1577 3.13E-05 1 704.5183 1201 -0.0394 0.0002
2 882.7678 1203 0.1547 1.19E-09 2 329.0658 1101 -0.0396 4.37E-09
3 884.7827 1203 0.1546 0.0002 3 369.0451 1101 -0.0421 0.0007
4 881.7562 1203 0.1496 0.0001 4 677.4993 1201 -0.0431 1.35E-05
5 883.7714 1203 0.1464 1.47E-09 5 257.1028 1101 -0.0445 0.0002
6 886.7939 1203 0.1464 0.0007 6 651.1128 1102 -0.0452 2.56E-05
7 880.7523 1203 0.146 2.06E-08 7 153.0385 1101 -0.046 2.22E-05
8 565.515 1203 0.1446 0.0001 8 614.1486 1102 -0.0492 4.53E-06
9 878.738 1203 0.1415 0.0001 9 613.1584 1102 -0.0498 1.02E-07
10 879.7417 1203 0.1383 0.0006 10 330.0691 1101 -0.0499 4.73E-08
11 909.7878 1203 0.1375 0.0007 11 367.0216 1101 -0.0509 1.03E-05
12 828.7222 1203 0.1367 2.55E-05 12 307.0838 1101 -0.0521 1.86E-06
13 907.7727 1203 0.1353 0.0001 13 678.5029 1201 -0.0542 0.0001
14 908.7837 1203 0.133 7.25E-07 14 672.0897 1102 -0.0551 0.0001
15 852.7199 1203 0.1318 0.0007 15 612.1554 1102 -0.0578 1.17E-06
16 906.7684 1203 0.1312 1.37E-07 16 295.0586 1101 -0.0582 5.36E-06
17 910.7991 1203 0.1269 0.0006 17 347.0625 1102 -0.0619 0.0006
18 912.8166 1203 0.1245 0.001 18 650.1103 1102 -0.0642 9.44E-06
19 536.5163 1203 0.1233 3.19E-05 19 404.9776 1101 -0.0703 0.0001
20 631.5623 1203 0.1216 0.0003 20 345.0399 1101 -0.0723 9.08E-06
21 492.3814 1203 0.1202 1.48E-07
22 598.4584 1203 0.1177 0.0003
23 580.5348 1203 0.1156 0.0005
24 853.7244 1203 0.1156 0.0002
25 934.799 1203 0.1143 2.30E-06
26 911.8037 1203 0.1139 0.0009
27 564.5507 1203 0.1131 0.0001
28 830.737 1203 0.1127 0.0004
29 466.3651 1203 0.1099 0.0004
30 935.8016 1203 0.1083 0.0007
31 829.7263 1203 0.1077 4.10E-07
32 932.7821 1203 0.1069 0.0005
33 887.8029 1203 0.105 0.0007
34 930.7679 1203 0.1034 0.0003
35 937.819 1203 0.1023 7.37E-10
36 936.8133 1203 0.0952 0.0008
37 578.5278 1203 0.093 3.57E-08
38 579.5314 1203 0.0929 1.86E-07
39 591.5697 1203 0.0903 0.0004
40 600.5128 1203 0.0882 7.66E-09
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Table 4.2  Masses responsible for the separation of the MRC5 samples along principal 
component 2 (PC2) in the principal component analysis (PCA). 
The masses listed in these tables are responsible for the separation of the samples along PC2.  
These are masses that separate the control samples from the samples collected after the 
synchronization period.  Masses that increase after the synchronization period are listed at the 
top of the table (positive loadings score, highlighted green), and the masses that decreased after 
synchronization are listed at the bottom of the table (negative loadings score, highlighted red).  
The first column in the table contains the detected mass.  The second column lists the analysis 
mode that the mass was detected in (1101- positive ESI aqueous, 1102- negative ESI aqueous, 
1201- positive ESI organic butanol, 1202- negative ESI organic butanol, 1203- positive APCI 
organic ethyl acetate and 1204- negative APCI organic ethyl acetate).  The third column 
contains the PC2 loadings score from the PCA. The last column lists the p-value of the mass 
detected.  
 
 
Detected 
Mass
Analysis 
Mode
PC2- 
loadings 
score
P_Value
1 279.0847 1101 0.2581 1.97E-07
2 257.1028 1101 0.2275 0.0002
3 303.9936 1101 0.1745 0.0004
4 295.0586 1101 0.1657 5.36E-06
5 438.2485 1101 0.1581 0.0005
6 934.799 1203 0.1079 2.30E-06
7 910.7991 1203 0.0812 0.0006
8 909.7878 1203 0.0768 0.0007
9 878.738 1203 0.0765 0.0001
10 930.7679 1203 0.0746 0.0003
1 241.0927 1201 -0.217 0.001
2 650.1103 1102 -0.151 9.44E-06
3 607.0814 1102 -0.149 0.0001
4 564.5507 1203 -0.133 0.0001
5 345.0399 1101 -0.129 9.08E-06
6 672.0897 1102 -0.124 0.0001
7 612.1554 1102 -0.123 1.17E-06
8 613.1584 1102 -0.103 1.02E-07
9 614.1486 1102 -0.102 4.53E-06
10 619.5256 1203 -0.098 1.46E-05
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Figure 4.5  Hierarchical cluster analysis (HCA) of metabolites (p<0.001) detected in 
MRC5 cells as they progress through the cell cycle. 
Masses deemed significant (p<0.001) were hierarchically clustered using a Pearson correlation.  
Using this type of analysis will cluster together masses with similar changes in S/N across the 
samples.  Each sample is in duplicate.  Each column is one sample, and each row is one 
metabolite.  The colour of each cell in the array represents the relative intensity of the 
metabolite in each sample.  The samples are ordered from asynchronous population (control, -
48 hours)), then the 0 hour time point (after the 48 hour serum starvation), 30 min, 2 hr, 6 hr, 
12 hr, 24 hr and 48 hr (left to right). 
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This will typically result in the identification of about 30-50% of the masses detected in the 
analysis.  The remaining masses that did not match any of the known metabolites have to be 
identified one at a time with a molecular formula calculator.  The molecular calculator 
determines all of the possible combinations of elements that will result in the mass detected.  
Depending on the mass, the calculator may only find a single formula match or it may find 
hundreds of potential matches.  Once the list of possible formulas is determined the next step is 
to establish which of them are actually probable (taking the extract type and analysis mode into 
consideration).  Another consideration that has to be made is whether the mass detected is a 
parent mass or an adduct form of a metabolite (i.e. a sodium or potassium adduct). 
It was quickly realized that a large percentage of the metabolites detected in these 
analyses were lipids, and it was therefore necessary to determine formulae for as many of the 
lipid classes as possible.  The main groups of lipids that were detected in this analysis were 
triacylglycerols, phospholipids, 2-acyl-1-(1-alkenyl)-sn-glycerols and plasmalogens.  The 
masses and formulas were determined for each of these classes of lipids, including all possible 
combinations of fatty acid side chains. 
In order to visualize the expression patterns in each of the clusters, the average log2 
signal to noise of the masses were plotted (Figure 4.6).  Beside each graph there is a pie chart 
that shows the different classes of metabolites identified in each of the clusters, and the 
proportions of each class in the cluster.  The first cluster was mainly composed of 
triacylglycerols and 2-acyl-1-alkyl-sn-glycerols (a precursor molecule of plasmalogens) 
(Figure 4.6A).  These metabolites began to accumulate 6 hours after serum reintroduction.  The 
increase of these metabolites continues until the 24 hour time point, and then at 48 hours they 
decrease to the levels they were at in the control cells.  The majority of the masses in this 
cluster (67%) have been putatively identified as vinyl acylglycerols (VAGs, also known as 2-
Acyl-1-(1-alkenyl)-sn-glycerols) and triacylglycerols (TAGs).  The second cluster contained 
reduced and oxidized glutathione, which both showed dramatic decreases 6 hours after serum 
reintroduction and returning back to the levels detected in the control cells after 24 hours 
(Figure 4.6B).  The last two clusters were largely made up of phospholipids and plasmalogens, 
and the levels of these metabolites changed very little during the course of the experiment 
(Figure 4.6C,D). 
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Figure 4.6(A-C)  A graphical representation of the pattern of expression and class of 
metabolites clustered together in a hierarchical clustering analysis (Pearson correlation 
with complete linkage) of the cell cycle data. 
The average of the control normalized S/N of the masses in each of the clusters has been 
graphed in a line plot on the left hand side.  The grey lines above and below the average S/N 
represents the standard deviation between masses within the cluster.  The pie charts on the right 
hand side of the figure show the putatively identified metabolite classes of each cluster, as well 
as the percentage of each class that was identified. Figures continued on next page. 
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Figure 4-6 (D,E).  A graphical representation of the pattern of expression, and class of 
metabolites, clustered together in a hierarchical clustering analysis (Pearson correlation 
with complete linkage) of the Cell Cycle data. 
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The metabolites in the third cluster slightly decreased after the serum starvation, 
whereas the metabolites in the fourth cluster slightly increased with the starvation and returned 
back to the levels detected in the control cells after 24 hours.  Glycerophosphocholine was 
detected at increased levels after the serum starvation, and then steadily decreased after the 
serum was reintroduced (Figure 4.6E). 
Major metabolic changes occurred in MRC5 cells during the cell cycle (Figure 4.7).  
The 2-acyl-1-(1-alkenyl)-sn-glycerols (VAGs) and triacylgycerols (TAGs) follow a very 
similar expression pattern with a drop in levels after synchronization, then an increase at 6 
hours followed by a drop again at 48 hours.  Glycerophosphocholine increased with 
synchronization and then slowly decreased until the 48 hour time point where it was virtually 
absent.  Glutathione levels decreased at 6 hours, but then by 12 hours the level began to 
increase and by 48 hours it had reached levels similar to what was measured in the control 
sample.  Phosphatidylcholine levels increased upon synchronization and remained at constant 
levels across all samples.  Lastly, the phosphatidylethanolamine plasmalogens also appeared to 
stay at quite constant levels across all of the time points.  These results implicate several 
classes of lipids in the progression of the cell cycle, in particular TAGs and VAGs. 
4.1.4 Confirmation of Metabolite Identifications using High Throughput Triple 
Quadrupole Analysis 
A high-throughput method was developed on a Multiple Reaction Monitoring (MRM) 
Triple Quadrupole (TQ-MRM) to analyze 2-Acyl-1-(1-alkenyl)-sn-glycerols (VAGs) and 
Triacylglycerols (TAGs) levels in the MRC5 cell extracts (Figure 4.8).  This high throughput 
approach is based on the analysis of parent-daughter fragmentation (MRM) for the 
quantification of specific analytes of interest.  Using a targeted method to measure the levels of 
VAGs and TAGs will determine if the metabolite identifications that were made from the 
FTICR-MS data are correct.  High-throughput TQ-MRM analysis of the MRC5 cell extracts 
(triplicate samples for each time point) showed similar results to those found with the initial 
FTICR-MS analysis; increases in both VAGs and TAGs when the cells re-enter the cell cycle 
after the serum starvation (Figure 4.8).  The TAGs significantly (p<0.05) increased in the cells 
12 hours after the serum levels were returned to normal, whereas the VAGs were detected at 
significantly (p<0.05) elevated levels 6 hours after the serum starvation.  These results were 
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Figure 4.7  The relative intensities (log2, normalized to the 0 hour sample) of seven 
metabolites that show the most change during the progression of MRC5 cells through the 
cell cycle. 
Relative levels of 2-Acyl-1-(1-alkenyl)-sn-glycerols (VAGs), Triacylglycerols (TAGs), 
glycerophosphocholine, ethanolamine plasmalogens and phosphatidylcholines as MRC5 cells 
progress through the cell cycle.  Data has been normalized to the 0 hour time point.  The -48 
hour time point was collected 48 hours prior to serum starvation; the cells were therefore not a 
synchronously growing population.  All of the masses have p<0.001 as assessed by Student‟s t-
test.  Error bars represent the standard deviation between replicate samples. 
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Figure 4.8  High-throughput analyses of 2-acyl-1-(1-alkenyl)-sn-glycerols (VAGs) and 
triacylglycerols (TAGs) in MRC5 cells as they progress through the cell cycle. 
Cell extracts were analyzed with a high throughput analysis (MRM- triple quadrupole method) 
to confirm the putative identifications made from the FTICR-MS analysis.  The four plots 
show the increase of VAGs and TAGs within 12 hours of treatment. * p<0.05 relative to the 0 
hour time point.  Error bars represent the standard deviation between replicate samples. 
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
-4
8
 h
o
u
rs
0 
h
o
u
r
3
0
 m
in
u
te
s
2 
h
o
u
rs
6 
h
o
u
rs
12
 h
o
u
rs
24
 h
o
u
rs
48
 h
o
u
rs
R
at
io
(n
o
rm
al
iz
ed
 t
o
 0
 h
o
u
r)
TAG 16:0/18:1
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
4.00
-4
8
 h
o
u
rs
0
 h
o
u
r
3
0
 m
in
u
te
s
2
 h
o
u
rs
6
 h
o
u
rs
1
2
 h
o
u
rs
2
4
 h
o
u
rs
4
8
 h
o
u
rs
R
at
io
(n
o
rm
al
iz
ed
 t
o
 0
 h
o
u
r)
TAG 16:0/18:2
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
-4
8
 h
o
u
rs
0 
h
o
u
r
3
0
 m
in
u
te
s
2 
h
o
u
rs
6 
h
o
u
rs
12
 h
o
u
rs
24
 h
o
u
rs
48
 h
o
u
rs
R
a
ti
o
(n
o
rm
a
li
ze
d
 t
o
 0
 h
o
u
r)
VAG 16:0/22:6
0.00
0.50
1.00
1.50
2.00
2.50
3.00
3.50
-4
8
 h
o
u
rs
0 
h
o
u
r
3
0
 m
in
u
te
s
2 
h
o
u
rs
6 
h
o
u
rs
12
 h
o
u
rs
24
 h
o
u
rs
48
 h
o
u
rs
R
at
io
(n
o
rm
al
iz
ed
 t
o
 0
 h
o
u
r)
VAG 16:0/20:4
*
* *
*
*
*
*
*
*
*
  
63 
6
3
 
consistent with the FTICR-MS data. 
4.1.5 Real Time Polymerase Chain Reaction of MRC5 Cells 
2-Acyl-1-(1-alkenyl)-sn-glycerols and diacylglycerols are both generated by 
Phospholipase C (PLC)-mediated cleavage of ethanolamine plasmalogens and phospholipids 
respectively.  PLC enzymes cleave the polar head group from phospholipids at the phosphate 
group located at the sn3 position of the lipid (Katan, 2005).  There are six different families of 
PLC enzymes; γ, ε, β, ,  and δ, and within each family there are multiple isoforms (Katan, 
2005). A recent publication has demonstrated that diacylglycerols that are derived from plasma 
membrane phospholipids, through the action of PLC, are mainly used for triacylglycerol 
synthesis (Igal et al., 2001).  It was therefore decided to examine PLC transcript levels in the 
MRC5 cells as they progressed through the cell cycle (Figure 4.9).  A selection of four PLC 
isoforms: γ2, ε1, β1, and δ4 were analyzed.  PLCβ and PLCδ have both been found to localize 
in the cleavage furrow during cytokinesis (Naito et al., 2006), and were therefore selected for 
analysis.  I also selected PLCγ and ε as they are regulated differently than the other PLC 
isoforms. Most of the PLC isoforms are regulated by the GTP-binding subunits of G-proteins, 
interestingly PLCγ is regulated through receptor and non-receptor tyrosine kinases and PLCε is 
regulated directly by GTPases from the Ras family (Katan, 2005).  PLCβ1 mRNA levels did 
not significantly change as the cells progressed through the cell cycle (Figure 4.9).  PLCγ2 and 
ε had similar mRNA expression patterns, showing increases following synchronization (when 
the cells are in G0) and again 12hr after the serum had been added back into the media 
(possibly corresponding to the G1-S transition) (Figure 4.9).  PLCδ4 showed an increase in 
mRNA following synchronization and then steadily decreased as the cells progressed through 
the cell cycle (Figure 4.9).  The corresponding increase of PLC γ, ε, and δ gene expression to 
the induction of VAGs and TAGs, suggests that these genes may be involved in the metabolic 
shift that occurs 12 hours after synchronization. 
4.1.6 Discussion 
As far as I am aware, the work presented in this section is the first non-targeted 
examination of metabolic changes that accompany cell cycle progression.  The cell cycle is a  
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Figure 4.9  Real time PCR analyses of phospholipase-C (PLC)-β, γ, ε, and δ expression in 
MRC5 cells as they progress through the cell cycle. 
Real-time PCR was completed to quantify the expression of PLC in MRC5 cells as they 
progressed through the cell cycle.  Four isoforms of PLC were selected for analysis: PLCβ1, 
PLCγ2, PLCε, and PLCδ4.  All results were normalized to the control cells.  Error bars 
represent the standard deviation between replicate samples. 
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tightly controlled process, with checkpoints throughout the cycle to insure that errors do not 
take place, and that damaged cells are not able to divide.  The most important checkpoints in 
the cell cycle are at the G1/S and G2/M transitions, as it is at these points in the cell cycle 
where cancer related defects can occur (Erson and Petty, 2004).  Upon synchronization of the 
cells, levels of TAGs, VAGs and glutathione slightly decrease, and glycerophosphocholine and 
phospholipids slightly increase. Our results suggest that there is a robust elevation of 
triacylglycerols (TAGs) and 2-acyl-1-(1-alkenyl)-sn-glycerols (VAGs) which steadily 
accumulate up to the point of cell division.  It is likely that the MRC5 cells reached the G0/G1 
transition within 6 hours following the synchronization (Memili et al., 2004), and the G2/M 
transition was reached between 12 and 24 hour post synchronization (results collected from 
flow cytometry analysis).  The increase in the TAGs and VAGs may be linked to the 
checkpoints in the cell cycle. 
2-Acyl-1-(1-alkenyl)-sn-glycerols and diacylglycerols (DAGs) are generated by PLC-
mediated cleavage of ethanolamine plasmalogens and phospholipids respectively.  It has been 
reported that PLCδ1 accumulated in the nucleus of cells at the G1/S boundary and the G0 phase 
of the cell cycle (Stallings et al., 2005).  A siRNA knockdown strategy that specifically 
targeted PLCδ1 significantly decreased proliferation of rat C6 glioma cells and altered S phase 
progression in the cell cycle (Stallings et al., 2008).  Another group discovered that the 
interaction of AKT and PLCγ regulates the G2/M transition in the cell cycle, and in fact if this 
interaction is blocked, the cell arrests in the G2 stage of the cell cycle (Browaeys-Poly et al., 
2009). 
The elevated transcript levels of PLC γ, ε, and δ in the MRC5 cells as they progress 
through the cell cycle may be connected to the elevated levels of TAGs and VAGs.  Several 
papers have recently been published linking PLC, AKT, DAGs and plasmalogens to the cell 
cycle (Sun et al., 1997; Albi et al., 2004; Browaeys-Poly et al., 2009).  It has been proven that 
DAGs are cell cycle regulated, and that they are detected at increased levels at the G2/M 
transition phase of the cell cycle due to an increase in PLC activity (Sun et al., 1997).  The 
DAGs that are generated by the PLC activity are believed to be responsible for the activation of 
the nuclear protein kinase C (PKC) during the late G2 phase of the cycle, which is required for 
the transition into the mitotic phase (Sun et al., 1997).  Inhibition of PLC activity halts the cells 
in the G2 phase of the cell cycle (Sun et al., 1997). 
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Another interesting observation is that AKT regulates the activity of PLC , and if the 
AKT-PLC  interaction is disrupted, the entry into the mitotic phase of the cell cycle is 
expedited in MDA-MB-231 breast cancer cells (Browaeys-Poly et al., 2009).  AKT regulates 
both PLC and Checkpoint with forkhead and ring finger domains (Chfr) through 
phosphorylation, which in turn allows the release of the G2 checkpoint and the transition into 
the M phase of the cell cycle (Browaeys-Poly et al., 2009).  Chfr plays an important role as a 
checkpoint protein during the G2/M transition, as its activation holds the cell cycle in prophase 
by inhibiting the phosphorylation of cell division control protein 2 homolog (CDC2), more 
commonly known as cyclin dependent kinase 1 (CDK1) (Erson and Petty, 2004).  CDK1 forms 
a complex with cyclin B1, referred to as the maturation promoting factor or the mitosis 
promoting factor (MPF) (Lindqvist et al., 2009).  If the interaction of AKT and PLC  is 
inhibited, AKT phosphorylates Chfr, inactivating the checkpoint protein and expediting the 
transition into the M phase of the cycle (Browaeys-Poly et al., 2009).  There have also been 
recent studies which have identified reduced expression and mutations of Chfr in multiple 
cancer cell lines (Erson and Petty, 2004).  Therefore, it may be interesting to examine cancer 
cells as they progress through the cell cycle to determine if the reduced regulation of the G1/S 
and G2/M transitions affects the expression of PLC and the synthesis of  lipids (in particular 
TAGs, DAGs and VAGs). 
A research group from Italy has identified plasmalogens as potential regulators of 
phosphatidylcholine-dependent phospholipase C (PC-PLC) and the cell cycle (Albi et al., 
2004).  The lipid fraction of chromatin is a minor component; however, it plays an important 
role in cell proliferation (Albi and Viola Magni, 2004).  The chromatin lipids, including 
phospholipids, cholesterol and plasmalogens, increase during DNA replication and are often 
localized to newly synthesized RNA in condensed chromatin (Albi and Viola Magni, 2004).  
The fraction of plasmalogens to diacyl-phospholipids in the chromatin is higher than that 
present in the homogenate, cytosol and nuclear membranes (Albi et al., 2004).  They also 
discovered that PC-PLC has a higher affinity for ether phospholipids as compared to the diacyl 
equivalents (Albi et al., 2004).  The hypothesis that has resulted from this work is that 
plasmalogens are transported into the nucleus where they activate PC-PLC to produce alkyl-
acyl glycerols, which, in turn, stimulate PKC.  The detection of increased VAGs at the G2/M 
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transition in the MRC5 cells may be linked to the activity of PC-PLC on plasmalogens in the 
chromatin and cellular membranes. 
I was unable to conclude whether the observed induction of lipids is an obligate 
requirement for cell division, or whether it is simply an associated effect.  Initial efforts had 
examined the possibility of inhibiting Phospholipase C, using an inhibitor for PLC, such as U-
73122 (Liu et al., 2004a).  I hypothesized that if the results indicated that cells were unable to 
progress through the cell cycle following addition of the serum in the presence of the PLC 
inhibitor, then it would be possible to suggest that the changes in the lipid profile would be a 
requirement for cell cycle progression.  However, it became evident that simply inhibiting PLC 
was not going to provide the targeted inhibition of the synthesis of TAGs and VAGs that I had 
hoped for.  A more specific inhibitor or knock-down system is required to effectively complete 
this experiment. 
4.2 Metabolomic Changes Associated With Differentiation  
4.2.1 Data Alignment and Array Generation 
Undifferentiated monocytic U937 cells were treated with phorbol 12-myristate 13-
acetate (PMA), a protein kinase C activator, which induces maturation from a monocytic cell 
into a macrophage (Kitamura et al., 2004).  The cells begin a number of phenotypic changes 
during this process, including adherence to the plate surface, gain of macrophage 
characteristics (phagocytosis, antibody-dependent cellular cytotoxicity, antigen presentation 
and chemotaxis), and the loss of proliferative potential (Kwon and Kim, 2003; Verhoeckx et 
al., 2004).  Photographs were taken at each time point during the PMA treatment to document 
the hallmark phenotypic changes that occur during differentiation, such as rapid adherence, 
followed by the progression into macrophages within 24 hours of treatment (Figure 4.10). 
The U937 cells were harvested at various time points throughout the differentiation 
process and analyzed using flow injection FTICR-MS as described in the previous section.  A 
total of 1,589 masses were detected when the U937 cells were analysed with the FTICR-MS.  
The complete dataset was subject to a Student‟s t-test, resulting in 386 masses with p< 0.001 
(Figure 4.11).  The resulting spectra were aligned in an array, which is organized with the 
masses detected, and the analysis modes they were detected in, on the left hand side of the  
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Figure 4.10  Photographs taken from 0 to 96 hours during treatment of U937 cells with 
phorbol 12-myristate-13-acetate (PMA). 
Cells begin to attach after 1 hour of treatment with PMA, a protein kinase C activator.  After 48 
hours of treatment, cells are beginning to differentiate into macrophages, as evident by the long 
dark spindle looking cells that can be seen in the pictures taken at 48, 72 and 96 hours.  
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Figure 4.11  Metabolite array of masses 
(p<0.001) detected in U937 cells as they 
differentiate. 
A two dimensional array containing masses that 
significantly change as U937 cells differentiate 
(p<0.001).  Each column is 1 sample, and each 
row is 1 metabolite.  The experiment was 
completed in duplicate on two occasions, 
resulting in 4 replicates.  The colour of each cell 
in the array represents the relative intensity of 
the metabolite in each sample. The samples are 
ordered from untreated through to 96 hr of 
treatment, repeated for each of the 4 replicates.  
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array (coloured grey).  Each row in the array contains the data for a single unique mass.  Each 
individual sample is listed along the top of the array, and they have been ordered from the 
control (monocytes) through to the cells collected at 96 hours (left to right).  This is repeated 
for the other three replicates.  The relative intensities (log2 transformed) of the masses have 
been coloured according to the scale located to the left of the array.  The R
2 
value for the entire 
experiment was found to be 0.78, which is acceptable considering that the two duplicate 
experiments were performed a few months apart. 
4.2.2 Unsupervised Statistical Analyses 
The principal component analysis of the dataset (p<0.001) showed a clear separation of 
the samples (Figure 4.12), which suggested changes in the metabolome of the cells as they 
transition from monocytes into macrophages. The samples collected during the 48, 72 and 96 
hour time points clearly separated from the earlier time points, and the 12 and 24 hour samples 
appear to be in transition between the early and later time points across PC1.  This suggested 
that there were minimal metabolic changes taking place within the first six hours, and that the 
most dramatic changes occurred between 6 and 48 hours after PMA addition. 
The masses responsible for the separation of the samples in the PCA analysis are listed 
in Table 4.3.  These are the masses with the most positive and negative loadings scores from 
the principal component analysis.  The top half of the table contains the masses that increase 
during differentiation (positive PC1 loadings score, highlighted green).  Each mass has been 
assigned a putative formula and metabolite identification. The last column in the table shows 
the possible combinations of fatty acid side chains of the identified lipids.  From these 
identifications it appears that an increase in plasmalogens (1-Alkenyl-2-Acyl-plasmenyl 
phosphatidylethanolamines) occurs in U937 cells as they differentiate into macrophages.  
Another group of metabolites that increase during differentiation have been identified as 1-
alkenyl-2-Acyl-sn-glycerols.  These molecules, also known as vinyl acyl glycerols (VAGs), are 
vinyl ether lipids synthesized in the same metabolic pathway as plasmalogens. The masses that 
were found to decrease during differentiation are listed in the bottom half of the table (negative 
PC1 loadings score, highlighted red).  There does not seem to be a specific family of 
metabolites that decrease during differentiation.  Adducts of diacyl phospholipids (both
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Figure 4.12  Principal component analysis of metabolites (p<0.001) detected in U937 cells 
as they differentiate. 
PCA is a linear transformation that converts data to a new coordinate system such that the 
greatest variance within the data comes to lie on the first coordinate (called the first principal 
component, PC1), the second greatest variance on the second coordinate (PC2), and so on.  The 
closer the samples cluster together in a PCA plot the more metabolically similar they are.  The 
48, 72 and 96 hour time points cluster on the right hand side of PC1, separately from the 12 
and 24 hour samples which appear to be in a transition between the early time points and the 
later time points. 
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Table 4.3  Metabolites responsible for the separation of differentiating U937 samples in 
the principal component analysis (PCA). 
Masses that increase during differentiation are listed in the top portion of the table (positive 
loadings score, highlighted green), and the masses that decrease during differentiation are at 
the bottom of the table (negative loadings score, highlighted red).  The first column contains 
the detected mass.  The second column lists the analysis mode that the mass was detected in.  
The third column contains the loadings score from the PCA.  The center of the table displays 
the array, showing the relative intensity of the masses in each of the samples.  The last three 
columns list the putative formula and metabolite identifications.  
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Parent 
Mass
Analysis 
Mode
PC1L P_Value
Putative 
Formula
Preliminary Metabolite Identification Potential Side chains
296.057 1102 0.1289 1.65E-08 C10H16O8S
306.086 1102 0.1198 2.88E-09 No ID
282.063 1101 0.1165 1.52E-08 No ID
699.519 1204 0.1047 5.46E-13 C39H74NO7P 1-a lkenyl -2-acyl -PlsPE R1: [C18:1] R2: [C16:1] R3: [PE]
699.52 1203 0.1046 2.86E-13 C39H74NO7P 1-a lkenyl -2-acyl -PlsPE R1: [C18:1] R2: [C16:1] R3: [PE]
492.418 1203 0.1032 4.56E-09 C31H56O4 1-a lkenyl -2-acyl -sn-glycerol R1: [C18:2] R2: [C10:0] R3: [OH]
660.609 1203 0.0985 1.88E-10 No ID
713.539 1204 0.0983 0.0001 No ID
260.081 1101 0.0964 2.95E-09 No ID
238.099 1102 0.0957 1.38E-13 No ID
558.501 1203 0.0953 3.74E-08 C37H66O3
894.806 1203 0.0951 4.64E-07 C59H106O5
699.52 1202 0.0933 1.08E-06 C39H74NO7P 1-a lkenyl -2-acyl -PlsPE R1: [C18:1] R2: [C16:1] R3: [PE]
686.623 1203 0.093 6.21E-11 C45H82O4 1-a lkenyl -2-acyl -sn-glycerol R1: [C22:6] R2: [C20:0] R3: [OH]
727.551 1203 0.0901 1.02E-16 C41H78NO7P 1-a lkenyl -2-acyl -PlsPE R1: [C18:1] R2: [C18:1] R3: [PE]
414.35 1203 0.0891 1.65E-07 C28H46O2 4-Methylcholesta-8,14-diene-3,23-diol
684.606 1203 0.0883 4.78E-10 C45H80O4 1-a lkenyl -2-acyl -sn-glycerol R1: [C22:4] R2: [C20:0] R3: [OH]
239.102 1102 0.0878 5.61E-09 C9H13N5O3 Dihydrobiopterin
755.578 1204 0.0861 4.38E-05 No ID
238.099 1101 0.081 5.98E-09 C16H14O2 2-(2-Fluorenyl )propanoic acid
727.556 1204 0.0808 3.59E-12 C41H78NO7P 1-a lkenyl -2-acyl -PlsPE R1: [C18:1] R2: [C18:1] R3: [PE]
729.567 1203 0.08 3.45E-11 C41H80NO7P 1-a lkenyl -2-acyl -PlsPE R1: [C18:1] R2: [C18:0] R3: [PE]
614.566 1203 0.0781 9.34E-08 C41H74O3
699.52 1201 0.0774 5.40E-08 C39H74NO7P 1-a lkenyl -2-acyl -PlsPE R1: [C18:1] R2: [C16:1] R3: [PE]
785.594 1101 0.0769 0.0001 C44H84NO8P 1,2-acylPtdPC R1: [C18:1] R2: [C18:1] R3: [PC]
376.313 1204 0.0755 1.12E-06 C28H40
518.434 1203 0.0742 1.87E-06 C33H58O4 1-a lkenyl -2-acyl -sn-glycerol R1: [C18:3] R2: [C12:0] R3: [OH]
298.037 1101 0.0735 0.0005 No ID
725.538 1203 0.0725 4.88E-05 C41H76NO7P 1-a lkenyl -2-acyl -PlsPE R1: [C18:3] R2: [C18:0] R3: [PE]
697.504 1203 0.0719 6.27E-08 C39H72NO7P 1-a lkenyl -2-acyl -PlsPE R1: [C18:3] R2: [C16:0] R3: [PE]
638.565 1203 0.0718 6.35E-07 C43H74O3
674.553 1204 0.0714 4.02E-06 No ID
347.062 1102 0.0707 2.06E-06 C10H14N5O7P AMP
779.584 1203 0.0691 2.17E-11 C45H82NO7P 1-a lkenyl -2-acyl -PlsPE R1: [C20:4] R2: [C20:0] R3: [PE]
729.572 1204 0.0688 4.21E-10 No ID
779.582 1204 0.0683 6.53E-10 C45H82NO7P 1-a lkenyl -2-acyl -PlsPE R1: [C20:4] R2: [C20:0] R3: [PE]
609.516 1204 -0.039 2.13E-05 C37H71NO3S
727.512 1201 -0.04 0.0003 C38H75NO8PNa "1,2-acylPtdPC" (Na adduct) R1: [C16:0] R2: [C14:0] R3: [PC]
563.51 1204 -0.041 0.0001 C36H69NOS
307.084 1101 -0.048 0.0004 C10H17N3O6S Glutathione
803.463 1201 -0.048 1.17E-05 C41H76NO7PK2 1-a lkyl -2-acyl -sn-glycero-3-PlsPE R1: [C18:1] R2: [C18:2] R3: [PE]
819.517 1201 -0.05 0.0008 C44H79NO8PK "1,2-acylPtdPC" R1: [C20:4] R2: [C16:0] R3: [PC]
637.548 1204 -0.052 1.52E-06 C39H75NO3S
803.544 1201 -0.055 0.001 C44H79NO8PNa "1,2-acylPtdPC"(Na adduct) R1: [C20:4] R2: [C16:0] R3: [PC]
827.569 1202 -0.056 1.14E-10 C45H82NO10P "1,2-acylPtdPE(2OH)" R1: [C18:0] R2: [C22:4] R3: [PE(2OH)]
693.611 1204 -0.061 0.0001 C43H83NO3S
115.039 1102 -0.066 6.18E-11 No ID
219.043 1102 -0.083 2.60E-11 No ID
313.032 1102 -0.095 1.07E-06 No ID
297.058 1102 -0.097 1.99E-13 C13H16NO3PS
243.004 1101 -0.1 0.0001 No ID
205.048 1101 -0.13 6.71E-09 C10H9NONa 2 3-(2-Hydroxyethyl )indole (Na2 adduct)
229.071 1102 -0.139 1.05E-11 No ID
221.022 1101 -0.172 8.97E-08 C7H13NO2K2 2-Aminoheptanoic acid (K2 adduct)
Table 2.  Metabolites responsible for the separation of  differentiating U937 
samples in the principal component analysis.  Masses that increase during 
differentiation are listed in the top portion of the table (positive loadings 
score, highlighted green), and the masses that decrease during differentiation 
are in the lower portion (negative loadings score, highlighted red.
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phosphatidylethanolamine and phosphatidylcholine) were putatively identified as metabolites 
that decrease during differentiation.  Glutathione also appears to decrease during 
differentiation. 
When the data set (p<0.001, log2 normalized) was hierarchically clustered, using a 
Pearson correlation, five distinct groups were revealed (Figure 4.13).  The first cluster of 
metabolites was largely composed of ethanolamine phospholipids and small aqueous molecules 
(Figure 4.14a).  All of the metabolites in cluster 1 slightly decreased in intensity with the 
addition of PMA, followed by an increase at 6 hours and a decrease after 48 hours.  The 
second, third and fourth clusters contained metabolites that steadily increased 6 hours after the 
PMA treatment (Figure 4.14b,c,d).  A large percentage of these metabolites have been 
putatively identified as plasmalogens and 2-Acyl-1-(1-alkenyl)-sn-glycerols (diacylglycerol 
plasmalogens).  Interestingly there were not any phospholipids in these three clusters.  The 
final cluster contained a group of metabolites that increased after 48 hours of PMA treatment 
(Figure 4.14e).  This group was largely made up of plasmalogens and choline phospholipids.   
The most dramatic metabolic changes that occurred as the cells differentiated were 
increased levels of plasmalogens (Figure 4.15).  The masses began to increase 48 hours after 
PMA treatment and continued to increase until the last time point collected at 96 hours. 
4.2.3 Confirmation of Lipid Changes using High Throughput Triple Quadrupole 
Analysis 
Although the metabolite predictions from the accurate masses allowed for the putative 
identification of ethanolamine plasmalogens (PlsEtn) as well as potential side-chain speciation, 
a Multiple Reaction Monitoring (MRM) Triple Quadrupole method was developed to ensure 
that our preliminary identifications made from the FTICR-MS data were correct.  This high 
throughput approach involves the selection of a specific parent mass, followed by its 
fragmentation (using collision induced dissociation or CID via an inert gas) into specific 
daughter ions.  This type of analysis is like finding the „fingerprint‟ of the molecule; no two 
molecules will have the same daughter ions.  Sample extracts were re-analyzed with this 
method, which specifically measured phosphatidylethanolamines and ethanolamine 
plasmalogens.  A comparison of the results between the targeted triple quadrupole method and 
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Figure 4.13  Hierarchical cluster analysis (HCA) of metabolites (p<0.001) detected in 
U937 cells as they differentiate. 
Masses deemed significant (p<0.001) were hierarchically clustered using a Pearson correlation.  
Using this type of analysis will cluster together masses with similar changes in S/N across the 
samples.  Each column is 1 sample, and each row is 1 metabolite.  The color of each cell in the 
array represents the relative intensity of the metabolite in each sample. The samples are 
ordered from untreated through to 96 hours of treatment, repeated for each of the 4 replicates.  
The results of the HCA identified five clusters of masses.   
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Figure 4.14(a-c)  A graphical representation of the pattern of expression and class of 
metabolites clustered together in a hierarchical clustering analysis (Pearson correlation 
with complete linkage) of the U937 differentiation data. 
The average of the control normalized S/N of the masses in each of the clusters has been 
graphed in a line plot on the left hand side.  The grey lines above and below the average S/N 
represent the standard deviations between the masses within each cluster.  The column graphs 
on the right hand side of the figure show the putatively identified metabolite classes of each 
cluster, as well as the percentage that each class contributes to the cluster. Figure continued on 
next page. 
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Figure 4-14 (d,e)  A graphical representation of the pattern of expression and class of 
metabolites clustered together in a hierarchical clustering analysis (Pearson correlation 
with complete linkage) of the U937 differentiation data. 
The average of the control normalized S/N of the masses in each of the clusters has been 
graphed in a line plot on the left hand side.  The grey lines above and below the average S/N 
represent the standard deviations between the masses within each cluster.  The column graphs 
on the right hand side of the figure show the putatively identified metabolite classes of each 
cluster, as well as the percentage that each class contributes to the cluster. 
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Figure 4.15  Ethanolamine plasmalogen (PlsEtn) profiles during the differentiation of 
U937 cells. 
The average relative intensities (raw S/N) of select ethanolamine plasmalogens during the 
differentiation of U937 cells.  The error bars represent the standard deviation between triplicate 
samples. The formula and the potential fatty acid side chains of each mass are listed in the 
legend of the figure.  The error bars represent the standard deviation between replicate samples. 
(F-test‟s of these masses resulted in p<0.001) 
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Figure 4.16  FTICR-MS and triple-quadrupole analyses of ethanolamine plasmalogens, in 
U937 cells as they differentiate. 
Cell extracts were analyzed with multiple reaction monitoring- triple quadrupole method.  The 
five graphs have the FTICR-MS data plotted on the primary y axis and the high throughput 
data is plotted on the secondary y axis.  The error bars represent the standard deviation between 
replicate samples.  FTICR-MS data (F-test, p<0.001), triple-quadrupole data * p<0.05 relative 
to the control time point. 
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the predicted matching plasmalogens from the FTICR-MS is shown in Figure 4.16.  The 
increased levels of PlsEtn 16:0/18:2, PlsEtn 18:1/18:1, PlsEtn18:0/20:4, PlsEtn 18:0/18:1 and 
PlsEtn 18:0/22:6 closely resemble the increased levels of the corresponding masses detected in 
the FTICR-MS analysis.  The increases of the PlsEtn in the U937 cells begin between 12 and 
24 hours after the PMA treatment. 
4.2.4 Real Time Polymerase Chain Reaction of Peroxisome Related Transcripts in 
Differentiating U937 cells 
The increase in ether lipids during the differentiation suggested a possible role of 
enzymes involved in ether lipid synthesis or peroxisomal activity.  The transcript levels of 
several key enzymes in the pathway were therefore assessed in the monocytes (controls) and 
macrophages (cells treated with PMA for 48 hours) using real-time polymerase chain reaction 
(RT-PCR) (Figure 4.17).  Surprisingly, the transcript levels of dihydroxyacetone-phosphate 
acyltransferase (DHAPAT), a key enzyme in the synthesis of ether lipids, decreased following 
48 hours of PMA treatment (Figure 4.17a).  The experiments were repeated with consistent 
results, prompting an examination of some of the other genes involved in ether lipid synthesis 
and peroxisomal function.  The transcript levels of fatty acid synthase (FASN), the key enzyme 
in fatty acid synthesis, also decreased slightly during differentiation (Figure 4.17a).  1-Acyl-
Sn-Glycerol-3-.Phosphate Acyltransferase (AGPAT1 and 2), another key enzyme in the ether 
lipid synthesis pathway was also examined using RT-PCR, which also showed decreased levels 
as the U937 cells differentiated (AGPAT1 more significantly) (Figure 4.17a).  Pex11a is 
typically used as a marker of peroxisome proliferation, and also decreases as the cells 
differentiate (Figure 4.17a).  Glycerol-3-phosphate acyltransferase (GPAT) catalyzes the initial 
and rate limiting step in phospholipid synthesis, and was also detected at significantly lower 
levels in the differentiated U937 cells as compared to the levels detected in the monocytes 
(Figure 4.17a).  Catalase activity, as another peroxisomal marker, was also measured in the 
cells and found to decreases during differentiation (data not shown).  The results were 
intriguing, as it was expected that an increase in the transcription of genes encoding enzymes 
involved in ether lipid synthesis or peroxisome activity would have been detected.  Two genes 
that are known to have increased expression in differentiating U937 cells, SRC and αV-integrin 
(ITGAV) (Kitamura et al., 2004; Shrivastav et al., 2008), were tested.  Both SRC and ITGAV 
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Figure 4.17  Percent expression of peroxisome related transcripts in differentiating U937 
cells as detected with real time PCR (RT-PCR). 
a. Peroxisome related transcript levels in monocytes (control) and macrophages (PMA 48 hr).  
Results have been normalized to the control. DHAPAT- dihydroxyacetone-phosphate 
acyltransferase, FASN- fatty acid synthase, AGPAT- 1-acyl-sn-glycerol-3-phosphate 
acyltransferase, Pex11A- peroxisomal membrane protein 11A, GPAT- glycerol-3-phosphate 
acyltransferase.  b. Percent expression of gene transcripts known to increase during 
differentiation.  SRC- Sarcoma gene, ITGAV- αV integrin.  * p<0.05 relative to control.  The 
error bars represent the standard deviation between replicate samples. 
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expression significantly increased during differentiation of the U937 cells (Figure 4.17b) as 
expected, further solidifying that the detected decrease in the transcription of the genes related 
to ether lipid synthesis and peroxisome proliferation during differentiation was real. 
4.2.5 Citrate Export Inhibition in Differentiating U937 Cells 
The question which emerged from these studies was whether the induction of the 
plasmalogens was a requirement for differentiation, or merely an association.  I also questioned 
if there was a dependence on de novo synthesis of fatty acids during the induction of 
plasmalogen synthesis.  1,2,3-Benzenetricarboxylic acid (BTA) is a compound that prevents 
the export of citrate out of the mitochondria through the inhibition of the tricarboxylate carrier 
in the mitochondrial inner membrane (Kajimoto et al., 2005).  The inhibition of the 
tricarboxylate carrier subsequently reduces the amount of citrate available in the cytoplasm to 
be converted into acetyl CoA, which is required for de novo synthesis of fatty acids and 
cholesterol.  Once exported out of the mitochondria, citrate has multiple fates.  It is first broken 
down by ATP-citrate lyase which generates acetyl coenzyme A (AcCoA) and oxaloacetic acid 
(OAA) (Wellen et al., 2009).  The AcCoA is used for fatty acid synthesis, cholesterol synthesis 
and for the acetylation of histones (Costello and Franklin, 2005; Wellen et al., 2009).   
U937 cells were pre-treated with BTA for 3 hours prior to the PMA treatment to ensure 
that citrate export was inhibited prior to the induction of differentiation.  After 24 hours of co-
treatment with BTA and PMA, the U937 cells showed no morphological signs of 
differentiating, including lack of adherence (Figure 4.18).  Cells still in suspension at 24 hours 
after treatment with both BTA and PMA were stained with Trypan blue and were found to be 
viable.  The co-treated suspended cells were then rinsed with PBS, and then re-plated in fresh 
RPMI media lacking PMA and BTA.  Within 6 hours of being plated in new media, the cells 
become adherent, and within 48 hours they showed a morphological differentiated phenotype 
(Figure 4.18).  The results suggest that PMA does indeed initiate a terminal differentiation 
program, but one which can be reversibly blocked by preventing mitochondrial citrate export. 
The levels of phospholipids during these treatments were subsequently measured. A 
comprehensive assessment of ethanolamine plasmalogen (PlsEtn) and 
Phosphatidylethanolamine (PtdEtn) levels using a triple-quadrupole tandem mass spectrometer 
was performed on the cell pellet extracts from the BTA experiment, including; control, BTA, 
  
82 
8
2
 
 
Figure 4.18  Photographs of U937 cells that have been treated with PMA and 1,2,3 
benzene tricarboxylic acid (BTA). 
Images from microscope at 10x and 20x magnification. A) Monocytic U937 cells (control).  B) 
Differentiated U937 cells, PMA treated for 48 hours, cells adherent.  C) U937 cells treated 
with BTA for 48 hours, cells in suspension.  D) U937 cells treated with BTA and PMA for 24 
hours, cells in suspension.  E)  Re-plated cells, BTA and PMA removed, cells are now 
adherent. 
Control (cells suspended) PMA (cells attached)
BTA (cells suspended) BTA and PMA (cells suspended)
Suspended cells from BTA and PMA treatment, rinsed in PBS 
and put into normal media for 48 hours, after which they 
attached and differentiated (20x magnification)
BA
C D
E
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PMA, BTA and PMA, and re-plated samples (Figure 4.19).  The relative levels of a PlsEtn and 
a PtdEtn, with the same specific fatty acid side chains, in all treatment combinations are shown. 
The first four bars in each plot show the relative levels of the lipids in monocytes 
(undifferentiated) in the absence and presence of BTA (Figure 4.19).  BTA treatment caused a 
significant decrease (p<0.05) in most of the PtdEtn analyzed in the monocytes (Table 4.4).  The 
PtdEtn that did not appear to be affected by the BTA treatment were those with 18:0/18:3, 
18:1/18:3, 18:1/20:4 and 18:1/22:6 fatty acid side chain combinations.  Interestingly, the BTA 
treatment appeared to cause a decrease in the PlsEtn that contained either an 18:1 or 18:2 at the 
sn2 position, and either no change or slight increase in the PlsEtn that contained an 18:3, 20:4 
or 22:6 at the sn2 position in the undifferentiated U937 cells.   
The next four bars in each of the plots shows the relative levels of PlsEtn and PtdEtn in PMA 
treated U937‟s in the absence and presence of BTA (Figure 4.19).  The first column in this 
group shows the relative levels of PlsEtn in differentiated (48 hour PMA treated) U937 cells, 
and all of the measured plasmalogens significantly increase as the cells differentiate (p<0.05) 
(consistent with the results of the FTICR-MS analysis).  Interestingly, the PtdEtn do not 
increase during PMA-induced differentiation.  In fact, the only significant changes detected 
were decreased levels of those containing arachidonic acid (16:0/22:6), or docosahexaenoic 
acid (16:/20:4) (Figure 4.19) (Table 4.4).  When the cells were co-treated with BTA and PMA 
all of the PtdEtn in the panel decreased to similar, or lower, levels that were detected in the 
BTA treated monocytes (Figure 4.19).  The PlsEtn containing 18:1, 18:2 or 18:3 in the sn2 
position decrease in the cells co-treated with PMA and BTA, to the levels detected in the 
monocytes treated with BTA alone (Figure 4.19) (Table 4.4).  The PlsEtn which contain either 
20:4 or 22:6 in the sn2 position either remain at the same relative levels that were detected in 
the differentiated cells, or show a significant increase as in the case of the lipids that contain 
either 18:1 or 18:0 in the sn1 position (Figure 4.19) (Table 4.4). 
Following 24 hours of BTA- PMA co-treatment, and no visual signs of differentiation, 
monocyte cells still in suspension were washed and re-plated in fresh media lacking BTA or 
PMA.  The relative phospholipid levels 48 hours after re-plating are shown in the last two bars 
of the plots in Figure 4.19.  As previously mentioned, when the cells were co-treated with both 
BTA and PMA they did not complete the differentiation process.  However, once these cells 
were rinsed and plated in fresh media they attached to the plate surface within 6 hours.  The 
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Figure 4.19  High throughput analysis of phosphatidylethanolamines (PtdEtn) and 
plasmenylethanolamines (PlsEtn) in U937 cells that have been treated with PMA and  
1,2,3 benzene tricarboxylic acid (BTA ). 
Each graph shows the relative levels of PtdEtn and PlsEtn with the same fatty acid side chains 
per million cells.  Data has been normalized to the control sample (no BTA or PMA).  
Statistics for these graphs is presented in Table 4.4.  The error bars represent the standard 
deviation between replicate samples. 
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Table 4.4  The univariate t-test analyses for the results of the high throughput analysis of 
U937 cells treated with PMA and/or BTA (presented in Figure 4.19). 
Each value in the table is the two-tailed t-test result for the comparison of different treatments 
(listed on the left hand side of each table) for each lipid analyzed (listed at the top of each 
table).  If P-value<0.05, the cell has been grayed.  (C-control, BTA- 1,2,3 Benzene 
Tricarboxylic Acid, PMA- Phorbol 12-myristate 13-acetate)   
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analysis of lipid levels in the re-plated cells revealed statistically significant increases in all of 
the phosphatidylethanolamines analyzed in comparison to the levels of these lipids in the cells 
treated with both PMA and BTA (Figure 4.19) (Table 4.4).  The analysis of plasmalogens in 
the re-plated cells revealed that PlsEtn16:0/18:1, PlsEtn16:0/18:2 and PlsEtn16:0/18:3 
increased to levels similar to those detected in the PMA treated cells (Figure 4.19).  The 
remaining PlsEtn levels significantly increased in the re-plated cells, to levels more than two 
fold greater than in the PMA treated cells (Figure 4.19) (Table 4.4).  Interestingly, the PtdEtn 
levels in the re-plated cells also varied depending on the fatty acid side chains at the sn1 and 
the sn2 position of the lipid.  The ethanolamine plasmalogens containing either arachidonic 
acid (22:6) or docosahexaenoic acid (20:4) in the sn2 position showed the most significant 
increase (Figure 4.19) (Table 4.4). 
Since citrate is required for cholesterol synthesis through the production of acetyl-CoA 
precursors through the activity of citrate lyase, I examined total cholesterol levels to determine 
if the inhibition of citrate from the mitochondria would impact cholesterol synthesis.  An 
assessment of total cholesterol levels, using a triple-quadrupole tandem mass spectrometer, was 
performed on the cell pellet extracts from the BTA experiment, including; control, BTA, PMA, 
BTA and PMA combination treatment, and re-plated samples. Similar to the phospholipid 
results, increased cholesterol levels were detected in the 48 hour PMA treatment, which 
reflects the increase observed in the FTICR-MS data (Figure 4.20).  The treatment of the U937 
cells, undifferentiated, with BTA for 24 and 48 hours decreased total cholesterol levels in the 
cells.  The U937 cells that were pre-treated with BTA prior to the PMA treatment show 
decreased levels of total cholesterol, in comparison to the levels detected in the PMA treated 
cells.  When the cells that were originally treated with BTA and PMA were rinsed and re-
plated in fresh media the total cholesterol levels increased to the levels detected in the cells 
treated with PMA for 48 hours.  Since both plasmalogen and cholesterol levels were affected 
by BTA treatment during differentiation, I examined the third possible metabolic fate of acetyl-
CoA, which is histone acetylation.  A recent publication shows that histone acetylation in 
mammalian cells is dependent on the generation of cytosolic AcCoA by ATP-citrate lyase 
(Wellen et al., 2009). 
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Figure 4.20  Analysis of cholesterol in U937 cells that have been treated with PMA and 
1,2,3 benzene tricarboxylic acid (BTA ). 
The values have been normalized to the level of cholesterol in the control (un-differentiated) 
cells.  *p<0.05 relative to the control time point.  The error bars represent the standard 
deviation between replicate samples. 
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Figure 4.21  The effects of PMA and BTA treatment on histone 3 acetylation in U937 
cells.   
U937 cells were treated with the indicated compounds for 48 hours.  Protein lysates were 
resolved by SDS-PAGE and probed for acetylated Histone3 (H3
acetyl(Lys9)
) by Western blot 
analysis.  GAPDH was used as loading control. 
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Western blot analysis of the BTA treated cells showed a remarkable reduction of 
acetylation of histone 3 (H3
acetyl
) (Figure 4.21).  Interestingly, when the cells were treated with  
both BTA and PMA the acetylation of H3 was not inhibited.  Although the results show that 
the BTA alone can block H3 acetylation, this can be over-ridden by the activation of PKC.  
This result suggests that PMA may activate a different pathway that is capable of acetylating 
histones or generating cytosolic citrate or AcCoA. 
4.2.6 Discussion 
Comprehensive metabolomic analysis of differentiating human promyelomonocytic 
leukemic cell line U937 revealed dramatic alterations in multiple classes of 
glycerophospholipids.  The most significant, and novel finding, is that preferential increase of 
plasmalogens, relative to diacyl phospholipids, occurring between 6 and 48 hours post PMA 
induced differentiation (Figure 4.22A-B).  Multiple Reaction Monitoring (MRM) Triple 
Quadrupole mass spectrometry was used to confirm these results.  The monocyte form of the 
cell is a small spherical cell which is free-floating in the media.  Within 3 hours of the addition 
of PMA to the media, the cells became adherent and begin to differentiate.  This dramatic 
physical change would likely require a major alteration in membrane composition, and 
consistent with our results, may be modulated by significant increases in phospholipids and 
plasmalogens.  An increase in the percentage of plasmalogens in the cell membrane will result 
in a more fluid and flexible membrane.  Plasmalogens also have a number of other functions in 
cells: they mediate membrane dynamics, they act as antioxidants in the presence of reactive 
species, they store polyunsaturated fatty acids (PUFAs), and have been found to be involved in 
intracellular signalling in cells (Nagan and Zoeller, 2001; Brites et al., 2004).  Interestingly, an 
elevation of the phosphatidylethanolamine pool, including plasmalogens, was also detected 
when P19 teratocarcinoma cells where induced to differentiate into cardiac myocytes 
(Fotheringham et al., 2000).  In another study researchers determined that the elevation of 
phosphatidylethanolamine levels in the differentiating P19 cells was not essential for 
differentiation to proceed (Xu et al., 2000).   
It is quite conceivable that the increased levels of ethanolamine plasmalogens during 
the differentiation of U937 cells may be due to the dramatic changes in the membrane structure  
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Figure 4.22(A-D)  A summary of the results attained from the analyses of U937 cells 
during differentiation and BTA inhibition of differentiation. 
Lipid synthesis and histone acetylation in U937 cells.  A) The monocyte form of the cell, is 
considered to be the control of the experiment.  Simplified pathways for lipid synthesis and 
histone acetylation are shown.  The relative levels of lipids and histone acetylation detected in 
the monocyte cells is considered to be baseline for all other comparisons.  B)  U937 cell treated 
with phorbol 12-myristate 13-acetate (PMA).  Increased levels of cholesterol and plasmalogens 
(PlsEtn) are observed, as illustrated with green arrows, as compared to the levels detected in 
the monocyte cells.  Figure continued on next page.  
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Figure 4.22C-D  A summary of the results attained from the analyses of U937 cells during 
differentiation and BTA inhibition of differentiation (continued from previous page). 
C)  Inhibition of citrate export from mitochondria with 1,2,3-Benzenetricarboxylic acid (BTA) 
(red strikethrough).  Decreased levels of phospholipids and cholesterol were detected (red 
arrows).  Acetylation of histone 3 (H3) was also decreased (red arrow).  D)  Co-treatment with 
BTA and PMA.  Decreased levels of phospholipids and cholesterol were detected (red arrows).  
Acetylation of Histone 3 similar to levels detected in PMA treated cells. 
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Figure 4.22E  A summary of the results attained from the analyses of U937 cells during 
differentiation and BTA inhibition of differentiation (continued from previous page). 
E)  Cells that were treated with both BTA and PMA were removed from their media, rinsed 
and re-plated in fresh media without BTA or PMA.  After a period of 48 hours in the fresh 
media increased levels of phospholipids and cholesterol were detected (green arrows).  Due to 
a reduced number of cells collected it was not possible to analyze histone acetylation. 
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of the cells as they shift from monocytes to macrophages.  Phospholipid mixtures containing 
diacylphospholipids generally form lamellar gel at low temperatures, and mixtures containing 
plasmalogens become liquid-crystalline at the same temperature (Brites et al., 2004). An 
increase in the percentage of plasmalogens in the cell membrane will result in a more fluid and 
flexible membrane (Lohner, 1996).  It is also possible that the increase of plasmalogens 
detected in the macrophage cells is due to a self-protection mechanism.  Macrophages release 
reactive oxygen species (ROS), known as a respiratory burst, in response to phagocytosis 
(Forman and Torres, 2001).  The increased production of ROS, such as H2O2 and superoxide, 
in U937 cells plays an important function and characteristic during differentiation (Harris and 
Ralph, 1985).  These reactive oxygen species could be very damaging unless the cell can 
develop a method of protecting itself.  One of the key roles of plasmalogens is to protect the 
cell from reactive oxygen species, which may explain why an increase of these particular 
phospholipids would be necessary in U937 cells as they differentiate.  The vinyl-ether bond in 
plasmalogens increases the lipid susceptibility to oxidative attack in comparison to their diacyl 
counterparts (Brites et al., 2004).  Plasmalogens can protect cells from oxidative stress by 
scavenging radicals at the vinyl-ether linkage.  Plasmalogens have also been shown to be 
capable of inhibiting iron-induced peroxidation of PUFAs and copper-induced oxidation of 
lipoproteins (Brites et al., 2004). 
Ethanolamine plasmalogens, especially those containing arachidonic acid, have also 
been recently identified as major components of lipid rafts in cellular membranes (Pike et al., 
2002).  Lipid rafts are specialized cholesterol-enriched lipid domains that facilitate interactions 
between lipid and protein components of signalling pathways, regulate membrane trafficking, 
and cytoskeletal composition (Fan et al.; Pike et al., 2002).  Several signalling components are 
highly enriched in lipid rafts, such as: Heteromeric G proteins, growth factor receptors, SRC 
family kinases, MAP kinase and protein kinase C (Pike et al., 2002).  It is hypothesized that the 
enrichment of arachidonic acid containing plasmalogens in lipid rafts may be for the 
production of free arachidonic acid during cellular signalling (Pike et al., 2002).  In another 
study a relationship was identified between lipid rafts and pro-survival signalling pathways 
induced by reactive oxygen species (Yang et al., 2006). 
The question that these results raised was whether the induction of plasmalogens was 
required for differentiation, or merely an associated effect.  One way to address this was to 
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block the de novo synthesis of fatty acids using citrate export inhibitor 1,2,3-
Benzenetricarboxylic acid (BTA).  The BTA treatment in the monocytic U937 cells caused a 
reduction in growth and in the synthesis of lipids, including: cholesterol, 
phosphatidylethanolamines and ethanolamine plasmalogens (with the exception of those that 
contain linolenic acid (18:3), arachidonic acid (20:4), or docosahexanoic acid (22:6)) (Figure 
4.22C).  Another interesting observation is that plasmalogens containing essential fatty acids, 
linoleic acid (18:2) and linolenic acid (18:3), are affected by both PMA and BTA treatments.  
As the cells are not capable of synthesizing these fatty acids it is somewhat perplexing as to 
how they are incorporated into the lipids detected.  It is possible that they are in the foetal 
bovine serum that is added to the serum and then transported into the cell.  The inhibition of 
citrate export from the mitochondria also affected the acetylation of histone 3. 
Cells co-treated with BTA and PMA (BTA was added 3 hours prior to PMA) showed 
decreased levels of all phosphatidylethanolamines, as well as ethanolamine plasmalogens (with 
the exception of those containing arachidonic acid or docosahexanoic acid) (Figure 4.22D).  It 
is interesting that histone-3 acetylation was not inhibited in the combination treatment, as seen 
in the BTA treated cells, suggesting that an alternative method of acetylation can be induced 
with PMA treatment.  Numerous gene expression changes are likely initiated during 
differentiation, and therefore acetylation of histones would be required.  Recently published 
work shows that PMA treatment of LNCaP cells, a prostate cancer cell line, resulted in overall 
acetylation of histones H3 and H4 (Rowe et al., 2008).  Rowe‟s group determined that PMA 
treatment lead to the induction of KAI1, a metastasis suppressor down-regulated in many 
human cancers (Rowe et al., 2008).  Another interesting finding was that when a PKC 
inhibitor, apigenin, was added to the cells the acetylation of H3 by PMA was blocked (Rowe et 
al., 2008).  Interestingly, acetylation of H4 was not blocked by the PKC inhibitor, suggesting 
the effect of PMA on H4 acetylation may not be specifically regulated by the PKC pathway 
(Rowe et al., 2008). 
When the media from the combination treatment is removed, and the cells are rinsed and 
re-fed with normal media, plasmalogens and cholesterol increase to the same levels detected in 
the PMA treated cells (Figure 4.22E).  After re-plating the cells in fresh media the cells 
attached to the plate surface and appeared to differentiate without new addition of PMA.  These 
findings suggest that PMA is able to initiate the differentiation process but the inhibition of 
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citrate export prevents the process from completing.  U937 cells may require plasmalogens and 
cholesterol in order to differentiate; however, further experiments will be required in order to 
prove this hypothesis.   
4.3 Phenotypic Transformations of Cancer Cells 
4.3.1 Comprehensive Non-Targeted Metabolic Analysis of CNA14 Cells Grown at 34°C 
and 39°C 
Transformation of a normal cell into a cancer cell is accomplished by a multitude of 
phenotypic changes including: self-sufficiency in growth signals, insensitivity to anti-growth 
signals, tissue invasion and metastasis, limitless replicative potential, sustained angiogenesis 
and evading apoptosis (Hanahan and Weinberg, 2000).  To determine whether metabolic 
changes are associated with the transformation of normal cells into a cancer cell, a 
metabolomic analysis was completed on a cell line harbouring a temperature sensitive mutant 
of an oncogene.  CNA14 cells were derived from a parental rat fibroblast cell line, Rat2, and 
contain a temperature sensitive mutation of the oncogene p130
gag-fps
.  CNA14 cells have a 
normal phenotype at 39ºC but are tumourigenic at 34ºC, due to the apparent incompatibility 
between a temperature-sensitive version of the oncogene p130
gag-fps
 (functional at 34ºC, but not 
at 39ºC) and p53 (present at 39ºC, but absent at 34ºC).  The CNA14 cells grown at 34ºC and 
39ºC are phenotypically different (Figure 4.23).  The cells grown at 39ºC are normal fibroblast 
cells, whereas the cells that are grown at 34ºC no longer have the morphology of fibroblasts.  
Western blot analyses, previously completed by Dr. R. Warrington, on the CNA14 cells grown 
at 34 ºC, 37 ºC and 39ºC showed that at 39ºC p53 is present and that p130
gag-fps
 is absent, and 
the reverse is seen in the cells grown at 34ºC, where p130
gag-fps
 is present and p53 is no longer 
detected (un-published data).  Both p53 and p130
gag-fps
 are detected in the cells grown at 37ºC, 
and therefore negate each other at this temperature.   The objective therefore was to 
characterize differences between cells grown at the two temperatures.  Since the metabolic and 
transcriptomic comparisons are being made with essentially „isogenic‟ cells, the results 
obtained from this particular study should provide many new insights into the molecular 
differences between tumourigenic and normal cells. 
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Figure 4.23  CNA14 cells, grown at 39˚C and 34˚C, show different phenotypes at each 
temperature. 
CNA14 cells grown at 39˚C have a morphology consistent with fibroblast cells.  When the 
cells are grown at 34˚C they become irregular in shape, with some cells appearing elongated 
and narrow, and others almost spherical. 
 
39°C- Normal Phenotype 34°C- Tumourigenic Phenotype
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Included in this experiment were three control cell lines (grown at 34 ºC, 37 ºC and 
39ºC): the parental cell line (Rat2), a rat fibroblast cell line (NW16) expressing the wild type 
version of the p130
gag-fps
 oncogene, and a mouse embryonic cell line (10T1/2) to ensure that the  
metabolic changes that were observed were due to changes in growth phenotype and not the 
result of the temperature shift.   
A principal component analysis (PCA) of the control cell lines, NW16, 10T1/2 and 
Rat2, showed that there were very little metabolic differences due to temperature change 
(p<0.01, log2 normalized) (Figure 4.24).  The NW16 cells and Rat2 cells cluster tightly 
together, regardless of the temperature they were grown at.  In comparison, the CNA14 cells 
grown at the three different temperatures clearly separate. This suggests that the metabolic 
differences seen in CNA14 cells at each temperature were a result of the alteration in growth 
phenotype rather than an effect of the temperature shift alone. 
The data sets of two duplicate CNA14 experiments were combined (2011 metabolites), 
resulting in the comparison of four replicates.  A hierarchical cluster (Pearson correlation, 
complete linkage, p<0.01, log2 normalized) was completed on the dataset, resulting in 2 
distinct clusters of metabolites.  The first cluster contains metabolites elevated in the cells 
grown at 39ºC (normal phenotype), and the second cluster contains the metabolites elevated in 
the cells grown at 34ºC (tumourigenic phenotype) (Figure 4.25).  The masses elevated in the 
CNA14 cells grown at 39ºC were putatively identified as glycerophosphocholine (parental and 
adduct forms), phospholipids, triacylglycerols (TAGs) and vinyl acyl glycerols (VAGs) (Table 
4.5).  The masses in the second cluster, those elevated in the cells grown at 34ºC, have been 
putatively identified as ethanolamine and choline phospholipids and plasmalogens (Table 4.6).  
Glycerophosphocholine is a precursor for phospholipids and ether lipids, and was elevated in 
the CNA14 cells grown at 39°C (Figure 4.26).  Some of the other putatively identified classes 
of metabolites elevated in the CNA14 cells grown at 39°C include TAGs, VAGs and 
phosphatidylethanolamines (Figure 4.26).  The phospholipids, including plasmalogens, which 
are elevated in the tumour cells, are at very low levels or absent in the normal cells (Figure 
4.26). 
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Figure 4.24  Principal component analysis (PCA) of CNA14, Rat2, 10T1/2 and NW16 cell 
lines grown at 34°C, 37°C and 39°C. 
The closer the samples cluster together in a PCA plot the more metabolically similar they are.  
The further the samples separate from each other along PC1 the more metabolically different 
the samples are.  The plot on the left hand side of the figure is coloured by cell line, and the 
plot on the right is coloured by temperature. 
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Figure 4.25  A hierarchical cluster, Pearson correlation with complete linkage, of CNA14 
cells (grown at 34˚C and 39˚C). 
The top one third of the array contains masses that are detected at elevated levels in the CNA14 
cells grown at 39°C, and the masses in the bottom two thirds of the array are detected at 
elevated levels in the CNA14 cells grown at 39°C. (F-test- p<0.01, data is log2 normalized) 
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Table 4.5  Deduced metabolite identifications of the masses decreased in the CNA14 cells 
grown at 34°C (tumourigenic phenotype) as compared to the cells grown at 39°C (normal 
phenotype). 
This table is an expansion of the first cluster in Figure 4.25.  The first column contains the 
metabolite identification.  Some masses are identified as the parent form of the molecule, 
where as others are adduct forms of the molecule (containing a sodium or potassium adduct for 
example), this information is listed in the second column.  The theoretical mass of the assigned 
metabolite is listed in the third column and the corresponding formula in the fourth column.  
The PPM error calculated between the theoretical mass and detected mass (in the sixth column) 
is listed in the fifth column.  The analytical mode that the mass was detected in is listed in the 
seventh column.  The p-value calculated across the samples is listed in the eighth column.  The 
2-demensional array of the data is shown on the right hand side of the table.  The colours in the 
array represent the relative intensity of the mass in each sample (the legend for colours is 
located at the bottom of the table).  
 
 
dBase_Match Adduct T_Mass Formula Error
Detecte
d Mass
Analys is  
Mode
P_Value
2
_
2
_
3
_
3
_
5
_
5
_
6
_
6
_
Glycerylphosphorylcholine parent 257.1028 C8H20NO6P 0.09 257.1028 1101 0.0011
- - - - - 333.2761 1204 0.0019
Phosphatidylethanolamine, arachidonic, arachidic parent 795.5778 C45H82NO8P 0.26 795.578 1203 0.0079
C13 796.5809 1203 0.0085
Glycerylphosphorylcholine Na 257.1028 C8H20NO6P 0.1 279.0848 1101 1.82E-06
Phosphatidylethanolamine, linolenic, caprylic, hydroxy parent 617.3693 C31H56NO9P 0.76 617.3688 1202 2.58E-05
15-Rosene-5,19-diol; 5?-form, 19-Tigloyl parent 388.2977 C25H40O3 0.91 388.2981 1203 0.0028
Spirost-5-en-3-ol; (3?,25R)-form, Hexadecanoyl parent 652.5431 C43H72O4 0.21 652.5432 1203 0.0023
Diacylglyceroplasmalogen, EPA, arachidic parent 654.5587 C43H74O4 0.43 654.5584 1203 0.0005
C13 - - - - 655.5618 1203 0.0006
Phosphatidylethanolamine, lignoceric, arachidonic, parent 883.6302 C49H90NO10P 0.03 883.6302 1202 0.0006
Iosarcol, INN K-K 861.9069 C21H29I3N4O9 0.77 937.8193 1203 0.0033
Glycerylphosphorylcholine K 257.1028 C8H20NO6P 0.05 295.0587 1101 0.0093
1,3,7-Cembratrien-11-ol; (1E,3E,7E,11?)-form, Ac parent 332.2715 C22H36O2 0.81 332.2718 1204 0.0031
Phosphatidylethanolamine, arachidonic, arachidic parent 795.5778 C45H82NO8P 0.39 795.5781 1202 0.002
C13 - - - - 796.5825 1202 0.0045
Phosphatidylethanolamine, lignoceric, EPA, dihydroxy parent 881.6146 C49H88NO10P 1.34 881.6134 1202 0.006
- - - - - 529.3163 1202 0.0085
Phosphatidylethanolamine, arachidonic, arachidic parent 795.5778 C45H82NO8P 3.15 795.5803 1204 0.0044
C13 - - - - 796.5834 1204 0.0056
- - - - - 615.3539 1202 0.0079
- - - - - 935.8019 1203 0.0029
triacylglyceride, myristic, EPA, lignoceric parent 936.8146 C61H108O6 0.17 936.8144 1203 0.0094
triacylglyceride, myristic, arachidonic, lignoceric parent 938.8302 C61H110O6 2.35 938.828 1203 0.0073
C13 778.5727 1201 0.0034
Phosphatidylethanolamine, EPA, arachidic Na 793.5621 C45H80NO8P 0.62 815.5436 1201 0.0001
Phosphatidylethanolamine, arachidonic, arachidic Na 795.5778 C45H82NO8P 0.05 817.5597 1201 0.0005
C13 818.5628 1201 0.0007
temperature
34°C 39°C
1 2 3 4Replicates
Cluster 1
Cluster 2
Cluster 3
Cluster 4
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Control-0hr
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Table 4.6  Deduced metabolite identifications of the masses elevated in the CNA14 cells 
grown at 34°C as compared to the cells grown at 39°C. 
This table is set up in the same manner as Table 4.5, for a complete description of the table 
please see previous figure.  These are the masses in the second cluster of the HCA in Figure 
4.25.     
 
dBase_Match Adduct T_Mass Formula Error
Detecte
d Mass
Analys is  
Mode
P_Value
2
_
2
_
3
_
3
_
5
_
5
_
6
_
6
_
1-(2-Isopropyl-1-methylcyclobutyl)-4-methyl-4-nonene-1,8- parent 278.2246 C18H30O2 2.23 278.2252 1204 0.0049
- - - - - 573.485 1203 5.96E-07
Diacylglyceroplasmalogen, oleic, linolenic parent 600.5117 C39H68O4 1.07 600.5111 1201 0.0044
Phosphatidalethanolamine, arachidonic, oleic, hydroxy parent 765.5309 C43H76NO8P 0.87 765.5302 1201 0.0009
C13 766.5334 1201 0.0023
Phosphatidylcholine, arachidonic, linoleic parent 805.5621 C46H81NO8P
+ 1.91 805.5606 1201 0.0019
C13 - - - - 806.5636 1201 0.0015
Phosphatidalethanolamine, oleic, linoleic, hydroxy Na 741.5309 C41H76NO8P 0.11 763.5129 1201 0.0003
C13 764.5158 1201 0.0001
N-methylphosphatidylethanlamine, linolenic, arachidic parent 783.5778 C44H82NO8P 0.4 783.5781 1201 0.0005
C13 - - - - 784.581 1201 0.0002
N-methylphosphatidylethanlamine, linolenic, arachidic K 783.5778 C44H82NO8P 0.92 821.5344 1201 0.0034
13-Hydroxy-3-cleroden-15-oic acid; (ent-13?)-form, Me ester parent 336.2664 C21H36O3 0.16 336.2665 1203 0.0067
Diacylglyceroplasmalogen, arachodonic, myristic parent 572.4804 C37H64O4 1.33 572.4812 1203 0.0045
Phosphatidylethanolamine,linolenic, palmitic parent 713.4996 C39H72NO8P 3.71 713.5022 1204 0.0066
C13 - - - - 365.2989 1201 0.0083
Phosphatidylethanolamine, lauric, caprylic, hydroxy parent 539.3223 C25H50NO9P 2.08 539.3212 1202 0.0079
Phosphatidalethanolamine, linoleic, palmitic (plasmalogen) parent 699.5203 C39H74NO7P 0 699.5203 1202 0.0049
Phosphatidylethanolamine, palmitoleic, palmitoleic parent 687.484 C37H70NO8P 0.96 687.4833 1204 0.0028
Phosphatidylethanolamine, linoleic, linolenic parent 737.4996 C41H72NO8P 2.37 737.4978 1201 0.001
C13 NH4 755.5911 C43H81NO9 0.68 772.6183 1201 0.0034
Reticulatamol parent 534.5012 C35H66O3 1.32 534.5019 1203 0.0097
Phosphatidalethanolamine, linoleic, palmitic (plasmalogen) parent 699.5203 C39H74NO7P 0.57 699.5199 1204 0.0061
Phosphatidalethanolamine, linoleic, palmitic (plasmalogen) parent 699.5203 C39H74NO7P 0.29 699.5201 1203 0.003
1,9-Tridecanediol; 1-Docosanoyl Na 538.5325 C35H70O3 3.63 560.5164 1203 0.0058
C13 770.602 1201 0.0033
14-Hydroxyheneicosanoic acid, 9CI Na 342.3134 C21H42O3 0.16 364.2954 1201 0.0011
- - - - - 757.4954 1201 0.0018
Phosphatidylcholine, linoleic, palmitic parent 757.5621 C42H81NO8P
+ 1.14 757.563 1201 0.0022
C13 758.5661 1201 0.002
Phosphatidalcholine, linoleic, stearic (plasmalogen) parent 769.5985 C44H85NO7P
+ 0.73 769.5991 1201 0.0002
Phosphatidalcholine, nervonic, lauric (plasmalogen) parent 771.6142 C44H87NO7P
+ 1.06 771.615 1201 0.0003
C13 - - - - 772.5825 1201 0.0015
Phosphatidalcholine, linoleic (plasmalogen) parent 519.3316 C26H51NO7P
+ 0.24 519.3317 1201 0.0003
Phosphatidylethanolamine, linoleic, arachidic parent 771.5778 C43H82NO8P 1.18 771.5787 1201 0.0003
Phosphatidalethanolamine,linolenic, palmitic (plasmalogen) parent 697.5046 C39H72NO7P 0.07 697.5046 1204 0.0009
C13 - - - - 700.5238 1203 0.0004
N,N-dimethylphosphatidylethanlamine, linoleic, myristic parent 715.5152 C39H74NO8P 0.7 715.5157 1201 0.0034
N,N-dimethylphosphatidylethanlamine, arachodonic, myristic parent 739.5152 C41H74NO8P 0.4 739.5149 1201 0.003
C13 742.571 1201 0.0092
Phosphatidylcholine, linoleic, myristic Na 729.5308 C40H77NO8P
+ 0.26 751.5126 1201 0.0097
Phosphatidylcholine, linoleic, palmitic Na 757.5621 C42H81NO8P
+ 0.94 779.5448 1201 0.0095
Phosphatidalethanolamine, oleic, linoleic, hydroxy parent 741.5309 C41H76NO8P 0.5 741.5305 1201 0.0001
C13 - - - - 742.5332 1201 0.0003
Phosphatidylcholine,linolenic, palmitic Na 755.5465 C42H79NO8P
+ 0.87 777.5291 1201 0.0005
C13 778.5322 1201 0.0002
Phosphatidylethanolamine,linolenic, palmitic parent 713.4996 C39H72NO8P 1.19 713.4987 1201 0.0066
Phosphatidalethanolamine, linolenic, linolenic (plasmalogen) Na 719.489 C41H70NO7P 1.32 741.47 1201 0.0099
Phosphatidalcholine, oleic, palmitoleic (plasmalogen) parent 741.5673 C42H81NO7P
+ 0.58 741.5677 1201 0.0018
N,N-dimethylphosphatidylethanlamine, linoleic, palmitic parent 743.5465 C41H78NO8P 0.67 743.546 1201 0.0029
C13 744.5493 1201 0.0041
Phosphatidalcholine, logniceric, caprylic (plasmalogen) parent 717.5672 C40H81NO7P
+ 1.21 717.5681 1201 0.0043
Phosphatidalcholine, nervonic, capric (plasmalogen) parent 743.5829 C42H83NO7P
+ 0.16 743.583 1201 0.0011
C13 744.5863 1201 0.0015
Phosphatidylcholine, linoleic, myristic parent 729.5308 C40H77NO8P
+ 0.6 729.5304 1201 0.0067
C13 730.5338 1201 0.0062
Phosphatidalcholine, linoleic, stearic, hydroxy (plasmalogen) parent 785.5935 C44H85NO8P
+ 0.2 785.5933 1201 0.0042
C13 786.5964 1201 0.0062
Phosphatidalcholine, behinic, lauric (plasmalogen) parent 745.5985 C42H85NO7P
+ 0.31 745.5983 1201 0.0041
C13 - - - - 746.6017 1201 0.0071
C13 - - - - 718.5712 1201 0.0059
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Figure 4.26(A,B)  A graphical representation of the pattern of expression, and class, of 
metabolites that differ between CNA14 cells grown at 39°C and 34°C. 
A)  The classes of metabolites that were detected at higher levels in the CNA14 cells growing 
at 39°C (normal phenotype).  The graph on right hand side shows levels of 
glycerophosphocholine in cells grown at 39°C.  B)  The classes of metabolites that were 
detected at higher levels in the CNA14 cells growing at 34°C (tumourigenic phenotype).  
Levels of plasmalogens in the cells grown at 34°C are shown in the graph on the right hand 
side.  The error bars represent the standard deviation between replicate samples. 
 
 
Unknown
Phospholipids- all 
ethanolamine
Glycerophosphocholine
DAG plasmalogens
TAGs
0%
25%
50%
75%
100%
Glycerophosphocholine 
Unknown
Phospholipids
Plasmalogens
DAG plasmalogens
0%
25%
50%
75%
100%
Higher in cells grown at 39°C (normal phenotype) 
Higher in cells grown at 34°C (cancer phenotype) 
34°C 39°C 
34°C 39°C 
Plas malogens 
0
1
2
3
4
5
6
34 34 34 34 39 39 39 39
0
1
2
3
4
5
6
7
34 34 34 34 39 39 39 39
A 
B 
Unknown
Phospholipids- all 
ethanolamine
Glycerophosphocholine
DAG plasmalogens
TAGs
0%
25%
50%
75%
100%
Glycerophosphocholine 
Unknown
Phospholipids
Plasmalogens
DAG plasmalogens
0%
25%
50%
75%
100%
Higher in cells grown at 39°C (normal phenotype) 
Higher in cells grown at 34°C (cancer phenotype) 
34°C 39°C 
34°C 39°C 
Plas malogens 
0
1
2
3
4
5
6
34 34 34 34 39 39 39 39
0
1
2
3
4
5
6
7
34 34 34 34 39 39 39 39
A 
B 
Unknown
21%
Phospholipids-
all 
ethanolamine
42%
Glycerophosph
ocholine
16%
VAGs
10%
TAGs
11%
Unknown
6%
Phospholipids
44%
Plasmalogens
44%
VAGs
6%
0
1
2
3
4
5
6
7
8
9
76
5.
53
09
74
1.
53
09
69
9.
52
03
69
9.
52
03
76
9.
59
85
77
1.
61
42
51
9.
33
16
69
7.
50
46
74
1.
53
09
71
9.
48
9
74
1.
56
73
71
7.
56
72
74
3.
58
29
72
9.
53
08
78
5.
59
35
74
5.
59
85
S/
N
(l
o
g2
 t
ra
n
sf
o
rm
e
d
)
Plasmalogens
34
39
0
1
2
3
4
5
6
34 39
A
ve
ra
ge
 S
/N
(L
o
g2
 t
ra
n
sf
o
rm
e
d
)
Glycerophosphocholine
A
B
  
103 
1
0
3
 
 
Figure 4.27  Scans of the phosphorimaging screens of two BD Atlas
TM
 plastic rat 4K 
microarrays (BD Biosciences Clontech). 
The microarray of the CNA14 cells grown at 34°C is on top and the microarray of the CNA14 
cells grown at 39°C is on the bottom.  An example of some of the differences between the 
arrays has been expanded on the right hand side.  A complete list of the significant gene 
expression differences (minimum two-fold difference) between the cells grown at the two 
temperatures is located in Table 4.7. 
Red-  enolase 1, alpha 
Blue- lactate dehydrogenase A 
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4.3.2 Gene Expression of CNA14 Cells at 34ºC and 39ºC 
Due to the apparent metabolic diversity between the CNA14 cells grown at 34ºC and 
39ºC, it was decided to investigate whether any genes were responsible for the metabolic 
differences detected.  A BD AtlasTM plastic rat 4K microarray (BD Biosciences Clontech) was  
used, as per manufacturer‟s directions, to analyze the gene expression differences between the 
CNA14 cells grown at 34°C and 39°C.  The analysis revealed variability in gene expression 
between the CNA14 cells grown at 34ºC and those grown at 39ºC (Figure 4.27).  The majority 
of differences between the two different temperatures appear to be higher expression in the 
tumourigenic phenotype (34ºC) as compared to the normal phenotype (39ºC).  The significant 
gene expression differences (at least a twofold difference in expression) between the CNA14 
cells grown at 34 and 39ºC are summarized in Table 4.7.  The genes highlighted grey (under 
the name column in the table) are those that have higher expression levels in the cells grown at 
34ºC, and those that are white have higher expression levels in the cells grown at 39ºC. 
There was an increase in the expression of hypoxia inducible factor 1 (HIF-1α) which 
has not only been found to be important in the metabolic adaptation to hypoxia through its role 
in the conversion of glucose to lactate, but it also actively suppresses the TCA cycle by trans-
activating the gene that encodes pyruvate dehydrogenase kinase 1 (PDK1) (Kim et al., 2006) 
(Figure 4.28).  HIF-1α is believed to be a metabolic switch that is responsible for shunting 
glucose metabolism from the mitochondria to glycolysis in order to continue production of 
ATP and to prevent the synthesis of reactive oxygen species (Kim et al., 2006).  Increased 
expression of two glycolytic enzymes, lactate dehydrogenase and enolase1α, were detected in 
the cells grown at 34°C.  The increase in glycolytic enzymes in the „tumourigenic‟ CNA14 
cells suggests that the Warburg phenomenon may be occurring in the cells that are expressing 
the oncogene.  Expression of the gene that encodes for zymogen granule membrane protein 
was also found to be greater in the cells grown at 34ºC.  The zymogen granule membrane 
protein is a major glycosylphosphatidylinositol anchored membrane glycoprotein that is 
associated with cholesterol and lipid rafts (Kalus et al., 2002).  I also detected an increase in 
the expression of the gene that encodes the mitochondrial uncoupling protein which attenuates 
mitochondrial reactive oxygen species (ROS) production and protects the cell against cellular 
damage (Brand and Esteves, 2005).  It was also interesting that ornithine carbamoyltransferase,  
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Table 4.7(A,B)  Gene expression differences between CNA14 cells grown at 34°C and 39°C. 
Genes were selected as significant if expression was at least twofold different between the cells grown at 34°C or 39°C. The first 
table contains the genes that are reduced in the cells grown at 34°C.  The following two pages contain the genes that are elevated in 
the cells grown at 34°C. 
A. Genes with reduced expression in the CNA14 cells grown at 34°C as compared to levels detected in the CNA14 cells grown 
at 39°C.  
 
 
avg 34 sd 34 %SD avg 39 sd 39 %SD ratio log(ratio) Name
1 33.491 0.882 2.634 128.810 27.471 21.327 0.260 -1.943 tubulin T beta15
2 53.825 6.028 11.199 189.129 7.960 4.209 0.285 -1.813 small proteoglycan I (biglycan), bone (BSPG1) (bone/cartilage proteclycan 1 precursor)
3 341.304 38.437 11.262 1144.216 132.588 11.588 0.298 -1.745 ornithine carbamoyltransferase
4 78.701 0.716 0.910 250.809 37.036 14.767 0.314 -1.672 collagen alpha2(I) (col1a2)
5 175.048 4.865 2.779 516.718 114.495 22.158 0.339 -1.562 src related tyrosine kinase
6 144.709 13.550 9.364 421.080 80.932 19.220 0.344 -1.541 early growth response 3
7 274.590 14.315 5.213 738.818 45.499 6.158 0.372 -1.428 growth response protein (CL-6)
8 298.339 2.919 0.978 802.544 39.278 4.894 0.372 -1.428 salivary proline-rich protein (RP15)
9 50.111 8.356 16.675 133.898 17.091 12.764 0.374 -1.418 secreted acidic cystein-rich glycoprotein (osteonectin)
10 162.388 16.624 10.237 409.534 60.010 14.653 0.397 -1.335 isoprenylated 67 kD protein
11 345.294 43.588 12.623 821.553 38.891 4.734 0.420 -1.251 hemopexin
12 192.006 9.003 4.689 449.169 7.048 1.569 0.427 -1.226 isovaleryl Coenzyme A dehydrogenase
13 33.791 0.345 1.020 72.858 13.304 18.261 0.464 -1.108 hereditary haemochromatosis-like protein
14 127.326 3.990 3.134 263.553 12.770 4.845 0.483 -1.050 farnesyl pyrophosphate synthetase, testis-specific
15 51.531 0.836 1.623 104.451 9.590 9.181 0.493 -1.019 defensin-2, beta
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Table 4.7  continued. 
 
B.  Genes with increased expression in the CNA14 cells grown at 34°C as compared to levels detected in the CNA14 cells grown at 
39°C (table continued on next page).  
 
 
avg 34 sd 34 %SD avg 39 sd 39 %SD ratio log(ratio) Name
1 174.376 25.560 14.658 33.596 5.747 17.106 5.190 2.376 lin-10 protein homolog (lin-10)
2 991.176 42.538 4.292 196.215 17.034 8.681 5.051 2.337 zymogen granule membrane protein GP-2
3 133.163 27.637 20.755 28.488 1.100 3.860 4.674 2.225 cytochrome P450, subfamily XIB, polypeptide 1 (steroid 11-beta-hydroxylase)
4 187.630 17.664 9.414 40.164 5.694 14.177 4.672 2.224 synaptonemal complex protein 3
5 141.068 5.972 4.233 33.508 1.849 5.518 4.210 2.074 coatomer protein beta'-COP
6 144.649 3.081 2.130 40.995 0.240 0.586 3.528 1.819 espin
7 328.336 13.981 4.258 105.161 8.978 8.538 3.122 1.643 macrophage migration inhibitory factor (MIF); glutathione-binding 13-kDa protein
8 1150.100 160.474 13.953 368.819 4.145 1.124 3.118 1.641 enolase 1, alpha
9 426.335 96.891 22.727 141.470 7.941 5.613 3.014 1.591 ribosomal protein S26
10 581.868 18.558 3.189 207.435 5.749 2.771 2.805 1.488 lactate dehydrogenase A
11 74.593 15.624 20.945 27.098 1.142 4.214 2.753 1.461 toll-like receptor 4
12 161.284 13.992 8.675 59.169 0.027 0.045 2.726 1.447 acidic ribosomal protein P0
13 259.504 7.306 2.815 95.401 1.299 1.362 2.720 1.444 ribosomal protein L14
14 665.599 100.093 15.038 253.136 29.760 11.757 2.629 1.395 phospholamban
15 424.368 28.182 6.641 162.144 8.385 5.171 2.617 1.388 crystallin B alpha
16 357.969 27.324 7.633 138.053 23.168 16.782 2.593 1.375 cytochrome P450, an olfactory-specific steroid hydroxylase
17 916.591 38.210 4.169 354.343 18.311 5.167 2.587 1.371 neuraminidase 2
18 480.415 27.821 5.791 186.416 21.091 11.314 2.577 1.366 ribosomal protein L6
19 68.166 19.242 28.228 26.609 1.193 4.484 2.562 1.357 Phosphocholine cytidylyltransferase
20 414.855 73.171 17.638 163.675 24.590 15.023 2.535 1.342 ubiquitin carboxy-terminal hydrolase L1
21 276.458 7.011 2.536 110.376 16.757 15.181 2.505 1.325 cyclic nucleotide phosphodiesterase (CaM-PDE)
22 66.999 2.611 3.897 27.205 2.835 10.423 2.463 1.300 toll-like receptor 4
23 427.553 61.974 14.495 178.321 7.250 4.065 2.398 1.262 diacylglycerol kinase 90kD
24 120.941 10.131 8.377 50.450 7.746 15.355 2.397 1.261 late gestation lung protein 2 (Lgl2)
25 96.703 20.870 21.582 40.738 6.986 17.149 2.374 1.247 protein tyrosine phosphatase and tensin homolog/mutated in multiple advanced cancers protein (PTEN/MMAC1)
26 460.348 58.686 12.748 196.535 2.691 1.369 2.342 1.228 phospholipase B
27 73.888 3.649 4.938 31.706 2.286 7.209 2.330 1.221 sec22 homolog (rsec22)
28 161.014 5.450 3.385 70.189 0.256 0.365 2.294 1.198 uncoupling protein 2, mitochondrial
29 382.298 32.817 8.584 167.595 0.223 0.133 2.281 1.190 medium-chain S-acyl fatty acid synthetase thio ester hydrolase (MCH)
30 65.763 4.642 7.059 28.961 3.555 12.275 2.271 1.183 integrin alpha 7A
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Table 4.7  continued. 
 
B. Continued (Genes with increased expression in the CNA14 cells grown at 34°C as compared to levels detected in the CNA14 
cells grown at 39°C). 
 
 
avg 34 sd 34 %SD avg 39 sd 39 %SD ratio log(ratio) Name
31 60.420 9.652 15.975 26.976 0.546 2.025 2.240 1.163 thyroid hormone responsive protein
32 166.233 12.321 7.412 74.970 1.821 2.429 2.217 1.149 ribosomal protein L41
33 107.719 10.163 9.435 48.590 3.037 6.250 2.217 1.149 protein inhibitor of neuronal nitric oxide synthase (PIN)
34 288.423 5.109 1.771 130.870 16.631 12.708 2.204 1.140 ubiquitin and ribosomal protein S27a
35 152.605 25.474 16.692 69.423 6.817 9.819 2.198 1.136 heterogeneous nuclear ribonucleoprotein A/B
36 364.698 2.351 0.645 166.600 27.146 16.294 2.189 1.130 protein-glutamine gamma-glutamyltransferase
37 56.851 9.763 17.174 25.973 0.004 0.014 2.189 1.130 ninjurin 2
38 1060.816 67.361 6.350 484.883 11.282 2.327 2.188 1.129 ribosomal protein L29
39 775.376 33.978 4.382 357.403 44.855 12.550 2.169 1.117 hydroxyindole-O-methyltransferase
40 5771.263 302.398 5.240 2666.318 196.261 7.361 2.165 1.114 tubulin alpha 1 (TUBA1)
41 63.155 13.633 21.587 29.336 2.077 7.080 2.153 1.106 tropomyosin non-muscle isoform NM1 (TPM-gamma)
42 636.124 17.658 2.776 296.044 24.019 8.113 2.149 1.103 130 kD-Ins(1,4,5)P3 binding protein
43 125.803 2.450 1.948 58.999 1.925 3.263 2.132 1.092 guanine nucleotide binding protein beta 2 subunit
44 97.716 7.879 8.063 45.941 3.424 7.453 2.127 1.089 carboxypeptidase E (CPE); CPH
45 518.283 90.930 17.545 244.746 48.630 19.869 2.118 1.082 PHAS-I
46 247.280 21.132 8.546 117.259 2.028 1.729 2.109 1.076 D-beta-hydroxybutyrate dehydrogenase
47 153.445 3.942 2.569 72.866 0.320 0.439 2.106 1.074 cytochrome c oxidase polypeptide Vb (COX5B)
48 66.298 11.091 16.729 31.499 1.204 3.822 2.105 1.074 dishevelled-1 (dvl-1)
49 497.139 47.123 9.479 239.894 0.327 0.136 2.072 1.051 ATP synthase, subunit c, P2 gene
50 1054.455 134.856 12.789 511.901 17.991 3.514 2.060 1.043 acyl-CoA synthetase II, brain
51 65.414 9.017 13.785 31.959 1.837 5.747 2.047 1.033 histone H1-0
52 71.465 6.230 8.717 35.028 6.608 18.865 2.040 1.029 mitogen-activated protein kinase kinase 1 (MAP kinase kinase 1; MAPKK1; MAP2K1; PRKMK1); MAPK/ERK ki
53 108.053 0.735 0.681 53.070 3.528 6.649 2.036 1.026 2,4-dienoyl-CoA reductase precursor
54 96.134 12.008 12.491 47.340 3.129 6.610 2.031 1.022 aldehyde oxidase (female form)
55 395.285 25.870 6.545 195.826 16.566 8.459 2.019 1.013 ribosomal protein S10
56 69.576 5.351 7.691 34.559 3.817 11.044 2.013 1.010 testis enhanced gene transcript
57 921.485 178.389 19.359 458.810 46.524 10.140 2.008 1.006 Ig germline gamma-1 H-chain C-region
58 69.410 12.120 17.461 34.606 5.857 16.924 2.006 1.004 histone H3.3
59 85.058 4.465 5.250 42.446 1.575 3.711 2.004 1.003 nuclear pore complex protein nup155
60 80.854 7.992 9.885 40.358 1.018 2.523 2.003 1.002 zinc finger protein (pMLZ-4)
61 2843.238 410.256 14.429 1419.364 139.744 9.846 2.003 1.002 peptidylprolyl isomerase A (cyclophilin A)
62 63.086 6.390 10.130 34.069 2.158 6.336 1.852 0.889 hypoxia-inducible factor-1 alpha (Hif1a) *
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Figure 4.28  The log10 ratio of the expression of selected genes at 34°C as compared to 
those in the cells grown at 39°C. 
These particular genes were selected due their particular relevance to glycolysis and lipid 
synthesis.  The green depicts the genes which are expressed at higher levels in the 
tumourigenic phenotype and the red is for the gene expressed at a higher level in the normal 
phenotype. 
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the second enzyme in the urea cycle which converts ornithine to citrulline, was found to be 
reduced in the cells grown at 34ºC.  The urea cycle produces fumarate, which feeds into the 
TCA cycle.  Therefore, it is possible that the decrease in ornithine carbamoyltransferase is 
another mechanism that the cancer cell has developed to prevent the TCA cycle from 
functioning.  These connections are hypotheses of the relationships that may exist between the 
results of the transcriptomics and the metabolomics data, and therefore further research will be 
required to either confirm or refute them. 
There are many interesting expression differences in CNA14 cells grown at 34°C and 
39ºC, including zymogen granule membrane protein GP-2.  It encodes for a major 
glycosylphosphatidylinositol anchored membrane glycoprotein that is associated with 
cholesterol and lipid rafts (Kalus et al., 2002).  It is significantly higher (5 times) in the CNA14 
cells that were grown at 34ºC.  There are also a group of genes that encode for ribosomal 
proteins that are considerably higher in the tumourigenic cells, indicating increased cell 
growth.  Elevated transcript levels of hydroxyindole-O-methyltransferase (HIOMT) were also 
detected in the cells grown at 34 ºC.  HIOMT catalyzes the final reaction in the melatonin 
synthesis pathway, and has been detected at elevated levels in pineal parenchymal tumor (PPT) 
cells (Fukuda et al., 2010).  Mitochondrial uncoupling protein 2 (UCP2) transcript levels were 
also elevated in the cells grown at 34 ºC.  UCP2 attenuates mitochondrial ROS production, 
therefore protection the cell against cellular damage, as well as catalyzing the export of fatty 
acids and anions out of the mitochondria (Baffy, 2010) .  Elevated levels of dishevelled-1 (dvl-
1) transcripts were found in the tumourigenic cells.  The Dishevelled family of proteins play a 
regulatory role in the WNT signalling pathway and have been found to be elevated in 
numerous cancers (Zhao et al., 2010).  Phospholipase B converts phospholipids into fatty 
acids, by cleaving both fatty acid residues from the phospholipids (Morgan et al., 2004), and is 
found to be expressed at a higher level in the 34ºC cells.  Macrophage migration inhibitory 
factor (MIF) promotes malignant cell transformation (Mitchell, 2004) and the gene which 
encodes it is at a higher level of expression in the CNA14 cells grown at 34ºC.  The gene for 
D-beta-hydroxybutarate dehydrogenase, was expressed twice as high in the tumourigenic form 
of CNA14.  The gene product is a membrane enzyme that requires lecithin for activity and 
plays an essential role in energy metabolism (Grover et al., 1975).  The gene which encodes for 
lactate dehydrogenase A, which catalyzes the interconversion of pyruvate to lactate and the 
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oxidation of hydroxybutyrate (Koukourakis et al., 2006), is also elevated in the CNA14 cells 
grown at 34ºC.  Another important enzyme in the glycolytic pathway, enolase 1 alpha, is a 
cytoplasmic glycolytic enzyme that is responsible for the formation of phosphoenolpyruvate 
(Chang et al., 2003) and was also found to be elevated in the cells grown at 34ºC. 
There were only a few genes that showed higher expression in the CNA14 cells grown 
at 39ºC as compared to the cells grown at 34ºC.  The gene encoding secreted acidic cysteine-
rich glycoprotein (also known as osteonectin) is one of the genes with higher expression in the 
normal cells.  The gene product regulates the activity of fibroblast growth factor 2 and has an 
antiproliferative effect (Yan and Sage, 1999).  The gene which encodes for ornithine 
carbamoyltransferase, the second enzyme in the urea cycle which converts ornithine to 
citrulline, is also significantly higher in the cells grown at 39ºC. 
4.3.3 Temperature Shift  
I was interested to know if the oncogenic phenotype was reversible.  The cells that had 
been originally grown at 34 ºC were shifted to 39 ºC, and the cells grown at 39 ºC were shifted 
to 34 ºC.  The PCA of the CNA14 temperature shift experiment shows a clear separation of the 
cells originally grown at 34ºC and 39ºC along principal component 1 (PC1) (Figure 4.29).  
Interestingly, the temperature shift did not result in a conversion of metabolic profiles even 
after a shift of 96 hours.  Although the cells appeared to phenotypically change when 
temperature shifted, metabolically there was very little change.  Movement of the samples 
along principal components 2 and 3 was also examined and it became evident that the 
differences between the cells grown at 34ºC and shifted to 39ºC were found along PC2 and 
movement of the 39ºC cells, being shifted to 34ºC, was found along PC3 (Figure 4.29).  These 
results may prove that it is not possible to metabolically shift CNA14 cells from a normal 
profile to a tumour profile (and tumour to normal) within 96 hours.  Although phenotypically 
they may have appeared to take on characteristics of the other cell type, their metabolic 
pathways do not significantly change.  This suggests that oncogenic transformation, 
metabolically, is irreversible. 
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Figure 4.29  PCA of CNA14, cells grown at 34°C and  shifted to 39°C, and cells grown at 
39°C and shifted to 34°C. 
The PCA of the temperature shift experiments, from the PC2 and PC3 views.  The cells shifted 
from 34˚C to 39˚C show movement along PC2, whereas the cells shifted from 39˚C to 34˚C 
show movement along PC3. 
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4.3.4 Discussion 
In the metabolomic analysis of CNA14 cells, a dramatic increase was observed in 
phospholipids (phosphatidylcholines, phosphatidylethanolamines, and plasmalogens) as well as 
triacylglycerols and diacylglycerols in the cells grown at 34°C (tumourigenic phenotype) 
compared to the cells grown at 39°C (showing a normal phenotype).  There are a few 
phospholipids that are found to be moderately elevated in the normal cells; however, the 
majority of those detected were higher in the tumour phenotype.  There is also a difference in 
the level of glycerophosphocholine in the cells grown at the two temperatures.  Much higher 
levels were observed in the normal cells as compared to near absent levels in the transformed 
phenotype.  This observation suggests that glycerophosphocholine may be a precursor 
molecule for the lipids that are elevated in the cells grown at 34°C. 
In our attempt to explain these observations, I methodically searched the literature for 
any previous reports linking metabolic deregulation to known cellular changes that occur in 
cancer.  In 1926, Warburg proposed a model of tumourigenesis involving altered energy 
production in tumours (Langbein et al., 2006).  This model, which is now known as the 
Warburg hypothesis, states that cancer cells shift to a high level of aerobic glycolysis, even in 
the presence of oxygen, and low respiration to metabolize glucose (Warburg, 1956).  Under 
normal physiological conditions, cellular energy metabolism is preferentially based on 
oxidative phosphorylation, which is considerably more efficient than glycolysis.  Warburg 
hypothesized an alternative state of energy metabolism in cancer systems, which included an 
impaired mitochondrial function and increased dependence on glycolysis as a source of energy, 
even under aerobic conditions (Warburg, 1956).  According to this hypothesis, the ability of 
cancer cells to generate ATP via mitochondrial respiration is impaired, which likely triggers 
alternative metabolic pathways by the over-expression of glycolytic enzymes.  This alternative 
method of energy production may be a response, or perhaps a requirement, due to the rapid 
growth of cancer cells and consequently the expansion of a tumour mass which may result in 
an insufficient supply of blood to the tissue.  This would create a hypoxic environment with 
limited mitochondrial respiration, causing cancer cells to utilize the glycolytic pathway as its 
main source of energy (Xu et al., 2005).  If the cancer cells automatically switch to glycolysis, 
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Figure 4.30  A model of glycolysis and lipid synthesis in cancer.  
This model is a compilation of well known metabolic pathways, such as glycolysis and the 
pentose phosphate pathway, cancer induced alterations to metabolic pathways and the results 
of our analysis of CNA14 cells.  Glucose uptake is increased in most cancer cells (green 
arrow).  The increased glucose in the cell is metabolized by the glycolytic pathway or the 
pentose phosphate pathway.  Citrate is exported out of the mitochondria in most cancer cells 
(three green arrows) and is used to synthesize cytosolic acetyl-CoA.  The coloured boxes 
highlight the metabolites detected at increased levels in our analyses. 
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rather than respiration as a source of energy, then a lack of oxygen will not prevent the cells 
from growing. 
The metabolic pathways are initially altered in cancer systems with the increased 
uptake of glucose in the cells (Figure 4.30).  The result of the increased levels of glucose is an 
up-regulation of both glycolysis and the pentose phosphate pathway.  As mentioned previously, 
cancer cells typically utilize aerobic glycolysis (even in the presence of oxygen) as a source of 
energy, which is known as the Warburg effect.  This effect can be seen in the model with an 
increase in glycolysis and increased lactate production.  Typically in normal cells citrate is 
converted into isocitrate, which then proceeds into the TCA cycle (Costello and Franklin, 
2005).  Tumour cells have also been found to exhibit both a truncated TCA cycle and an  
increase in the export of citrate out of the mitochondria into the cytoplasm (Parlo and Coleman, 
1984). 
The export of citrate depletes the availability of citrate for oxidation and therefore may 
likely be the cause of the limited respiration observed in the cancer cells.  Reduced levels of 
mitochondrial aconitase, the enzyme responsible for the conversion of citrate into isocitrate, 
have also been reported in cancer systems and may also lead to the truncation of the TCA cycle 
(Ristow, 2006). 
Another important observation regarding cancer metabolism, made over half a century 
ago, was that tumours have an increased rate of de-novo fatty acid synthesis (Medes et al., 
1953).  Numerous researchers have exploited this finding and through the inhibition of fatty 
acid synthesis have arrested cell proliferation and induced the death of the diseased cells in 
various types of cancer (Pizer et al., 1996; Brusselmans et al., 2005).  These observations 
clearly fit the model created (Figure 4.30) as de-novo fatty acid synthesis would be required in 
order for the cancer cells to increase the synthesis of the multiple classes of lipids found to be 
at elevated levels in the cells expressing the cancer phenotype. 
There has been a recent discovery of a transketolase like gene (TKTL1) that is up-
regulated in most cancers as well as numerous neurodegenerative diseases and diabetes (Coy et 
al., 2005).  It encodes a transketolase enzyme that enables the conversion of xylulose 5-
phosphate into glyceraldehyde-3-phosphate and Acetyl-CoA (Langbein et al., 2006).  The 
conversion of xylulose 5-phosphate into glyceraldehyde-3-phosphate, which is unique to 
cancer systems, may signify the level of importance that the products of glycolysis have in 
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Figure 4.31  The model of glycolysis and lipid synthesis in cancer, in combination with the 
results of the gene expression analysis of the CNA14 cells.  
Some of the key results of the gene expression analysis have been overlaid with the metabolic 
changes that have been associated with cancer development and progression.  The green 
(increased in CNA14 cells grown at 34°C) and red (decreased in CNA14 cells grown at 34°C) 
boxes highlight the gene changes, and the other coloured boxes highlight the metabolites that 
were detected at elevated levels (in the CNA14 cells grown at 34°C) in our analyses. 
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cancer development. This discovery clearly fits into the presented model and further suggests 
that a cancer cells heavily relies on glycolysis and the related end-products for the development 
of the cancer phenotype. 
Some of the gene expression differences that were detected in the CNA14 cells have 
been overlaid onto the glycolysis and lipid synthesis model that was discussed above (Figure 
4.31).  In the analysis of transcriptional changes occurring in the CNA14 system, increases of 
two glycolytic genes encoding lactate dehydrogenase and enolase 1 alpha were detected in the 
cells grown at 34ºC which show the transformed phenotype.  It was also interesting that 
ornithine carbamoyltransferase, the second enzyme in the urea cycle which converts ornithine 
to citrulline, was found to be reduced in the cells grown at 34ºC.  The urea cycle produces 
fumarate, which feeds into the TCA cycle.  Therefore, it is possible that the decrease in 
ornithine carbamoyltransferase is another mechanism that the cancer cell has developed to 
prevent the TCA cycle from functioning.  These connections are hypotheses of the 
relationships that may exist between the results of the transcriptomics and the metabolomics 
data, and therefore further research will be required to either confirm or refute them. 
Recent findings in cancer research have rekindled interest in Warburg‟s theory,  
including an observation that, during tumourigenesis, an increase in glucose uptake and lactate 
production occurs and that the fully transformed state is most dependent on glycolysis and 
minimally dependent on the mitochondria for ATP synthesis (Ramanathan et al., 2005).  One 
major reason for the shift to glycolysis in cancer systems is likely to provide a source of acetyl 
CoA for the mitochondrial synthesis of citrate, which provides the source for cytosolic acetyl 
CoA (Costello and Franklin, 2005).  Cytosolic acetyl CoA is the essential precursor molecule 
for the synthesis of fatty acids, which in turn are the major building blocks for lipid molecules.  
The strong correlation between the rate of aerobic glycolysis and the aggressiveness of the 
cancer likely indicates that the glycolytic phenotype offers a significant proliferative advantage 
and may be a crucial component of the malignant phenotype (Gatenby and Gillies, 2004). 
There have also been many connections made between cancer causing genes and 
glucose metabolism, including AKT which has been found to stimulate glucose metabolism in 
cancer cells, as well as AMP-activated protein kinase which links glucose metabolism and cell 
cycle (Langbein et al., 2006).  Reports have also showed that mitochondria in rapidly growing 
tumour cells are generally smaller and show less cristae than mitochondria from normal tissues, 
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and also that the actual number of mitochondria in tumour cells is reduced (Ristow, 2006).  The 
fact that the glycolytic rate in cancers is increased has been detected and reported by many 
researchers over the past 70 years.  It is still unknown whether this is due to the reduced 
mitochondria activity, or rather that the mitochondria activity is reduced due to the increased 
glycolytic activity. 
It is well known that the inactivation of the p53 tumour suppressor gene has been found 
to occur in almost half of all human tumours (Mori et al., 2004), and recently it was found that 
p53 modulates the balance between the utilization of the glycolytic and respiratory pathways 
(Matoba et al., 2006).  A recently published review suggests that there are four main 
advantages for aerobic glycolysis in cancer: the cells will be able to survive fluctuating levels 
of oxygen, the lactic acid produced during glycolysis conditions their environment for tumour 
invasion and suppresses anticancer immune effectors, the cells can metabolize glucose through 
the pentose phosphate pathway which in turn generates NADPH, and lastly cancer cells can 
use the glycolytic intermediates for anabolic reactions (Kroemer and Pouyssegur, 2008). 
Despite numerous reports by many different researchers whose research complements, 
or supports, Warburg‟s theory, the underlying cause of the effect is still not well understood.  It 
is also unknown if the same causes always underlie this effect in cancers, or if genetic 
influences play any part (Unwin et al., 2003).  The glycolytic phenotype in cancer is believed 
to be present because it offers a growth advantage and not because it is the result of a 
secondary response from another pathway during carcinogenesis (Gatenby and Gillies, 2004).  
The glycolytic phenotype suppresses apoptosis and the by-products of glycolysis contribute to 
the degradation of the extracellular matrix, and increase cell mobility and metastatic potential 
(Bonnet et al., 2007).  Recently it was also discovered that activated T cells also have 
dramatically increased metabolic requirements, and in order to meet the energy and 
biosynthetic needs the T cells increase glucose uptake and employ aerobic glycolysis (Cham et 
al., 2008; Maciver et al., 2008). 
All of these pieces of information add strength to the hypothesis of the pivotal role of 
glycolysis in cancer systems and the dependence that the cells have on the products of glucose 
metabolism for the development and progression of cancer.  Our discovery of significant 
changes in lipid synthesis in cancer systems, as well as during the fundamental cellular 
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processes involved in cancer development, may provide the evidence required to understand 
the correlation between cancer and glycolysis. 
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5 Final Conclusions and Future Directions 
The results presented in this thesis have demonstrated that non-targeted metabolomic 
profiling approaches can reveal non-intuitive insights into basic cellular processes.  The 
biochemical composition of biological material associated with particular cellular or 
physiological responses can be characterized first, followed by the generation of hypotheses 
based on the data collected.  This type of analysis represents a non-traditional scientific 
approach, in that specific hypotheses regarding the response of interest are generated 
subsequent to the analysis.  The use of a FTICR-MS in non-targeted metabolomic analyses has 
allowed the detection of a broad range of metabolites, including both known and novel 
molecules, in three independent models.  This would not have been possible if a targeted 
approach had been solely utilized.  The results of the metabolomic analyses suggest that 
particular lipid alterations are associated with all of the cellular processes being investigated.  
During the cell cycle, TAGs and VAGs were detected at elevated levels at the key regulatory 
checkpoints in the cell cycle.  Plasmalogens were detected at elevated levels during 
differentiation of monocytes into macrophages.  Furthermore, elevated lipids, in particular 
plasmalogens, were detected in cells expressing a temperature sensitive oncogene. 
These results suggest that alterations in the metabolism of specific classes of lipids may be 
not only essential in cell growth, proliferation, and differentiation, but also a requirement in 
cancer development.  Cellular membranes are formed by amphipathic lipids, such as 
phospholipids and plasmalogens, which contain hydrophilic and hydrophobic regions.  Cellular 
membranes not only segregate the external environment from the internal components of the 
cells, but they also enable the production of discrete organelles within the cell.  Lipids are 
required not only as structural components of the cell, but also for basic cellular functions such 
as cell signalling and energy storage.  It would therefore be logical that during fundamental 
cellular processes, such as cell cycle, differentiation and transformation, significant changes in 
lipid content would occur. 
During the cell cycle elevated levels of triacylglycerols (TAGs) and vinyl acylglycerols 
(VAGs) were detected as the cells approached the mitotic phase of the cycle.  An increase of 
phospholipase C (PLC) transcript levels was also detected in the cells prior to cell division.  
Phospholipase C is a class of enzymes that cleave phospholipids to release the phosphate head 
group of the molecule.  One type of lipid that PLC cleaves is phosphatidylinositol 4,5-
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bisphosphate (PIP2), which results in the production of inositol 1,4,5-triphosphate (IP3) and 
diacylglycerol (DAG).  PLC can also cleave ethanolamine plasmalogens, resulting in the 
production of VAGs and ethanolamine phosphates.  DAGs and VAGs are involved in the 
activation of protein kinase C, which in turn regulates many different cellular processes (Ford 
et al., 1989; Griner and Kazanietz, 2007).  It has also been hypothesized that VAGs may be 
competitive inhibitors of DAGs for PKC, and therefore may regulate PKC-mediated responses 
(Nagan and Zoeller, 2001).  PKC signalling has been implicated in growth control, 
differentiation and tumourigenesis (Fima et al., 2001).  Activation of PKC has been shown to 
regulate cell cycle progression during G1 and G2/M phases, either in a stimulatory or 
inhibitory manner (Fima et al., 2001).  PKC is also a major cellular receptor for phorbol esters, 
such as phorbol 12-myristate 13-acetate (PMA), which was used to initiate differentiation in 
U937 cells.  It is conceivable that PLC activity, signalling lipids (DAGs and VAGs) and PKC 
signalling are integral in all three of the fundamental cellular processes examined for this 
thesis.  DAG‟s are also precursors for phospholipids (phosphatidylethanolamines and 
phosphatidylcholines) as well as triacylglycerols.  It is therefore possible that after the DAG 
has activated PKC it will either be converted into a phospholipid for cellular membranes or 
into a TAG for the storage of fatty acids, depending on the requirements of the cells at that 
time. 
Plasmalogens were detected at elevated levels during differentiation of U937 cells and 
in CNA14 cells expressing a temperature sensitive oncogene p130
gag-fps
.  In addition to serving 
as structural components of cellular membranes, plasmalogens also function as sinks for 
polyunsaturated fatty acids, intracellular signalling molecules, mediators of membrane 
dynamics and endogenous antioxidants (Zoeller et al., 1999; Nagan and Zoeller, 2001; Brites et 
al., 2004).  The monocyte form of the U937 cell is a small spherical cell which is free floating 
in the media.  After the addition of PMA to the media, the cells become adherent and begin to 
differentiate within 3 hours.  This dramatic physical change would likely require a major, if not 
a complete, alteration in membrane composition, and consistent with our results, may be 
modulated by significant increases in plasmalogens. 
The results of our investigations have implicated glycerolipids, in particular 
phospholipids, in the process of cell cycle progression, differentiation and oncogenic 
transformation.  The majority of phospholipids are contained in the cellular membranes of 
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cells, and it is therefore logical to assume that the membrane structure is being affected during 
these processes.  Nutrient and ion transport, inter- and intracellular signalling, fusion, and 
receptor localization and interaction are all influenced by membrane composition.  It is likely 
that phospholipid alterations in the cell would affect the membrane structure and in turn alter 
these important cellular mechanisms. Model membranes that are composed entirely of 
ethanolamine plasmalogens transform from lamellar gel to non-lamellar or non-bilayer 
structures at lower temperatures than membranes composed of diacyl species (Lohner, 1996).  
The non-bilayer areas of the membrane are more susceptible to increased leakage of the 
membranes to ions and allow membrane-membrane fusions (Glaser and Gross, 1994; Nagan 
and Zoeller, 2001).  Membrane fusion is very important in several cellular processes including 
endocytosis and secretion (Nagan and Zoeller, 2001), both of which are characteristic of 
macrophage cells.  Ethanolamine plasmalogens, especially those containing arachidonic acid, 
have also been recently identified as major components of lipid rafts in cellular membranes 
(Pike et al., 2002).  Lipid rafts are specialized cholesterol-enriched lipid domains that facilitate 
interactions between lipid and protein components of signalling pathways, regulate membrane 
trafficking, and cytoskeletal composition (Fan et al.; Pike et al., 2002).  Lipid rafts also contain 
transforming growth factor (TGF)-β receptors, which regulate cell growth, apoptosis, 
differentiation and migration (Zuo and Chen, 2009). 
When de novo synthesis of lipids was inhibited with BTA treatment, the U937 cells 
were not able to complete the differentiation process.  Interestingly, when the inhibitor was 
removed, plasmalogen and cholesterol levels dramatically increased and the cells completed 
the differentiation process, suggesting that U937 cells require plasmalogens and cholesterol in 
order to differentiate.  However, further experiments will be required in order to prove this 
hypothesis.  A direct inhibition of plasmalogen synthesis, such as a knockdown of DHAPAT, 
in U937 cells may provide insight into the necessity of these lipids during the differentiation 
process.  It may also be interesting to analyze the cellular membranes of the U937 cells for 
non-lamellar regions and lipid rafts during differentiation to determine if the increase in 
plasmalogen levels is linked to these membrane structures. 
In order for cells to grow and replicate they must generate enough energy and synthesize, 
or acquire, all of the biomolecules to double their cellular content.  For highly proliferative 
cells, such as cancer cells, increased glucose uptake, up-regulated glycolysis, and reduced 
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cellular respiration (aerobic glycolysis or the Warburg effect) provide the cell with both the 
energy and metabolic intermediates required for rapid cell growth.  This reprogramming of the 
cell‟s core metabolic pathway confers a selective growth advantage ideal for cancer 
progression.  Interestingly, our examination of metabolic and gene expression differences in 
the CNA14 cells revealed increased levels of lipids and up-regulation of genes encoding 
glycolytic enzymes in the cells expressing the oncogene p130
gag-fps
.  A comparison of normal 
and transformed human cells would have been preferred; however, it is very difficult to culture 
normal cells and therefore was not feasible. 
There are many different types of analytical approaches currently being used to further our 
understanding of human health and disease states.  The question really becomes what actually 
defines a disease state?  Some researchers may believe that the answer can be discovered at the 
gene or protein level.  However, in order to measure the true health state of an individual one 
must not only consider the blueprint molecules, genes and proteins, but must also consider the 
phenotype.  The phenotype of a cell or organism is the complement of its physical 
characteristics, comprised primarily of proteins and small molecules.  Changes in phenotype 
result from genetic alterations, changes in environment (such as diet and lifestyle) and aging.  
Therefore, a metabolomics analysis in the study of human health, aging and disease can 
provide a wealth of knowledge unattainable with any other type of approach. 
The major and still yet unanswered question to the observations reported in this thesis is 
whether the observed changes are the cause of specific processes, or whether they are merely 
side effects?  It is possible that cancer cells require the de novo synthesis of lipids, and shifting 
the cell‟s core metabolic system to aerobic glycolysis provides the necessary metabolic 
intermediates and energy requirements.  On the other hand, the synthesis of the lipids may just 
be a result of the cancer cell‟s requirement for aerobic glycolysis.  Although the results 
presented in this thesis suggest that the lipid changes were a result of the three basic cellular 
processes being studied, it is possible that under real physiological conditions associated with 
human disease lipid changes may be the cause of the disease state.  Mutations to certain 
enzymes, changes in diet and environment, or even decreases in thermodynamic stability due 
to aging could alter the composition of the cellular membranes (de Grey, 2002; Dennis et al., 
2009).  Changes to the membrane structure could alter membrane lipid rafts and microdomain 
architecture, which may lead to de-regulation of the cell cycle or an inability to differentiate. 
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Future investigations should be focused on understanding why the increase of lipids occurs 
during these cellular processes and whether or not their de novo synthesis is a necessity or a 
side effect of upstream changes.  As previously mentioned, directly inhibiting the synthesis of 
specific classes of lipids in each of the cell lines studied could provide insight into the 
importance of the lipids during the cellular processes of interest.  It may also be interesting to 
create a knock-down animal model in which DHAPAT has been inhibited in the animal to 
determine if the animal‟s susceptibility to tumour development is altered with reduced 
plasmalogen levels.  It would also be very interesting to characterize the membrane and 
phospholipid composition of biospecimens collected from subjects affected with various 
diseases.  Better understanding how metabolic pathways work and how membrane composition 
can affect cellular mechanisms may one day lead to new approaches for their modulation, and 
potentially to new therapies. 
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